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Abstract 
 
Although cure rates have significantly improved for children with T-cell acute 
lymphoblastic leukemia (T-ALL), 20-30% undergo induction failure or relapse 
with most succumbing to disease. Leukemia-initiating cells (L-ICs) are 
hypothesized to be resistant to conventional chemotherapy and radiation and are 
thereby responsible for disease recurrence. Using an in vivo limiting dilution 
assay, we previously showed that the murine T-ALL L-IC is quite rare, with only 
0.003-0.05% of cells capable of initiating disease, and demonstrated that the L-
IC is a subset of the leukemic DN3 thymic progenitor population.  Work described 
in this thesis validates the L-IC assay using two transplantation methods to rule 
out effects of homing and/or microenvironment on T-ALL L-IC survival and 
maintenance. Using this assay, we demonstrate that sustained Notch1 signaling 
is required for T-ALL initiation in vivo and show that treatment with a Notch1 
inhibitor reduces or in some cases eliminates the L-IC population. We further 
analyze the effects of inhibiting c-Myc, a Notch1-regulated gene, on L-IC 
frequency and uncover an essential role for c-Myc in L-IC survival and 
expansion. Suppressing c-Myc by using specific shRNAs or a c-Myc inhibitor 
reduces the L-IC population and interferes with leukemia initiation. Together, 
these findings reveal a critical role of the Notch1-c-Myc pathway in T-ALL 
initiation and suggest that therapeutics targeted at this pathway could be used to 
treat and/or prevent disease relapse in patients. 
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   2 
T-ALL 
 T-cell acute lymphoblastic leukemia (T-ALL) is a disease of immature T-
lymphocytes and accounts for 15% of pediatric and 25% of adult cases of ALL, 
for a total of approximately 500 children and 250 adults diagnosed each year in 
the United States1,2. Patients often present with fever, bone pain, bleeding, 
lymphadenopathy, mediastinal mass, and extremely high white blood cell counts 
with evidence of atypical blasts in the periphery3–5. Classification of ALL is based 
on morphology of the cells found in blood smears and on flow cytometry of 
defined cell surface markers6.  
 T-ALL is a high-risk group within ALL as a whole. This is partly due to the 
fact that T-ALL cells will often infiltrate the CNS, causing neurological symptoms 
and increased mortality. T-cells express the CCR7 receptor on the cell surface, 
which permits the cells to cross into the CNS7. Overall survival for pediatric 
patients with T-ALL is estimated at 70%, compared to an 85% survival rate 
overall for ALL8–10. This prognosis is worse for adults (50%)11 and patients with 
an early precursor T-cell subtype (~57%)12–14. Once disease has relapsed the 
outlook for patients, both children and adults, is very poor with median survival 
being only one year and only 25% of relapsed patients surviving to 3 years11,15.  
Current chemotherapies are rigorous and harsh, especially on young 
children. First line therapy for T-ALL is a multidrug regimen consisting of three 
separate phases: induction, consolidation, and maintenance8. Induction therapy 
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consists of weekly treatment with vincristine, cortical steroids, asparaginase, and 
doxorubicin9,16; approximately 90% of patients will achieve a remission (as 
judged by bone marrow biopsy) after this phase16. Consolidation therapy is 
begun after remission is attained from induction therapy and consists of 
cytarabine, methotrexate, doxorubicin, cyclophosphamide, and etoposide17. 
These drugs are given in different combinations for up to six months and are 
adjusted according to each patients risk group and response rate18. Patients are 
lastly put on a less intensive maintenance therapy that can last 2-3 years. This 
usually consists of oral 6-mercaptopurine and periodic intrathecal methotrexate, 
with some patients also receiving low doses of vincristine and steroids19–21. 
Relapse will occur in approximately 20-25% of children8,10,22 and 50% of 
adults11 diagnosed with T-ALL. An estimated 3% of patients will die from 
toxicities associated with treatment, including cardiac events and infections23. 
Notably, to prevent central nervous system (CNS) involvement, patients are often 
treated with cranial irradiation and intrathecal high-dose chemotherapy8. This has 
led to the development of learning disorders in children and secondary 
malignancies later in life24,25. It is critical that targeted therapies be developed to 
help abate some of these side effects, while improving successful remission 
rates. 
 
 
   4 
Self-renewal plays a role in thymocyte development 
 T-ALL results from proliferation of immature thymocytes, so it is important 
to understand the normal steps in thymocyte maturation in order to better 
understand the progression of the disease. Murine thymocyte development is 
being increasingly well defined as flow cytometry and genomics techniques 
become more sophisticated. The steps and regulation of human thymocyte 
development are not as well defined, but is presumed to occur in an analogous 
fashion. Flow cytometry and monoclonal antibodies have allowed for the 
fractionation of hematopoietic stem cells (HSCs) and their progeny from murine 
bone marrow, using a combination of cluster of differentiation (CD) molecules 
and SLAM markers. These populations can then be sorted, reconstituted in mice, 
and their gene expression profile determined. T-cells go through a regimented 
developmental program of commitment and differentiation steps before becoming 
functional lymphocytes (outlined in Figure 1). These steps are often defined by 
the presence or absence of T-lineage markers CD4 and CD8 on the cell 
surface(reviewed in26 and 27). 
 All blood lineages can be derived from the HSCs, which reside in the bone 
marrow and can be divided into two groups: long-term (LT-HSC) and short-term 
(ST-HSC)28,29. LT-HSCs have a surface expression profile of CD34-, Flt3-, 
lineage (Lin)-, c-Kit+, Thylo, Sca+, CD150/Slamf1+, CD48/Slamf2-30–36. These cells 
have unlimited self-renewal capacity and the potential to give rise to any blood 
   5 
lineage. ST-HSCs have a similar cell surface expression pattern with CD34 being 
expressed in addition to those on LT-HSC population. ST-HSCs have limited 
self-renewal capacity compared to LT-HSCs, but still have the capacity to give 
rise to all progenitors necessary for blood development (reviewed in37).  The HSC 
differentiates into the short-lived multipotent progenitor population (MPP)38 with 
the expression of Flt3 and then is able to give rise to the lymphoid-primed 
multipotent progenitor39 and common myeloid progenitors (LMPPs and CMPs, 
respectively). 
  The LMPP resides in the bone marrow and has the ability to spawn both 
the B and T lineages. LMPP cells that express CCR9, c-Kit, Sca, and Flt3 will 
egress and migrate to the thymus where they have the option to become a T-
cell(reviewed in40). The first stage of T-cell development is termed the double-
negative 1 (DN1) population and has a surface marker profile of Lin-, CD44+, 
CD25-, c-Kit+41. These cells are not fully committed to the T-cell lineage and may 
reverse at any time to differentiate into B-cells, natural killer (NK) cells, dendritic 
cells, mast cells, or monocytes42–44. The early thymic precursor (ETP) population 
is a subset of the DN1 population, can be found in and outside of the thymus, 
and has the cell surface expression pattern Lin-/CD4lo, Sca+, c-Kithigh, IL7Rα-, 
and CCR9+, and includes Flt3L+ and Flt3L- subsets41,45,46. There is also evidence 
that once an ETP cell no longer expresses Flt3L, it no longer has B-cell potential 
and has the ability to differentiate into a mature T-lymphocyte42,47. Notch1 
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signaling is required early on in these stages to commit these progenitor cells to 
the T-cell lineage48–50. 
T-cells physically move through the thymus as they change their 
differentiation status to express new markers and critical T-cell genes. The DN2 
population begins to express CD25 and decreases surface expression of c-
Kit(reviewed in51 and40). This population is divided into DN2a and DN2b subsets 
and is characterized by a massive burst of proliferation. DN2a cells are plastic, 
like the DN1 population, and are not fully committed to the T-cell lineage. DN2b 
cells can begin to express CD352 and can differentiate along the γδ or αβ T-cell 
lineages. Rag1/2 proteins begin to rearrange the T-cell receptor (TCR) δ, γ, and 
β loci to determine to which lineage the cell will differentiate53. Cells that do not 
successfully rearrange one of these loci will undergo apoptosis. Cells that 
rearrange the TCRβ locus will continue to develop in the thymus while less is 
known about the development of the γδ T-cells54.  
 Once the cells reach the DN3 stage in thymocyte development, they begin 
to express the TCRβ chain on the cell surface and decrease CD44 and Kit 
expression. At this point they are fully committed to the T-cell differentiation 
program and cannot reverse direction. This population can be divided into DN3a 
and DN3b cells based on CD27 expression and CD25 staining intensity53. DN3a 
cells undergo proliferation arrest and express a high amount of Pre-Tα on the 
surface to form the Pre-TCR complex with the TCRβ chain and promote positive 
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selection of the thymocytes55,56. Pre-TCR signaling is critical for cells to move 
past the DN3 stage in development as it starts a MAPK signaling cascade and 
activates phospholipase-C, which activate critical T-cell transcription factors such 
as Ets-1, Id3, Runx-1, NFAT, NFκB, Myb, Gata3, Gfi1, and Lef156–62. Cells at the 
DN3b stage increase CD27 expression and resume proliferation. Here they start 
to reduce the expression of Notch1 target genes and increase expression of 
more mature TCR complex members such as Zap70. Cells then move into the 
DN4 stage of development as they lose expression of CD2526,40. 
 Cells continue to proliferate as they rearrange the TCRα chain at the 
double-positive (DP) stage of thymocyte development. Here, cells will express 
both CD4 and CD8, preceded by a transient immature single-positive (ISP) 
stage. At this stage, thymocytes undergo both positive and negative selection 
before they can mature to either CD4 or CD8 single positive cells and enter the 
periphery63,64. Only approximately 5% of cells will make it all the way through 
development; most will die in the thymus65.  
 Recent evidence has shown that thymocytes do have an intrinsic ability to 
self-renew and that this traditional path from bone marrow to T-cell may not 
always be taken(reviewed in66). In times of stress or reduced thymic import, T-
cells are able to repopulate the thymus to prevent a shortage of mature T-cells in 
the periphery. The target cell for this self-renewal phenotype in normal 
thymocytes is controversial, but evidence shows that it probably does not reside 
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in the immature ETP population67,68. A more differentiated cell has an intrinsic 
ability to self renew, but will only do so if necessary, as using this method of 
thymic repopulation reduces heterogeneity in the T-cell receptor α and β 
chains67.  
Activation of oncogenes and loss of tumor suppressors drive T-ALL 
Identifying the underlying genetic mutations driving T-ALL is one step 
towards finding targeted therapeutics. Oncogenic events in T-ALL enhance 
proliferation, inhibit differentiation, and possibly promote self-renewal of 
thymocytes. T-ALL is a multi-step process and none of these events are ever 
implicated in isolation. In order for leukemia to develop, mutations must occur in 
two separate pathways: one involving cell proliferation and one that disrupts 
normal hematopoietic development69. Unlike other leukemias such as acute 
myelogenous leukemia (AML), chronic myelogenous leukemia (CML), and B-cell 
ALL (B-ALL), translocation events are rare in T-ALL, but usually involve the TCR 
when they do occur.  
Genetic profiling of hundreds of patient samples has revealed that T-ALL 
is often associated with mutations or overexpression of TAL1, LMO1, LMO2, 
HOX11, NOTCH1, c-MYC, TLX3, c-MYB, or LYL170–80. In addition to oncogene 
activation, there are a number of tumor suppressors that are inactivated in T-ALL 
patients and often result in activation of oncogenic pathways or loss of growth 
control. Mutations, deletions, and loss of heterozygosity have been found in 
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FBW7, PTEN, p16INK4a, p14ARF, p53, and IKAROS in T-ALL patient 
samples(reviewed in71). Loss of FBW7 and IKAROS can result in increased 
NOTCH1 signaling while loss of PTEN increases cell growth and metabolism 
through the activation of the PI3K pathway. Inactivation of p53, p16INK4a, and/or 
p14ARF results in loss of apoptosis or cell cycle control, which can then allow for 
oncogenic growth to go unchecked. 
Tal1 as an oncogenic driver of T-ALL 
 Tal1, also called SCL or TCL5, encodes a basic-helix-loop-helix (bHLH) 
transcription factor critical for hematopoiesis. Expression of Tal1 initiates in the 
mouse embryo at day 7.5 and is seen in the brain, endothelial cells, and the 
erythroid, mast, megakaryocyte, and myeloid lineages at that time81–83. Tal1 is 
absolutely essential for development of all blood lineages84,85. Tal1-null mice die 
at embryonic day 8.5-10 due to complete lack of blood and defects in yolk sac 
hematopoiesis86. Without Tal1, the embryo has defective angiogenesis and the 
organism is unable to form megakaryocytes or HSCs85–88. Tal1 is expressed in 
HSCs and MPPs, but expression in thymocytes is downregulated very early in T-
cell development. There is little to no detection of Tal1 expression after the 
DN1/DN2 stage in thymocyte development and the protein has no role in T-cell 
maturation89,90. 
 bHLH transcription factors are divided into two groups: Class I and II. 
Class I bHLH proteins can bind DNA as homodimers or heterodimers while Class 
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II proteins can only bind DNA as heterodimers with Class I bHLH proteins. Tal1 is 
a Class II bHLH transcription factor and binds DNA with E-proteins such as E2-2, 
E47, E12, and Heb91–93. This heterodimer then becomes part of a transcriptional 
complex in hematopoietic cells along with Lmo2, Ldb1, Gata1/2 and Sp194–96. 
Once bound to E-box/Gata sequences, the complex recruits transcriptional 
coactivators such as p30097 and p/CAF98, or transcriptional repressors such as 
mSin3A99 to modulate transcription. 
 T-ALL patient samples often misexpress TAL1 resulting from a variety of 
genetic events, not all of which are well understood. Rare translocation events 
have been reported, one of which brings TAL1 into the TCRδ locus 
(t(1;14)(q33;11))100 and one which brings it into the TCRβ locus 
(t(1;7)(p32;q35))101. In approximately 20% of T-ALL patients, a 90kb genomic 
deletion event occurs which deletes the TAL1 proximal promoter and places 
TAL1 within range of the SIL promoter, which is strongly expressed in a variety of 
tissues, including the thymus102–104. These cryptic deletions only occur in αβ T-
cells, suggesting that the same machinery is used to create the SIL deletion as 
T-cell gene rearrangement105. It is estimated that 60% of pediatric and 45% of 
adult T-ALL patients express TAL1, so there is clearly a large portion of patients 
where Tal1 is misexpressed by an unknown mechanism104. 
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Tal1 mouse models of T-ALL 
 Because of the high frequency of TAL1 expression in patients, mouse 
models of T-ALL have attempted to use Tal1 as a driver of the disease, however 
few have been successful. The CD2 promoter106 expressed in early T-cell 
development and the SIL (Scl Interrupting Locus promoter)107,108 have been used 
to transgenically drive the expression of Tal1 in the thymus, but none of the mice 
developed T-ALL. When the Lck promoter (expressed at the DN2/DN3 stage of 
thymocyte development) was used to drive Tal1 expression in mice, 27% of the 
mice developed a lymphoblastic disease similar to T-ALL with T-cell blasts found 
in the thymus, kidney, liver, spleen, bone marrow, and central nervous system of 
the animals. The average latency of disease for these mice was 9-10 months, 
indicating that there must be additional oncogenic events that cooperate with 
Tal1 before disease is initiated109.  
 In T-ALL patients, TAL1 is found coordinately expressed with LMO1, 
LMO2, NOTCH1, and c-MYC as well as loss of the p14/ARF and p16/INK4A 
tumor suppressors(reviewed in71). In the Lck-Tal1 model of T-ALL, retroviral 
mutagenesis was performed with Moloney murine leukemia virus (MoMLV), 
which identified Notch1, c-Myc, and a dominant negative form of Ikaros as 
cooperating events in Tal1-driven T-ALL110. In the same mouse model, 
heterozygous loss of the INK4a/Arf locus accelerated leukemia development and 
increased disease penetrance to 100%111. The same was found when Lck-Tal1 
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mice were mated to mice that expressed Lmo1 or Lmo2 in the developing 
thymus112,113. In T-ALL, Tal1 is oncogenic, but must cooperate with other events 
in order to successfully initiate disease. These events include, but are not limited 
to, the loss or epigenetic silencing of the Ink4a/Arf locus, activation of the Notch1 
pathway, and missexpression of Lmo1/2.  
When Tal1 is misexpressed in the developing thymus, T-cell differentiation 
is blocked at the DN3 stage of thymocyte development114. At this stage, critical 
events take place that commit thymocytes to maturation: TCRβ is rearranged and 
the pre-TCRα complex is assembled. These events take place with the help of 
the Rag1/2 proteins, which rearrange the DNA at the TCR loci to produce 
successful signaling proteins(reviewed in40). There is evidence that Tal1 
expression at this stage disrupts the transcriptional activity of E-proteins such as 
E47 and HEB91,114. These E-proteins can drive the transcription of Rag 1/2114,115 
as well as other T-cell development genes such as PreTα116 and CD4117. The 
DNA-binding activity is not required for the development of T-ALL112,118, so it is 
probable that Tal1 binds the E-proteins and sequesters them away from the 
promoter, resulting in decreased transcription of genes like Rag1/2, PreTα, and 
CD4. This idea was further confirmed when Lck-Tal1 mice were mated to Heb+/- 
and E47+/- mice and the developmental block was enhanced and T-ALL was 
accelerated 114. 
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Tal1 promotes gene expression as a member of a transcriptional complex 
 Recent ChIP-seq and microarray expression data in T-ALL patient 
samples and human cell lines point to an even more complex regulatory circuit. 
In erythroid cells, TAL1 and E-proteins bind E-boxes often adjacent to GATA1 
sites to initiate transcription. However, in T-ALL, ChIP-seq experiments have 
shown that TAL1 binds E-boxes not only adjacent to GATA3 sites, but also 
RUNX and ETS sites. The TAL1 complex in T-ALL cells also contains RUNX1 
and Ets as members119,120. RUNX1 (and RUNX3) and ETS are critical genes in 
T-cell differentiation58,121,122, but their roles in T-ALL initiation and maintenance is 
unclear. In T-ALL, the TAL1 complex has been shown to inhibit differentiation, 
apoptosis, and tumor suppressor genes119,120, all of which contribute to the 
pathogenesis of the disease. These new data indicate that TAL1 not only acts as 
an inhibitor of normal E-protein function, but also can drive de novo transcription 
of a distinct set of target genes.  
Lmo2 collaborates with Tal1 to initiate leukemia 
The LIM-only domain proteins LMO1/2 are misexpressed in 80% of T-ALL 
patients positive for (or expressing) TAL1, and LMO2 misexpression alone is 
found in 9% of T-ALL patients70,71,123. The protein was discovered after mapping 
the t(11;14)(p13;q11) translocation in T-ALL, in which RAG proteins rearrange 
the LMO2 locus into the TCR locus70,124–126. LMO2 was also implicated as the 
oncogenic driver in leukemias resulting from gene therapy of SCID-X1 patients. 
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In four patients, retroviral insertion at the LMO2 locus induced T-ALL after a long 
latency127–130. 
 LMO2 is critical for normal hematopoiesis and forms a complex with 
TAL1/SCL, GATA-1, and LDB1 at erythroid gene promoters in order to drive 
hematopoietic gene expression95,131,132. Lmo2-null mice fail to survive past 
embryonic day 10.5 due to major defects in yolk sac erythropoiesis, a result that 
parallels Tal1-null mice 133. While it does not bind DNA directly, LMO2 is 
considered a transcription factor that activates and represses target genes by 
binding with different protein complexes(reviewed in134,135).  
Lmo proteins have been shown to cooperate with Tal1/Scl to accelerate 
leukemia in mice112,113 and this cooperation is not dependent on the DNA-binding 
activity of Tal1112. The differentiation block seen in the bi-transgenic mice is more 
pronounced than with either oncogene alone, suggesting that Lmo1/2 help Tal1 
sequester proteins from the promoter of genes critical in T-cell differentiation. 
Transgenic expression of Lmo2 alone in mice is also sufficient to initiate T-ALL at 
low penetrance and after long latency112,136. McCormack and colleagues also 
showed that forced Lmo2 expression early in the developing thymus results in 
aberrant self-renewal of thymocytes137, which could potentially explain the long 
latency found in the SCID-X1 patients and mouse models. The expression of 
LMO2 in these patients could allow the target cells time to accumulate secondary 
mutations in proliferation pathways, thus leading to leukemic transformation. 
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Notch1 structure and signaling 
 Notch1 is a prominent oncogene in T-ALL, with activating mutations found 
in every subtype of patients analyzed138. Notch1 is a single pass transmembrane 
receptor first described in Drosophila melanogaster in 1917 when a heterozygous 
mutation resulted in a notched wing phenotype (Morgan 1917). Since then, 
countless experiments have been conducted in flies (Drosophila melanogaster), 
worms (Caenorhabditis elegans), and mammals to elucidate Notch1 structure 
and function. There are four Notch homologues in mammals, designated Notch1-
4, and all have diverse functions in lineage commitment, developmental 
pathways, and human malignancies139–143. 
Notch1 and Notch2 are broadly expressed throughout the body while 
Notch3 and Notch4 are more restricted. Notch1 is expressed in the brain, liver, 
bone marrow, heart, lung, thymus, kidney, stomach, intestine, eye, skeletal 
muscle, and spinal cord. Notch2 is expressed in the brain, kidney, liver and 
stomach. Notch3 expression is restricted to smooth muscle, central nervous 
system and hematopoietic cells while Notch4 is solely expressed in vascular 
endothelial cells. This varied expression pattern can control the temporal and 
spatial patterning of Notch1 signaling in vivo(reviewed in144). 
 Notch1-4 bind five different ligands that are most often expressed on 
adjacent cells: Jagged1 (Jag1), Jagged 2 (Jag2), and Delta-like 1,3,4 
(Dll1,3,4)145–147. The ligands have a very similar structure to one another, with 
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Jag1 and Jag2 expressing an increased number of EGF repeats compared to the 
Dll ligands and also containing a cysteine-rich region that aids in protein 
interactions and signal transduction145.  
  The Notch receptors have two main functional domains: the extracellular 
(NEC) and transmembrane domains (NTM)148. The NEC domain contains EGF 
repeats and a negative regulatory region (NRR) for ligand recognition149. The 
NRR contains the heterodimerization domain (HD) and a series of Notch repeats. 
The NTM domain contains RAM and ankyrin repeat (ANK) domains for protein 
interactions150,151. Notch1 and Notch2 contain sizeable transactivation (TAD) 
domains, but these are much smaller and less important in Notch3 and 
Notch4152. All the Notch receptors also contain a PEST domain at the C-terminus 
of the NTM, which controls receptor turnover153.  
 Three cleavage events take place in order to release the Notch1 
intracellular domain (ICD) that is capable of activating target genes (Figure 2). 
The first event takes place in the Golgi as the final step in the protein maturation 
process. A Furin protease cleaves the NEC from the NTM; these two domains 
will remain covalently linked as they make their way into the plasma membrane 
at the cell surface148. Upon ligand binding154–156, TACE, a member of the ADAM 
family of proteases, cleaves the NEC from the NTM at the HD region157. This 
then signals the gamma-secretase complex, which cleaves the NTM at Valine 
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1744, thus releasing the ICD from the membrane. The nuclear localization 
sequence (NLS) then allows translocation the ICD to the nucleus158. 
 The Notch1 ICD, also called ICN1, binds CSL (named for CBF1/RBPJ in 
mammals, Suppressor of Hairless in D. melanogaster, Lag1 in C. elegans) in the 
nucleus along with coactivators Mastermind-like 1 (MAML) and CBP/p300159–161. 
CSL is a transcriptional repressor that binds DNA at the consensus site 
TGGGAA almost constitutively162,163. When ICN1 is not present, CSL is bound 
with repressors such as KyoT2, CIR, N-Cor/SMRT, SKIP, Sin3A, SAP18, SAP30, 
RBAp46/48, or HDACs164–169. ICN1 displaces these repressors on its specific 
target genes such as Deltex1, Notch3, Nrarp, Prtcra, Cyclin D3, p21, c-Myc, 
CDK4/6 and CD25 and activates their transcription110,170–172. Recent structural 
evidence has shown that Notch1 must dimerize at the promoter of some of its 
target genes critical for T-cell development and leukemogenesis, such as Pre-Tα 
and c-Myc, but not others, such as Hey1 and CD25173. This indicates that Notch1 
transcriptional activation is more complex than previously thought, and could 
reveal another layer of transcriptional regulation. 
Regulation of Notch1 signaling 
 Because of their role in so many critical developmental processes, tight 
regulation of the Notch receptors is required for the control of apoptosis, 
proliferation, differentiation, and self-renewal. This is accomplished by a few 
different mechanisms and can be cell-type specific. The Fringe family of 
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enzymes (Lunatic, Manic, and Radical) modifies the EGF repeats on the Notch 
receptors, which result in changes in ligand binding specificity174,175. In general 
these modifications result in increased interactions with Dll ligands and 
decreased affinity for Jag ligands176 . Depending on the cell type and availability 
of ligands, these modifications could increase or decrease Notch signaling.  
 The regulation of Notch protein stability is an additional way cells control 
the amount of Notch signaling at any given time. This is accomplished by three 
main proteins: Itch, Numb, and Fbxw7. Itch Is an E3 ligase of the HECT family 
that targets Notch proteins for degradation by the lysosome177–179 and Numb is a 
protein that negatively regulates Notch by recruiting ubiquitination machinery 
such as Itch to the Notch1 receptor180. 
 Fbw7 (also called Fbxw7, Sel-10, or hCdc4) controls Notch1 protein 
stability by degrading Notch through the ubiquitination-proteasome pathway181–
184. Fbw7 is a member of the Skip-Cullin-Fbox (SCF) degradation complex, an E3 
ubiquitin ligase complex that targets the protein for degradation in the 
proteasome185. The CyclinC/CDK8 complex is recruited by MAML and 
phosphorylates Notch1 in the TAD and PEST domains. Fbw7 then binds the 
phosphorylated residues in the PEST domain, targeting it for degradation186. 
Fbw7 and the SCF complex also target other proteins such as Cyclin E, c-Myc, c-
Jun, and mTOR for degradation187–190. Fbw7 often undergoes inactivating 
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mutations in T-ALL that results in increased stability of these oncogenes, 
underscoring the importance of Fbw7 in controlling cell growth.  
Notch1 signaling in development 
 Notch receptor signaling is critical for many developmental pathways, as 
demonstrated by the embryonic lethality of Notch1 and Notch2 knockout mice, 
which die by embryonic day 11.5191,192. Ligands Dll1, Dll4, and Jag1 are also 
critical for development, as knockout mice die from embryonic day 9.5-12.5 from 
various defects193,194. Notch3 and Notch4 are less crucial for developmental 
processes as whole body knockout mice are viable, however they do often 
present with vascular defects195. In humans, Alagille Syndrome is characterized 
by a JAG1 deletion. Patients with this syndrome present with liver, heart, eye, 
bone, and kidney defects, pointing to the broad role of NOTCH signaling in 
human development196,197. There is also a stroke disorder called CADASIL 
(cerebral autosomal dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy) that is characterized by mutations in the Notch3 gene198. 
 Notch1 signaling is required for the successful commitment of several 
different lineages in mammals. In skin, Notch1 is involved in follicle development 
by maintaining the epithelial stem cells and is thought to maintain pigment cells. 
There has also been a role reported for activated Notch1 in the pathogenesis of 
melanoma(reviewed in199).  In contrast, loss of CSL or Notch1 results in 
hyperkeratinization of the epidermis and squamous cell carcinoma. Because 
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Notch1 can act as both an oncogene and a tumor suppressor in the 
skin(reviewed in200), this points to an important role for Notch signaling in 
maintaining the balance of specialized cells in the skin201–203. In the vasculature, 
Notch1 signaling pushes vascular endothelial cells towards an arterial fate 
instead of a venous one. In animals where Notch1 signaling has been perturbed, 
there is often an imbalance in arteries and veins resulting in severe vascular 
defects195,204,205. Finally, in the intestine, Notch1 signaling controls the balance of 
absorptive enterocytes and secretory goblet cells. Notch1 signaling promotes the 
formation of enterocytes at the expense of goblet cells and Notch1 inhibition 
through use of gamma-secretase inhibitors switches this fate to an increase in 
goblet cells. This results in gastrointestinal toxicity due to excessive mucus 
secretion and lack of nutrient absorption206–208. 
 In lymphopoiesis, Notch1 is required for the specification of the T-cell 
lineage over the B-cell lineage. Conditional Notch1 knockout mice have a 
decrease in overall T-cells and a huge increase in B-cells while Notch1 
overexpression models show the opposite phenotype49,209,210. Ligands Jag1, 
Jag2, Dll1, Dll3, and Dll4 are expressed on thymic epithelial cells as well as the 
bone marrow stroma, facilitating the Notch1 signaling cascade27,140,144,211–213. 
Notch1 is especially critical at specifying T-cell lineage commitment at the DN1 
stage of development. At this stage, DN1 cells can still become B-cells if Notch1 
signaling does not promote T-cell differentiation41,43,171,214. Notch1 signaling is 
required through T-cell development up through the DN3 stage at which point it is 
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downregulated. Conditional knockout mice showed a developmental block at the 
DN3 stage and defects in TCR signaling, pointing to a critical role of Notch1 at 
this particular stage in development210,215. 
 Self-renewal of stem cells is critical for maintaining adult tissues and 
emerging evidence suggest a role for self-renewal in malignancy. Stem cells are 
defined as cells that have the ability to generate an unlimited amount of daughter 
stem cells (self-renewal) and still are able to expand and differentiate into a 
desired tissue(reviewed in216,217). Notch1 signaling is required for the 
maintenance of several types of adult tissue stem cells from neuronal to 
endothelial to mammary and intestinal lineages206,218–222. In the neuronal stem 
cell (NSC), Notch signaling is required for the maintaining stem cell numbers, as 
evidenced by knockout mice that displayed a decreased number of NSCs221,222. 
Similarly, in the intestine, loss of CSL confers a decrease in intestinal stem cell 
number while forced expression of Notch1 results in stem cell hyperplasia206. 
 The role of Notch1 signaling in HSCs is a current topic of debate. It is 
clear that Notch1 is required for generation of HSCs in the embryo, but it is less 
clear whether Notch1 is required for the maintenance of HSC self-renewal in the 
adult223.  Increasing Notch1 signaling results in a block in differentiation 
consistent with an increase in HSCs and increased HSC self renewal ex vivo224–
226. However, loss of Notch1 signaling either by dominant negative (DN)-MAML 
or genetic deletion of Jag1 or Notch1 itself has no effect on HSC self-
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renewal227,228. A recent report of Itch-/- mice implicates Itch in the negative 
regulation of HSCs. Itch-/- mice harbored HSCs with increased proliferative 
capacity coordinate with increased Notch1 signaling, but retained self-renewal 
capabilities229. This suggests that Notch1 plays a role in maintaining the number 
of HSCs in the bone marrow, but does not alter the self-renewal capacity of the 
cells. Another report suggests that Notch2 is in control of HSC homeostasis, but 
neither Notch2 nor Notch1 have any role in HSC self-renewal once homeostasis 
is reached230. Overall, there is still controversy surrounding the exact role of 
Notch1 in hematopoiesis, but these data along with the requirement for Notch1 
signaling in the development of T-cells, marginal zone B-cells, and 
megakaryocytes(reviewed in171) could indicate that Notch1 signaling only plays a 
role in promoting the differentiation and proliferation of the HSCs. 
Notch1 is a prominent oncogene in T-ALL 
 The NOTCH1 pathway is upregulated in approximately 70% of T-ALL 
patients either by activating mutations in the NOTCH1 receptor itself (50%) or by 
inactivating mutations in the negative regulator FBW7 (20%)71,74,231–233. NOTCH1 
was discovered as an oncogene in T-ALL when the t(7;9)(q34;q34.3) 
translocation was mapped. This translocation is very rare in T-ALL and the 
subtype only accounts for 1% of T-ALL cases. The translocation puts NOTCH1 
into the TCR locus resulting in a truncated NOTCH1 protein with the strong TCR 
enhancer234.  This allele, sometimes called the TAN1 allele, has been shown to 
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transform cells in vitro and also results in a T-ALL disease in vivo when 
transduced into adult bone marrow235–237. It has been shown that the ANK, TAD, 
and NLS are all required for this transformation event163,238. 
 Most of the NOTCH1 mutations found in T-ALL patient samples have 
been mapped to either the HD or PEST regions of the receptor. HD mutations 
result in ligand-independent cleavage of the receptor while PEST mutations 
result in increased ICN1 protein stability138,182,239. These mutations can occur 
together in the same patient either on the same or separate alleles. When these 
two mutations occur on the same allele, a 10-fold increase in NOTCH1 reporter 
activity has been observed138. A 5’ deletion event that mimics an HD mutation 
was reported in one patient sample (1/69), but it is unclear how common these 
events are in the human disease240. In a small subset of patients with mutant 
NOTCH1 (3%), a tandem duplication of the JME region occurs resulting in ligand 
independent activation241. These NOTCH1 alleles found in patients have not 
been shown to be transforming on their own in mouse models and are not as 
strong as the ICD resulting from the TAN allele. However, these alleles have 
been shown to cooperate and accelerate disease in a model of K-Ras induced T-
ALL242. This implies that while NOTCH1 mutations are prevalent in T-ALL 
patients, these mutations are rarely initiating events; additional mutations must 
occur before a cell is fully transformed. 
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 NOTCH2 mutations have not been found in patient samples, but alleles 
have been found that are able to transform immortalized rat kidney cells235. 
NOTCH2 has the potential to be oncogenic, but appears to be irrelevant in terms 
of human T-ALL. NOTCH3, however, has been shown to be mutated in a subset 
of relapsed T-ALL patients243. This oncogenicity has been confirmed in a mouse 
model as well where Notch3 was overexpressed in murine bone marrow and 
resulted in a T-ALL like disease244. 
 Activating Notch1 mutations have also been found in several mouse 
models of T-ALL113,245–248. In the Lck-Tal1 model, Notch1 mutations were found 
in 74% of the leukemias examined. Most of these mutations (91.5%) were found 
in the PEST domain while HD mutations were quite rare (8.5%)248. In this same 
model, however, many T-ALLs have upstream intragenic deletions in the Notch1 
locus that essentially mimicked the HD mutations found in patient samples(249 
and Chapter III). So while murine leukemias do not often harbor HD mutations for 
ligand-independent Notch1 cleavage, they have adapted a unique mutation event 
to end at the same result250. In the Lck-Tal1/Lmo2 and the pSil-TSCL/Lck-LMO1 
mouse models of T-ALL, Notch1 mutations were also found in preleukemic thymi, 
confirming that Notch1 mutations are a critical transforming feature of murine T-
ALL113,251. The Lck-Tal1 T-ALLs were sequenced for mutations in the other 3 
Notch receptors, but no mutations were found, solidifying a unique role for 
Notch1 in the pathogenesis of T-ALL248. 
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GSI as an anti-leukemic agent 
 The gamma-secretase (γ-secretase) complex initiates the final cleavage 
event that releases the NICD from the cell membrane so that it is able to 
translocate to the nucleus and activate target genes (Figure 2). The complex is 
composed of four essential proteins: nicastrin, presenilin, APH-1, and PEN-
2158,252–254. Notch1 is not the only substrate of the γ -secretase complex; it also 
cleaves Notch1 ligands, ErbB4, CD44, growth hormone receptor, N-cadherin, E-
cadherin, and amyloid precursor protein255–258. In T-ALL, administration of γ -
secretase inhibitors (GSIs) to murine cell lines results in a G1 cell cycle arrest 
and apoptosis110,246. Human cell lines are not as sensitive, but most do achieve 
the G1 cell cycle arrest after extended treatment172,259,260. Treatment of moribund 
mice with GSIs significantly extended survival261 and GSIs have been shown to 
decrease disease initiation in vivo when cells were pretreated with GSI in 
vitro251,262. 
 GSI treatment of T-ALL cell lines and primary mouse tumors results in 
decreased Notch1 expression and decreased expression of known Notch1 target 
genes110,251,261. This effect is very similar to that of overexpression of DN-
MAML263. In T-ALL, forced Notch1 expression is sufficient to rescue the cell cycle 
arrest observed with GSI treatment, suggesting that the other substrates of the γ-
secretase complex are not significantly affected by GSI in this cell type110. c-Myc 
will also rescue the phenotype110,172,259, but other Notch1 target genes such as 
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Hes1 and Hes5 have no effect263. Partial rescue of the GSI phenotype was seen 
with forced expression of Cyclin D3 and CDK4/6, which was probably not 
complete due to upregulation of CDK inhibitors such as p27 upon GSI 
treatment170. 
 Other methods to inhibit Notch1 and/or NICD are being investigated, but 
none have been entirely effective(reviewed in264). Monoclonal antibodies against 
human NOTCH1 have made it to clinical trials, but other ideas such as DN-
MAML mimics265,266 and ADAM protease inhibitors267 have not. Unfortunately, 
GSIs have not been very successful in the clinic due to on-target gastrointestinal 
toxicity. Because of the critical expression of Notch1 in the intestinal enterocytes, 
GSIs force a lineage switch to goblet cells and this causes massive diarrhea in 
patients accompanied by temporary hair loss and hair pigment loss208,268. These 
trials used a continuous administration of GSI. It has recently been shown that an 
intermittent dosing regimen may decrease gastrointestinal toxicity while not 
compromising efficacy261. Clinical trials with this dosing regimen have been 
completed in breast cancer and melanoma, but results have not yet been 
released269,270. It is also possible that administration of glucocorticoids along with 
the GSI will help abate these side effects with an added bonus of the steroids 
having intrinsic anti-leukemic activity208. Bristol-Myers-Squibb have begun a 
clinical trial with a GSI-dexamethasone combination for the treatment of T-
ALL271.  
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c-Myc expression is oncogenic in T-ALL 
 c-Myc is a direct transcriptional target of Notch1, as shown through GSI 
rescue experiments, chromatin immunoprecipitation (ChIP), and gene expression 
arrays110,172,259. Forced expression of c-Myc rescues the G1 arrest and apoptosis 
phenotype caused by GSI treatment in both human and mouse T-ALL cell lines. 
Both human and mouse T-ALL cell lines often have deletions or epigenetic 
modifications in the p53 and/or Ink4Arf loci, thus counteracting the 
overexpression of c-Myc71,111,272. Rescue does not occur in 100% of lines (8/10 
mouse lines, 3/5 human lines)110, however, indicating that while c-Myc is 
important to Notch1-induced T-ALL, it is not the only critical target gene for the 
pathogenesis of the disease. 
 c-Myc is an immediate early response gene for many ligands and cellular 
processes including Notch1, Wnt, and many receptor tyrosine 
kinases110,172,259,273–276. The gene was first discovered by a translocation event in 
Burkitt’s lymphoma, t(8;14), which juxtaposes the c-MYC locus and the IgH 
enhancer, driving its overexpression in B-cells277–279. c-Myc is also the cellular 
homologue of the v-myc oncogene in the avian myelocytoma virus MC29, which 
causes leukemia and sarcoma in chickens280,281. 
 Overexpression or deregulation of c-Myc is found in approximately 70% of 
human cancers. In addition to Burkitt’s lymphoma, c-Myc is implicated in the 
pathogenesis of multiple myeloma, colon, breast, and mast cell tumors(reviewed 
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in282). In multiple myeloma, c-Myc activation is accomplished by translocations 
into the IgH, IgL, and Igκ loci or by amplification events283. In other cancers, c-
Myc expression is upregulated by driving oncogenic activation of the Wnt-APC 
pathway in colon cancer276 or the Notch1 pathway in T-ALL110,172,259. Ectopic 
expression of c-Myc can transform mouse embryonic fibroblasts in conjunction 
with additional oncogenes284 and forced c-Myc expression in transgenic mice 
results in a variety of malignancies285–287. In most mouse models, however, 
secondary events are required for malignancy, as mice present with disease after 
a long latency288–290.  
c-Myc structure and regulation 
 c-Myc is a basic-helix-loop-helix leucine zipper (bHLH-Zip) transcription 
factor which binds E-box sequences as a dimer with the bHLH-Zip transcription 
factor Max291–295. In normal cells, c-Myc promotes cell cycle progression and 
contributes to growth-related pathways such as ribosome biogenesis, nucleotide 
metabolism, DNA replication, and RNA processing(reviewed in282). c-Myc mostly 
activates target genes at the transcriptional level, however it can also modulate 
protein expression by activating oncogenic miRNAs such as miR-17-92 cluster, 
and inhibiting tumor suppressor miRNAs, such as let-7296–298. It is also thought 
that c-Myc has a non-transcriptional role in cap-dependent translation, although 
this is not entirely understood299,300. Finally, c-Myc can act as a transcriptional 
repressor. Although the precise mechanism and conditions under which this 
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occurs in not clear, it is thought that c-Myc binds to Miz-1 to inhibit a subset of 
target genes275,301. 
 Because of its critical role in many growth pathways, c-Myc is normally 
under tight regulation to prevent overgrowth of cells and development of cancer. 
When c-Myc is overexpressed, cells undergo apoptosis through the p53-ARF 
pathway302,303 and through p53-independent mechanisms304,305. c-Myc 
expression is activated at the transcriptional level, and in some cases is 
regulated at the transcriptional level306. Secondary DNA structures can slow 
down the transcription of c-Myc mRNA and the binding of bromodomain proteins, 
such as Brd4, to activated histones can increase transcriptional elongation by 
recruiting Pol II, Mediator, and additional factors. In the absence of Brd4, 
transcription at the c-Myc promoter is drastically decreased307,308. c-Myc 
expression is controlled at the protein level by having a very short half-life of 15-
20 minutes309,310. c-Myc is phosphorylated at Ser62 and Thr58, often by GSK3β, 
which recruits the E3 ligase Fbw7 and targets the protein for degradation in the 
proteasome311,312. In malignancy, many tumors have adapted ways to decrease 
either or both of these steps to ensure that c-Myc protein levels remain high in 
tumor cells and maintain a rapid growth program.  
c-Myc controls proliferation of hematopoietic stem cells 
 In adult hematopoietic stem cells, c-Myc is required for commitment to 
terminal differentiation but not self-renewal of the stem cells. Loss or reduction of 
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c-Myc results in an accumulation of the HSC pool while overexpressing c-Myc 
results in a decrease in HSCs313. Consistent with this, when c-Myc expression is 
reduced, there is a decrease in differentiated cells from the lymphoid and myeloid 
lineages and an accumulation of p21, a cell cycle inhibitor. Therefore, c-Myc is 
required for pushing HSCs into the cell cycle in order to promote the formation of 
differentiated blood lineages314. This balance is controlled by the Fbw7-targeted 
degradation of c-Myc; Fbw7-null HSCs mimic the phenotype of c-Myc 
overexpression315,316.  
c-Myc also mediates the release of HSCs from the hematopoietic niche in 
the bone marrow, which helps them to mobilize and differentiate. When c-Myc 
protein levels were decreased in the bone marrow of mice, increased expression 
of N-cadherin, a cell surface adhesion molecule, correlated with the HSC 
accumulation314. Recently, it was shown that c-Myc plays a similar role in the 
CML L-IC. Increased c-Myc resulted in the switch from quiescence to 
proliferation in the L-IC population and sensitized cells to Imatinib 
treatment317,318. Likewise, in T-cell development, c-Myc is required for the 
proliferative burst in DN3/DN4 cells before the DP stage in development, but not 
for the self-renewal of these cells319. 
The c-Myc transcriptional signature 
 Many high-throughput technologies have been used to try and define a 
specific c-Myc signature, but none have truly succeeded. One group defined a 
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Myc-dependent serum response (MDSR)320 list that contained genes involved in 
growth pathways while other groups have shown a Myc core signature (MCS)321 
of 50 genes induced by c-Myc, with the most prominent pathway involved being 
ribosome biogenesis. Interestingly, the MCS is cell-type specific. Whole genome 
analysis revealed that the c-Myc preferred E-box 5’-CACGTG-3’ is the most 
frequent DNA-binding motif in the entire human genome322. It is estimated that at 
any given time, 15% of the genome is occupied by the c-Myc transcription 
factor323.  
 Because there seems to be no definitive c-Myc signature and so much of 
the genome is transcribed by c-Myc, researchers hypothesized that c-Myc could 
be a universal transcriptional amplifier and not necessarily a specific transcription 
factor. c-Myc has also been shown to recruit p-TEFb, a transcriptional elongation 
factor, to active promoters and initiate Pol II pause release, which contributes to 
this theory324. Recently, using ChIP-seq to c-Myc and Pol II, mRNA 
quantification, and analysis of active histone marks, two independent groups 
found that c-Myc is indeed a transcriptional amplifier in many cell types, including 
T-cells325,326. c-Myc overexpression leads to overall increased levels of mRNA in 
cells and amplifies the existing transcriptional programs of each given cell type. It 
still seems as though c-Myc regulates proliferation and overall biomass 
accumulation in a cell-dependent manner, i.e. when expressed in T-cells, c-Myc 
will amplify T-cell genes to promote proliferation321. 
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c-Myc as a target for therapeutics 
 While many tumors use c-Myc expression to promote proliferation and cell 
growth, not all of these tumors are addicted to c-Myc. In a normal, non-Myc 
addicted cell, c-Myc inhibition causes the cell to retreat to the G1 phase of the 
cell cycle327. In general, these cells will not die due to withdrawal of c-Myc. In a 
cell where c-Myc is overexpressed by translocations, amplifications, or additional 
oncogenes, cells often undergo apoptosis upon c-Myc withdrawal328,329. Tumors 
will often regress after c-Myc withdrawal, some to the point of cure even after 
brief withdrawal periods330. When this happens, tumors are said to be addicted to 
c-Myc. This addiction allows for a therapeutic window where normal cells should 
not be affected by c-Myc inhibition. 
 The fact that c-Myc is aberrantly expressed in approximately 70% of 
human cancers coupled with this recent data demonstrating that c-Myc is a 
universal amplifier makes c-Myc a very desirable target as a cancer therapeutic. 
In theory, if one could fully inhibit c-Myc in a tumor, it is possible that this would 
also inhibit other active oncogenic pathways by reducing the total mRNA of 
targets within those other pathways. Inhibition of BET bromodomain proteins, 
which activate c-Myc expression307,308, has been successful at inhibiting c-Myc 
transcription in murine models of multiple myeloma307 and AML331 as well as cell 
lines derived from human hematopoietic malignancies. There have also been 
attempts at developing small molecules to inhibit Myc-Max interactions, but these 
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have not as been successfully tested in in vivo models of disease332,333. 
Researchers are also screening drugs that target known Myc target genes as 
well as synthetic lethal genes334,335. Inhibiting c-Myc in human cancers may result 
in decreased tumor burden, but it remains to be seen if these therapeutics could 
eradicate disease by inhibiting the initiating cells. 
Leukemia-initiating cells often follow a cancer stem cell, hierarchical model 
 Leukemia-Initiating cells (L-ICs) are thought to facilitate relapse in multiple 
malignancies, including T-cell acute lymphoblastic leukemia (T-ALL)113,251,336,337. 
L-ICs are a rare population of leukemic cells that possess the ability to initiate 
disease in recipient mice, differentiate, and self-renew. These cells are thought to 
be resistant to conventional therapies and therefore able to repopulate disease 
once treatment is ceased, mediating relapse. In hematopoietic malignancies, the 
L-IC is often found to be a phenotypically immature cell such as a stem cell or a 
transformed progenitor cell(reviewed in217). There is still controversy in the field 
as to whether an L-IC could arise from a more mature cell, and there are cases 
of initiating activity found throughout the developmental hierarchy, such as in 
melanoma and B-ALL. A summary of the controversy in the field is highlighted in 
different models for tumor/leukemia heterogeneity (Figure 3).   
Pathways that drive L-IC proliferation, survival, and maintenance are likely 
similar to those that drive the differentiated leukemia, as many models suggest 
that leukemia arises from a small pool of L-ICs. Evidence also suggests that 
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pathways critical for stem cell maintenance may be involved in L-IC survival and 
self-renewal(reviewed in338). Levels of Pten expression have been shown to 
maintain the balance between normal stem cells and leukemia-stem cells (LSC), 
thus implicating PI3K/Akt/mTOR signaling in LSC survival and proliferation339,340. 
Aberrant expression of HSC genes such as Lmo2 in T-ALL137 and upregulation of 
Wnt signaling in CML have also been implicated in L-IC generation and self-
renewal341. In general, an L-IC must have genetic mutations in at least one set of 
genes that deregulate/block differentiation and in another pathway that promotes 
rapid proliferation of the cells. 
L-ICs were first described in AML as a population of patient cells able to 
initiate disease in non-obese diabetic/severe combined immunodeficient 
(NOD/SCID or NS) mice. This L-IC population expresses CD34 on the surface of 
cells, but not CD38, a phenotype very similar to normal HSCs342–344. Most 
subtypes of AML are organized in a hierarchical manner, like normal 
hematopoiesis, with the initiating mutation(s) occurring in the HSC. The inherent 
capacity of self-renewal found in the HSC is very important because it results in 
the long-term persistence of the stem cell, allowing the accumulation of multiple 
mutations in oncogenes and tumor suppressors that can eventually lead to 
malignancy(reviewed in345).  
 Recently, there has been increasing evidence that L-ICs can also arise 
from committed progenitor populations. Mouse models of AML have shown that 
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expression of fusion proteins such as MLL-ENL346, MLL-GAS7347, MLL-
AF9348,349, MOZ-TIF2350, and Cbfβ-SMMHC351 are able to transform progenitor 
cells with little or no inherent self-renewal capabilities. Similar to these AML 
subtypes, CML L-ICs also originate in a progenitor population352,353. In both 
mouse models and patient samples, granulocyte-macrophage progenitors 
(GMPs) gain the ability to self renew by activation of the β -catenin pathway 
through mutation of its negative regulator Gsk3β341. Progenitor populations have 
vast proliferative capabilities, as well as the ability to differentiate, but must 
somehow acquire the ability to self renew through transforming mutations if they 
are to become successful L-ICs. Identifying these mutations that confer self-
renewal properties may be one way to target the L-ICs in human malignancy. 
 Murine T-ALL L-ICs arise from a committed thymic progenitor, in a subset 
of the DN3/4 stage of thymocyte development113,251.  In xenotransplantation 
assays, functional activity of T-ALL patient samples has also been analyzed. An 
immature progenitor population defined by surface markers was found to be 
capable of initiating disease in immunodeficient, NOD/SCID/IL2γ-/- (NSG) mice. 
Researchers sorted CD34+ (found on HSCs) and CD7+ (a human marker for 
immature T-cells) cells and found that these cells were enriched in disease 
initiating activity compared to their CD7- or CD34-negative counterparts354. The 
NOTCH1 pathway, active in T-cell progenitors, was also shown to be involved in 
human T-ALL initiation in NSG mice262,355. It is possible for T-ALL to initiate in the 
bone marrow in cases of murine retroviral infection models238,242,356, but it is not 
   36 
entirely clear if bone marrow derived progenitors or stem cells are capable of 
being transformed into T-ALL L-ICs in the human disease. 
 Aside from self-renewal, an L-IC must adapt additional qualities of normal 
stem cells in order to remain active long-term and evade current anti-leukemia 
treatments. While not shown for all hematopoietic malignancies, it is thought that 
L-ICs are able to enter a state of quiescence in order to escape chemotherapies 
that target rapidly dividing cells, a common behavior of normal stem cells357–359. 
A quiescent L-IC population has been described in AML using mouse 
models360,361 and clonal tracking techniques342. A correlation between slow-
cycling cells and tumor-initiating cells (T-ICs) was also found in solid tumors such 
as colon362 and breast cancers363. Normal stem cells are able to exit 
quiescence357,359,361,364,365, and so it is thought that this exit may be a major 
mediator of relapse, especially because relapse can often occur years or even 
decades after initial treatment ceases366,367. Pushing quiescent L-ICs into cycle 
may be a viable treatment method to induce L-IC exhaustion and make cells 
more responsive to traditional chemotherapy, thus preventing disease 
relapse361,364. 
 Initiating cells in both leukemia and solid tumors have been shown to have 
intrinsic resistance to chemotherapy and radiation. In CML patients where 
disease was driven by BCR-ABL, L-ICs were found to be resistant to tyrosine 
kinase inhibitors such as imatinib while the bulk leukemia cells remained 
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sensitive to the drug368–373. In breast cancer, T-ICs were enriched in patients after 
cytotoxic chemotherapy374. The mechanism for this resistance could be linked to 
quiescence (as explained above), or could be due to increased expression of 
multi-drug resistance (MDR) transporters or other intracellular factors375. In AML, 
L-ICs and surrounding stromal cells were found to overexpress anti-apoptotic 
genes such as Bcl-XL and Bcl-2 to counteract cell death triggered by 
chemotherapy and radiation376,377. In solid tumors, CD133-positive gliomas 
express proteins to counteract DNA damaging agents378 and breast cancers 
express free radical scavengers379. Preleukemic thymocytes overexpressing 
Lmo2 showed increased resistance to radiation137, but the mechanism is 
currently unknown. The fact that these mechanisms exist highlights the need for 
specific anti-L-IC therapies not based on targeting rapidly dividing cells. 
Alternative models of cancer heterogeneity 
 Contrary to the idea of a hierarchical organization of leukemia/cancer, B-
cell acute lymphoblastic leukemia (B-ALL) is thought to undergo clonal 
evolution(reviewed in338). This model of malignancy takes place in situations 
where a tumor/leukemia has a high amount of genetic heterogeneity (Figure 3A). 
B-ALL has been profiled using copy number abnormality (CNA) analysis380,381 
and in situ hybridization382 to find that there are many subclones in any given 
patient and each of these subclones has a different functional capability to 
transplant the leukemia in xenograft models.  
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 One major difference between the hierarchical model (Figure 3B) and the 
clonal evolution model (Figure 3A) is the presence of epigenetic versus genetic 
heterogeneity. In the cancer stem model, heterogeneity in the tumor/leukemia is 
most often attained by differentiation of the tumor/leukemia to a cell type where 
disease-initiating capabilities are not possible. This is often achieved by 
epigenetic changes in the individual cells causing irreversible changes in gene 
expression profiles383. In contrast, in the clonal evolution model of tumorigenesis, 
the functional heterogeneity of each clone is achieved by individual oncogenic 
events (reviewed in384). There is likely epigenetic heterogeneity in addition to 
genetic mutations in the clonal evolution model. Because epigenetic changes can 
be transient and reversible, tumors with this type of heterogeneity may be difficult 
to target therapeutically.  
 One last model of cancer heterogeneity has been described. In this model, 
tumor microenvironment and available ligands dictate the ability of any given cell 
to initiate a tumor. This model is most often found in solid tumors, which differ 
from leukemias that tend to be systemic and therefore not entirely dependent on 
any given niche. In this model, any cell can be a disease-initiating cell if it is in 
the proper location. This functionality is very plastic and reversible; as a cell 
moves from one ligand source, its prominent gene expression profile changes to 
reflect the new microenvironment385,386. 
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 Clonal evolution may take place in T-ALL even though there is evidence of 
a functional L-IC hierarchy in the disease(reviewed in338). It is entirely possible for 
a single leukemia to inherit heterogeneity from multiple sources: developmental 
hierarchy, epigenetic changes, genetic mutations, and effects of a particular 
niche. Recent evidence suggests that there are multiple clones within T-ALL 
patient samples that have varying functional capabilities. The most aggressive of 
these clones manifest in relapsed patient samples and can be mapped back to 
the diagnostic sample336. In cases like this, a different approach towards therapy 
and relapse must be used, as targeting one leukemia-initiating clone may leave 
others untouched and therefore in a prime position to mediate relapse. Clonal 
evolution also takes place in pancreatic cancer and is thought to be one of the 
reasons why the disease has such a low survival rate even after treatment387. 
Methods for assaying cancer stem cells 
 Recently, lineage tracing has been used to define and characterize T-ICs 
in solid tumors388–390 but prior to this, the main assay for determining L-IC 
frequency was through transplantation. With this method, tumor or leukemia cells 
are taken from the original source, made into a single cell suspension, and 
transplanted into histocompatible hosts in limiting dilution. This artificial system 
has been used to determine T-IC/L-IC frequency and functional populations in 
these malignancies for decades(reviewed in217). Gene expression profiling has 
identified SLAM family genes enriched in HSCs, and then these receptors were 
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functionally confirmed with in vivo transplantation assays35. In other cases, 
specific developmental surface markers have enriched for a T-IC/L-IC population. 
Recently, less biased methods such as lineage tracing and clonal tracking have 
been used to determine the identity and function of normal and malignant stem 
cells without having to use transplantation methods388–390.  
 Therapeutic strategies to target the L-IC have been an interest to the field 
since their discovery. In AML, the adhesion molecule CD44 was targeted with 
monoclonal antibodies, which resulted in oxidative stress followed by terminal 
differentiation of the AML391. This terminal differentiation resulted in ablation of 
the LSC population from patient samples392. Similarly, in acute promyelocytic 
leukemia (APL), an AML subtype, terminal differentiation by use of all trans 
retinoic acid (ATRA) has been successful in patients393. Because T-ALL does not 
have the features of a normal HSC and is often composed of cells at various 
stages of differentiation, specific oncogenic pathways will need to be targeted in 
lieu of inducing differentiation in the cells. 
In this thesis, I will focus on defining and targeting the L-ICs in the Lck-
Tal1/Lmo2 mouse model of T-ALL. I will discuss transplant comparisons in a 
mouse model of T-ALL to validate our current L-IC assay. Using this assay, I will 
present data where we have successfully targeted the L-IC in this mouse model 
using shRNA and therapeutic approaches to inhibit Notch1 and c-Myc. 
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Figure 1. Thymocyte development. Thymocyte precursors are imported from 
the bone marrow. Upon entering the thymus and encountering Notch1 ligands, 
cells enter a series of discrete differentiation steps. Cells travel through the 
thymus and interact with the microenvironment as they differentiate and change 
their surface expression profile. They start by going through the four DN stages, 
then to the DP stage and finally reaching the CD4 or CD8 single-positive stages. 
At the end of the differentiation process, cells egress into the circulation and 
execute adaptive immune responses. (Adapted from: Zuniga Pflucker, JC. 2004. 
Nature Reviews Immunology 4, 67-72) 
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Figure 2. Notch1 signaling pathway. Upon ligand (Jag1, Jag2, Dll1, Dll3, Dll4) 
engagement, an ADAM protease cleaves the protein at the HD region. The 
receptor is endocytosed and the gamma-secretase complex releases the Notch1 
intracellular domain from the membrane where it then translocates to the nucleus 
and binds CSL. Upon CSL binding, corepressors are released and transcriptional 
coactivators are recruited to activate Notch1 target genes. Fbw7 then targets the 
Notch1 protein for degradation in the proteasome. 
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Figure 3. Models for tumor initiating cell heterogeneity. Current evidence 
supports a variety of models for how cancers gain the ability to initiate disease in 
secondary recipients, or how cancers can initiate relapse in a patient. A. The 
clonal evolution model suggests that there are a number of cells within a tumor 
that have gained mutations making them capable of initiating disease. B. The 
cancer stem cell (hierarchical) model proposes that a normal stem or progenitor 
cell with intrinsic self-renewal capabilities gains oncogenic mutations and is able 
to serially transplant disease while differentiated progeny cannot. C. These 
models can occur in isolation or combination within a single individual or 
malignancy.  
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CHAPTER II 
 
 
 
 
 
 
 
 
Thymic microenvironment does not 
influence frequency or activity of murine T-
ALL leukemia-initiating cells 
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Data from the following Chapter were submitted as a manuscript not yet in print: 
 
Tatarek, J. *, Hermance, N., Kelliher, M. (2013) T-cell acute lymphoblastic 
leukemia-initiating cell frequency is not influenced by method of transplant or 
microenvironment. J. Exp. Med, submitted  
 
Transplant surgeries were performed by Jessica Tesell and Nicole Hermance. 
Additional experiments and all data analysis were performed by Jessica Tesell. 
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Introduction 
 Leukemia-Initiating cells (L-ICs) are thought to mediate relapse in 
hematopoietic malignancies such as AML, CML, and T-ALL337,343,352. L-ICs are a 
rare population of leukemic cells that possess the ability to initiate disease in 
recipient mice, differentiate, and self-renew. It is also thought that these cells are 
able to evade conventional chemotherapy and radiation by remaining quiescent, 
expressing drug pumps on their surface, or counteracting damage by expressing 
survival proteins and free radical scavengers370,377–379,394. In murine Lck-
Tal1/Lmo2 T-ALL, the L-IC is quite rare, with only 0.003-0.05% of cells enriched 
in the ability to initiate disease in recipient mice251. This frequency is much lower 
than other hematopoietic malignancies where frequencies have been reported on 
the range of 0.05%-1% of cells being able to initiate disease113,344,395. This 
discrepancy could reflect intrinsic characteristics of the T-ALL L-IC or it could 
reflect limitations in the assay used to determine the frequency. 
Current assays for determining murine L-IC frequency involve 
transplanting a primary leukemia into syngeneic, histocompatible recipient 
mice(reviewed in338). Recently, concerns have been raised about whether this L-
IC assay accurately measures L-IC activity and whether it is influenced by factors 
such as engraftment, homing (to the thymus), survival in the circulation, and/or 
adaption to a foreign microenvironment. The conventional transplantation method 
for L-IC assays is either through the tail vein (IV) or peritoneum (IP). These 
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routes of transplant place cells into microenvironments that may not be ideal for 
the T-ALL L-ICs to initiate disease. Cells injected into the blood stream or 
peritoneum must endure shear stress on the order of 20dyn/cm2, a force that 
even normal lymphocytes must struggle to overcome396,397. Leukemic blasts 
derived from the mouse thymus may not express the necessary adhesion 
molecules to survive such forces and may die upon transplant, thus resulting in 
an apparently low L-IC frequency. It is imperative that we understand and 
accurately quantitate the L-ICs in this disease so that we can successfully 
develop and test anti-LIC therapies in animal models.  
Murine T-ALLs are immunophenotypically and functionally heterogeneous 
(Figure 4 and Table 1). We and others have demonstrated that the L-IC in T-ALL 
is a committed thymic DN3/4 progenitor, not a traditional stem cell113,251. These 
cells are present in Lck-Tal1/Lmo2 T-ALLs and are maintained upon transplant. 
This thymic progenitor has been shown to have the intrinsic ability to self renew 
when Lmo2 is overexpressed in developing thymocytes137 and we have shown 
that leukemic DN3 cells can transplant disease and give rise to more 
differentiated leukemic DP blasts251. Thymic progenitors require specific signals 
from the epithelium/microenvironment in order to successfully differentiate and 
exit the thymus to function as mature lymphocyte40,398. Notch1 signaling is critical 
for early thymocyte specification and development, especially through the DN3 
stage of thymocyte development41,43,214. Thus, access to Notch1 ligands such as 
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Dll4 and Jag2 in the thymic epithelium could be critical for L-IC survival and 
maintenance of L-IC activity.  
Here, we aimed to validate the L-IC assay by estimating L-IC frequency 
using two methods of transplant. We compared the effects of injecting cells into 
the peritoneum (IP) versus directly into the thymus (IT) on L-IC frequency, 
disease kinetics, and disease presentation in recipient animals. We found that L-
IC frequency is not influenced by site of injection and that the same leukemic 
clones expanded in vivo irrespective of method of transplant. This study confirms 
that the current assay for measuring L-IC frequency accurately estimates an 
intrinsic activity within these cells and suggests that this assay will accurately and 
sensitively assess effects of anti-LIC therapies. 
  
   49 
Results 
Mode of transplant does not alter disease kinetics or leukemia-initiating 
cell frequency  
 The thymic microenvironment is critical in promoting successful 
differentiation of DN3 cells, by supplementing the developing thymocytes with 
Notch1 ligands, cytokines such as IL7, and morphogenetic proteins such as 
BMP2 and Wnt399–401. We hypothesized that these cytokines and growth factors 
could influence the survival of leukemic DN3 (L-IC) population. In order to 
determine whether L-IC frequency is influenced by the ability of cells to home to 
the thymus, we serially diluted four independent Lck-Tal1/Lmo2 T-ALLs and 
transplanted each into syngeneic recipient mice by IP or IT injection under 
limiting dilution conditions. Mice transplanted with leukemic cells by IT injection 
were sublethally irradiated before leukemic cells were surgically implanted into 
the recipient thymus402,403. Transplanted mice were monitored for signs of 
leukemia and sacrificed when moribund. 
 In all four T-ALLs examined, mode of transplant did not significantly affect 
disease latency, with p-values ranging from 0.15-0.88 (Figure 5 A-D). Leukemia-
initiating cell frequency was calculated for each T-ALL injected IP versus IT 
(Figure 6 A-D) and a mean L-IC frequency was also calculated (Table 2). L-IC 
frequencies were found to be within the range of what we had previously 
published (0.009-0.042%, Table 2) and mode of transplant did not significantly 
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alter the frequency of L-ICs in any of the T-ALLs examined. This finding suggests 
that the leukemia-initiating cell frequency is a cell autonomous feature of the 
leukemia and is not influenced by differences in microenvironment or ability to 
survive in the circulation or peritoneum. 
Clonal selection is not influenced by method of injection 
 Due to the diverse methods of transplant examined, we hypothesized that 
different leukemic clones may expand in the IT or IP microenvironments. In order 
to determine if mode of transplant preferentially selected for certain leukemic 
clones, we analyzed leukemic tissues from recipient mice. Immunophenotyping 
conducted using flow cytometry for T-cell surface markers revealed that the 
leukemic DN3, L-IC, population was detected in all recipient animals, regardless 
of mode of transplant (Figure 7). Small increases in CD44-positive cells in the IP 
injected animals most likely reflect endogenous CD44 expression found in the 
mesenteric lymph node404 (site of leukemic burden and immunophenotype 
analysis), and likely do not contribute to disease pathogenesis. This slight 
increase in CD44 expression is seen in all IP injected animals from this study and 
others in our lab (data not shown). 
 We also assessed TCR-Vβ clonality by PCR, as previously described251, 
to determine if the IT or IP method of injection or corresponding 
microenvironment selected for certain leukemic clones. Wild-type thymi are 
polyclonal in terms of TCR-Vβ expression while Lck-Tal1/Lmo2 mouse T-ALLs 
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are oligoclonal. In each T-ALL examined, clonal selection did occur upon 
transplant; overall the number of TCR-Vβ families expressed was reduced in 
recipient mice compared to the primary T-ALL. However, in each T-ALL, the 
same leukemic TCR-Vβ clones were selected irrespective of whether cells were 
transplanted IT or IP (Table 3). This demonstrates that site of T-ALL cell injection 
does not select for particular leukemic clones. This finding also reaffirms the 
functional heterogeneity of murine T-ALLs; only certain leukemic clones are able 
to initiate disease in recipient mice. 
Disease presentation differs significantly with mode of transplant 
 Although L-IC frequency and clonal selection did not significantly change 
in IT versus IP transplant, differences in site of leukemic burden were observed. 
Mice transplanted with cells via IP injection presented with greatest disease 
burden in the spleen, whereas mice transplanted with cells via IT injection 
presented with leukemic cells mainly in the thymus (Figure 8). While 
disseminated leukemia did develop in all animals, the greatest burden was found 
at the injection site, suggesting that cells expand at the injection site prior to 
entering the bloodstream and infiltrating other organs.  
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Discussion 
 Here, we validated the assay to estimate the L-IC frequency in murine T-
ALL by demonstrating that L-IC activity is not influenced by extrinsic factors such 
as transplant microenvironment or survival of cells in the bloodstream. T-ALL 
cells were transplanted by two independent methods, both of which resulted in 
similar disease latencies and no significant differences in estimates of L-IC 
frequency. Leukemic DN3 cells were detected with both methods of transplant 
and identical clones expanded in IP or IT injected mice. This study validates our 
L-IC estimates and provides evidence that this assay can be used to evaluate 
anti-LIC therapies. 
 Recent reports have demonstrated that normal thymocytes have the ability 
to self-renew when there is a lack of bone marrow progenitor import into the 
thymus67,68. Lmo2, a collaborating oncogene in our mouse model, increases the 
self-renewal capacities of thymocytes, specifically at the DN3 stage in 
development137. Lmo2 upregulates a transcriptional program consistent with 
HSCs by inducing the expression of Hhex, Lyl1 and Gfi1137,405. Thus, in the Lck-
Tal1/Lmo2 mouse model, the DN3 population may gain properties of stem cells 
via the expression of Lmo2 that enable the cell to self-renew and gain further 
mutations needed for leukemic transformation.  
 Mature SP T-cells leave the thymus and intravasate into the blood stream 
and have the ability to then extravasate into tissues, processes that require 
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adhesion molecules and a tolerance for shear stress of the circulation396,397,406–
408. In T-ALL, specific T-cell adhesion molecules may be present on the cell 
surface to aid in migration of these cells. The immunoglobulin adhesion molecule 
EVA1 is expressed on thymic epithelial cells and developing thymocytes. It is 
required for progression of ETP/DN1 progenitors to DN3 thymocytes. Mice with 
EVA1 deletions exhibit impaired thymocyte engraftment 10-fold, so this protein 
could play a critical role in the transplantation of T-ALL cells409,410. Integrins in 
general are important in adhesion and migration of normal and cancer cells and 
could be important in engraftment of the T-ALL L-IC after transplant. In particular 
α4β1 is important for B- and T-lymphocyte entry in and out of the CNS411, and 
MadCAM1 is critical for T-cell entry to lymph nodes412,413. 
Our data suggest that once a preleukemic cell is transformed to an L-IC, it 
is able to adapt and proliferate in varied microenvironments and is no longer 
dependent on the thymus for its survival. This study confirms that the T-ALL L-IC 
has unique, intrinisic properties that allow the cell to adapt and initiate disease in 
recipient mice in a thymus-independent manner. Further study is necessary to 
determine what these exact properties are, but first the T-ALL L-IC must be 
purified based on cell surface markers or biological characteristics. We are 
confident that the L-IC assay accurately measures an activity within these cells, 
therefore future studies will analyze leukemic the DN3/4 population for the 
expression of adhesion molecules, T-cell co-stimulatory molecules, surface 
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transporters, and stem cell markers. We can then continue to use this assay to 
test the effects of therapeutics on targeting the L-IC in T-ALL.  
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Methods 
Mice 
 A cohort of Lck-Tal1/Lmo2 transgenic mice were maintained and 
monitored daily for development of leukemia112. Lck-Tal1/Lmo2 leukemic cells 
were transplanted into syngeneic recipient FVB/N mice (4-6 weeks old, The 
Jackson Laboratory) via intraperitoneal251 or intrathymic (see below) injection. 
The University of Massachusetts Medical School Institutional Animal Care and 
Use Committee approved all animal procedures.  
Intrathymic injections 
 Protocol performed as described previously402,403. Mice were sublethally 
irradiated with 400rads using a cesium irradiator prior to the procedure. Mice 
were anesthetized using Avertin (2, 2, 2-Tribromoethanol) and immobilized 
ventral side up. An incision was made from the sternum to the base of the chin, 
approximately 2-3cm. Two curved forceps were used to gently open the rib cage 
and remove salivary gland tissue above the trachea and thymus. Once thymus 
was visible at top of rib cage, 10ul of cell solution was injected into each lobe of 
the thymus using a 25ul fine-needle syringe (Hamilton #7654-01). Approximately 
3-4 staples (Protech International #205016) were used to close incision.  
L-IC statistics 
 Mice were transplanted with Lck-Tal1/Lmo2 leukemic cells via IP or IT 
injection. Leukemia-initiating cell (L-IC) frequency was calculated using Poisson 
distribution analysis and the ELDA software388. Kaplan-Meier survival curves and 
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statistical analyses were performed using GraphPad Prism software, Version 5.0. 
The hazard ratio and its 95% confidence interval was also measured, comparing 
the designated groups and adjusting for the dilutions of leukemic cells, using the 
Cox proportional hazards model analysis. A 2-sided P<.05 was considered 
statistically significant.  
FACS analysis 
 Single-cell suspensions of Lck-Tal1/Lmo2 leukemic cells were stained with 
cell surface antibodies as described previously. Flow cytometric analysis was 
performed on the LSRII or FACSCalibur machines (BD Biosciences). Data were 
analyzed using FlowJo Version 9.1 software (TreeStar). 
TCR-Vβ Clonality analysis 
 To determine clonality of each T-ALL, RNA was isolated from thymic 
tissue and cDNA synthesized. Rearrangements of the TCRβ-chain were assayed 
by standard qualitative PCR analysis as described previously251. 
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Figure 4.  Functional heterogeneity among mouse Lck-Tal1/Lmo2 T-ALLs.  
Leukemic cells from seven Lck-Tal1/Lmo2 mice were transplanted through 
limiting dilution into syngeneic mice.  Three representative Lck-Tal1/Lmo2 mouse 
T-ALLs are shown. Time to leukemia following transplantation of the indicated 
numbers of cells is shown. L-IC frequency for each mouse T-ALL was calculated 
by applying Poisson statistics using the Limiting Dilution software (StemCell 
Technologies). (4 of the 7 T-ALLs were transplanted and analyzed by Kathleen 
Cullion) 
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Table 1. Lck-Tal1/Lmo2 T-ALLs are functionally heterogeneous 
 
 Disease Penetrance 
Dilution 8129 2695 1002 2697 2692 1450 
106 4/4  N.D. 8/8  N.D. N.D. N.D. 
105 3/3  4/4  8/8  2/2  4/4  3/3  
104 3/4  3/4  8/8  1/3  2/4  N.D. 
103 1/4  2/4  7/8  0/3  0/4  2/3  
102 N.D. N.D. 2/8  N.D. N.D. 0/3  
Est. L-IC 
frequency 1:30,735 1:4,579 1:2,209 1:10,725 1:16,085 1:4,962 
% DN3 1.04 11.08 29.29 4.12 67.61 5.47 
N.D. not determined 
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Figure 5. Intrathymic injection of T-ALL cells does not alter disease 
progression. Lck-Tal1/Lmo2 tumor cells were injected into syngeneic wild type 
recipients via intraperitoneal (IP) or intrathymic (IT) injection and monitored for 
disease. The survival curve for each group of mice was estimated by the Kaplan-
Meier method and the difference in overall survival between the two groups 
assessed by the log-rank test. We further estimated the hazard ratio and its 95% 
confidence interval, comparing the IP with the IT group and adjusting for the 
three levels of cell dilution, using the Cox proportional hazards model analysis. A 
two-sided P value of <0.05 was considered to indicate statistical significance. 
Four independent tumors were analyzed. A. 5126 p<0.15, B. 6066 p<0.88, C. 
6200 p<0.39, D. 6263 p<0.67.  
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Table 2. L-IC frequency is not influenced by mode of transplant. 
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Figure 6. Leukemia-Initiating Cell (L-IC) frequency does not differ with 
mode of transplant. Murine T-ALL cells were injected into syngeneic wild type 
recipients (with carrier cells) in limiting dilution via intraperitoneal (IP) or 
intrathymic (IT) injection. Estimated L-IC frequencies are shown. L-IC frequency 
was calculated using Poisson statistics and ELDA software414. Four independent 
tumors were analyzed. A. 5126 p<0.93, B. 6066 p<0.51, C. 6200 p<0.66, D. 
6263 p<0.46. 
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Figure 7. The leukemic DN3 population is maintained with both IT and IP 
injection. Lck-Tal1/Lmo2 tumor cells were injected via IP or IT injection into 
syngeneic recipient mice. At sacrifice, the immunophenotype of the transplanted 
tumor was reanalyzed by flow cytometry and compared to the primary tumor. 
Four tumors were analyzed; one representative T-ALL (6200) is shown.  
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Table 3. TCR-Vβ clonal selection is not influenced by mode of transplant. 
 
 
 
Table 3. To determine clonality of each T-ALL, RNA was isolated from thymic 
tissue and cDNA synthesized. Rearrangements of the TCR-Vβ chain were 
assayed by standard qualitative PCR analysis as described previously251. 
Expression of each TCR-Vβ clone are displayed as analyzed on a 2% agarose 
gel. Each X represents an average of three independent experiments.   
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Figure 8. Method of T-ALL injection alters primary site of leukemic 
infiltration. T-ALL cells were injected into syngeneic wild-type recipients via 
intraperitoneal (IP) or intrathymic (IT) injection and monitored for disease. Upon 
sacrifice, spleen and thymus were harvested and measured; weights are shown 
in milligrams. An unpaired t-test was performed with a p<0.05 being considered 
significant. NS, not significant; * p<0.05, ***p<0.0005. A. 5126, B. 6066, C. 6200, 
D. 6263. 
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CHAPTER III 
 
 
 
 
 
Notch1 inhibition targets the leukemia-
initiating cells in a Tal1/Lmo2 mouse model 
of T-ALL  
   66 
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Introduction 
Experiments performed in Chapter II validate the method we are using to 
measure L-IC frequency and allow us to use this assay to identify pathways that 
contribute to L-IC frequency. The NOTCH1 pathway has been implicated in T-ALL 
initiation in a xenotransplant model using patient samples262 and Notch1 inhibition 
has been shown to have anti-leukemia effects in our mouse model261. These 
studies led us to start testing the effects of Notch1 inhibition on the murine T-ALL 
L-IC. 
Spontaneous gain of function Notch1 mutations are frequently observed in 
murine T-ALL models and occur mainly in the PEST domain245,246,248,415. Recently 
5' activating deletions in Notch1 have been found in multiple mouse T-ALL models 
including the model used in this study249,250. Two types of deletions have been 
described in these mouse models, designated Type 1 and 2. Type 1 deletions are 
Rag1/2 mediated and remove the 5' proximal promoter of Notch1. Transcription 
initiates at a cryptic promoter in exon 25, where changes in histone marks occur 
that allow this internal transcription initiation. The mechanism that creates the 
Type 2 deletions is not as well understood, but could result from random DNA 
breaks. These mutations leave the 5' proximal promoter intact, but remove from 
exon 2 to either exon 26 or 28. Both types of mutations result in translation 
initiation from an internal methionine, M1727. The truncated protein lacks the 
extracellular domain of the Notch1, but still inserts into the cell membrane and is 
sensitive to cleavage by the γ-secretase complex 249.   
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These 5' deletion events are common in mouse T-ALLs (6 out of 7 Lck-
Tal1/Lmo2 T-ALLs) but occur rarely, in human T-ALL. Only one patient sample 
with a 5’ deletion has been reported to date240. Instead, human T-ALLs often 
present with mutations in the HD domain of Notch1 resulting in ligand-
independent activation. The deletions described in mouse T-ALLs also result in 
ligand independent activation of the Notch1 signaling cascade, thus in mouse T-
ALL the Notch1 locus undergoes two mutation events. The deletion events or HD 
mutations allow for ligand-independent cleavage by ADAM proteases in situations 
where ligand may be limiting and then the PEST (or FBW7 in patients) mutations 
increase ICN1 protein stability. Together, these mutations result in constitutively 
active Notch1 signaling. 
To monitor Notch activity during leukemogenesis, we mated our Lck-
Tal1/Lmo2 mice with the Transgenic Notch Reporter (TNR) mouse line. The TNR 
mouse contains a transgene with four CSL-binding sites, a minimal SV40 
promoter, followed by an enhanced green fluorescent protein (GFP) 
sequence416,417. The TNR mouse has been shown to accurately report Notch 
activity during early thymocyte and neuronal development, angiogenesis, and hair 
follicle formation201,416–418. Using these mice, we detected Notch-active cells in the 
expanded DN population of preleukemic TNR/Tal1/Lmo2 animals. The proportion 
of GFP-positive, Notch-active, DN thymocytes in preleukemic TNR/Tal1/Lmo2 
animals was significantly greater than that observed in control littermates with no 
significant increase in Notch-active cells observed in the DP, CD4SP, or CD8SP 
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populations(Kate Cullion251). Although Notch1 activity is normally down-regulated 
at the DN4 stage419, we detected an expansion of GFP+, Notch-active DN3 and 
DN4 progenitors in the mice predisposed to leukemia.  
To examine the role of Notch1 in leukemia-initiating cell activity, we used 
the Lck-Tal1/Lmo2 mouse model of T-ALL in which more than 75% of the mouse 
T-ALLs develop spontaneous mutations in Notch1.  In vivo limiting dilution 
analyses have revealed that a rare L-IC population contributes to disease 
pathogenesis in this mouse T-ALL model. We found a committed thymic 
progenitor population enriched in disease potential and demonstrated that GSI 
treatment reduces and in some cases ablates L-IC activity.  The present study 
reveals that L-ICs contribute to mouse T-ALL pathogenesis and provides 
evidence that Notch1 inhibition will target the L-ICs. 
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Results 
Preleukemic Lck-Tal1/Lmo2 thymic progenitors exhibit aberrant Notch1 
activity.  
The increase in the absolute number of Notch1-active DN3/4 progenitors 
revealed in the TNR/Tal1/Lmo2 preleukemic mice(Kate Cullion251) suggested that 
sustained Notch1 activity might drive progenitor expansion during the 
preleukemic phase of the disease. To test this possibility, GFP-positive, Notch1 
active, DN3 and DN4 cells from preleukemic TNR/Tal1/Lmo2 mice were isolated 
and sequenced for the presence of Notch1 mutations.  We detected multiple 
Notch1 mutations in the DN3 and DN4 progenitors isolated from preleukemic 
TNR/Tal1/Lmo2 mice (Table 4).  Similar to what we observed in Tal1-mediated 
mouse T-ALLs,248 these mutations consisted of point mutations, insertions or 
deletions within exon 34 that introduce premature STOP codons or alter the 
reading frame, resulting in the truncation of PEST regulatory sequences. These 
mutations are predicted to increase Notch1 protein stability and explain the 
increased Notch1 reporter activity detected in the preleukemic TNR/Tal1/Lmo2 
thymic progenitor populations. Although PEST region mutations were observed 
(Table 1), 5' activating deletions were not detected in the preleukemic GFP-
positive DN3/4 progenitors (Todd Ashworth, not shown), raising the possibility 
that PEST region mutations precede the 5' activating deletions in Notch1 during 
leukemogenesis. 
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The presence of multiple Notch1 mutations in the preleukemic thymic 
progenitors led us to hypothesize that mutant Notch1 contributes to the 
expansion of DN3/4 progenitor clones in these mice. This hypothesis predicts 
that the preleukemic thymus will be oligoclonal in nature and reflect the 
expansion of multiple progenitor clones. To analyze the clonality of the 
preleukemic progenitors, wild type and preleukemic GFP-positive DN3 and DN4 
progenitors were purified and TCR-Vβ family gene expression was determined 
by PCR amplification of the cDNA. In wild type thymocytes, we detect expression 
of 15 of the 22 TCR-Vβ families examined, confirming the polyclonality of the wild 
type thymus (Figure 9). In each of the three Lck-Tal1/Lmo2 preleukemic mice 
examined, the DN3 and DN4 subpopulations expressed 3-6 TCR-Vβ families, 
consistent with an oligoclonal expansion (Figure 9).  Although the TCR-Vβ 
expression patterns differed among the three preleukemic mice examined, they 
were identical between the DN3 and DN4 progenitors within each mouse.  The 
predominance of multiple identical TCR-Vβ expressing clones in the preleukemic 
DN3 and DN4 populations suggests that the DN3 progenitors maintain their 
ability to differentiate to the DN4 stage.  Thus, in this mouse T-ALL model, the 
preleukemic phase of the disease is associated with the expansion of multiple 
Notch1-active thymic progenitors.  
Notch1 inhibition targets the L-ICs in a mouse T-ALL model 
  The presence of Notch1 mutations and the expansion of Notch1-active 
thymic progenitors in preleukemic Lck-Tal1/Lmo2 mice raise the possibility that a 
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sustained Notch1 signal confers extensive proliferative capabilities on committed 
thymic progenitors. Once thymocytes are fully transformed, Notch1 protein 
expression is similar in DN3 and DP cells (Figure 10), suggesting that the 
expanded DN3 progenitors differentiate into the DP cells of the tumor. This is 
surprising because under normal developmental conditions, Notch1 expression is 
transcriptionally downregulated by the DP stage. It is possible that the 5’ deletions 
and activation of the cryptic promoter in exon 25 of the Notch1 locus removes the 
normal transcriptional regulatory elements responsible for Notch1 silencing at the 
DP stage. Although we demonstrated that GSI treatment extends the survival of 
end stage leukemic mice261, effects on L-IC frequency or activity were not 
addressed in the prior study. Since relapse is hypothesized to reflect an inability to 
eliminate the L-IC population, whether L-ICs are susceptible to Notch inhibitors 
remains a critical, unanswered question. 
To examine the consequences of Notch1 inhibition on mouse L-IC activity, 
we initially treated mouse T-ALL cells in vitro with vehicle or GSI for 48 hours. 
This time period successfully decreases Notch1 protein levels in vitro (Figure 11).  
Serial dilutions of the vehicle- or GSI-treated leukemic cells were then 
transplanted into syngeneic recipients and treatment was maintained for 3 
weeks. GSI was administered by oral gavage using an intermittent dosing 
regimen we have shown minimizes the gastrointestinal toxicity associated with 
Notch inhibition261. We have demonstrated that this GSI dosing regimen reduces 
Notch1 target gene expression in leukemic cells261 (Figure 12). Five Lck-
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Tal1/Lmo2 tumors with mutations in Notch1 were examined in this study and 
remarkably, complete or partial responses were observed in 4 of 5 mouse T-
ALLs treated with GSI (Figure 13). For reasons not yet understood, GSI 
treatment of mouse T-ALL 1007 had minimal effects on leukemic cell viability 
(Table 7) and on disease latency and overall survival (Figure 13; log rank p< 
0.28).  
Transplantation of 105 or 104 vehicle-treated leukemic cells from mouse T-
ALLs 1426 or 2544 resulted in disease initiation in all transplanted recipients with 
an average latency of 31 and 55 days for 1426 and 28 and 39 days for 2544 
(Figure 13). Mice transplanted with leukemic cells from mouse 1426 or 2544 
treated with GSI failed to develop disease during the 180- or 90- day observation 
periods (Figure 13; log rank test p<0.0004 for 1426 and p<0.001 for 2544).  
These mice exhibited no evidence of disease at necropsy and histopathological 
examination of tissues failed to detect the presence of leukemic cells. GSI 
treatment of mice transplanted with leukemic cells from 1928 and 3304 reduced 
L-IC activity approximately 4- to 20-fold, respectively (Table 6) and significantly 
extended survival (Figure 13; log rank test p<0.02 for 1928 and p<0.0003 for 
3304). Consistent with our published work261, transplanted mice treated with GSI 
continued to gain weight throughout the treatment period and exhibited no signs 
of gastrointestinal toxicity (Figure 14). This study demonstrates that in some 
cases Notch1 inhibition in vivo reduces L-IC activity below the limits of detection 
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of this limiting dilution assay. These findings have clear translational implications 
and support the continued development of Notch therapeutics for T-ALL patients. 
It remains unclear why GSI treatment had no effect on mouse T-ALL 
1007.  All five mouse T-ALLs examined express high levels of intracellular 
Notch1 and harbor genomic insertions/deletions that result in PEST truncation 
(Figure 15A,B). All of these mouse T-ALLs also harbor 5' activating deletions in 
Notch1 that result in ligand independent Notch1 activation (Todd Ashworth, 
Figure 15C).  In 2 of 5 mouse T-ALLs analyzed (1007 and 3304) the deletions 
are likely Rag-mediated Type 1 deletions (not shown) and further support our 
finding that the Rag-active DN3 population is important in disease initiation. 
Mouse T-ALL 1007 fails to respond to GSI treatment potentially due to mutations 
in Pten or Fbw7260,420–422. Alternatively, L-IC activity in this mouse T-ALL may not 
depend on Notch1, but rather on the activation of other thymocyte self-renewal 
pathways potentially mediated by Lmo2137.  
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Discussion 
  We hypothesized that deregulated Notch1 activity during the preleukemic 
phase may confer extensive proliferative properties on committed thymic 
progenitors. We demonstrate that the DN3 population is enriched in leukemia-
initiating activity and provide evidence that Notch inhibition reduces and in some 
cases, eliminates L-IC activity. These findings have implications for translational 
research and suggest that Notch therapeutics may prove beneficial for T-ALL 
patients.  
In spite of the L-IC frequency differences, both our study and the one 
conducted by Tremblay et al. find the DN3 subpopulation enriched in leukemia 
initiating potential113. Tremblay and colleagues also detect reduced L-IC activity in 
the DN4 population of SCL/LMO1 mice and argue that transgenic expression of 
intracellular mutant NOTCH1, SCL and LMO1 is sufficient to transform a thymic 
progenitor into a L-IC. Although we have not tested this, we predict that the DN4 
population associated with Lck-Tal1/Lmo2 tumors will also harbor L-ICs.   
The time to disease progression and the estimates of L-IC frequency in 
our model suggest that additional genetic events define the L-ICs within the DN3 
population.  The detection of PEST region mutations in endogenous Notch1 in an 
oligoclonal, thymic progenitor population roughly 60-90 days before disease is 
evident argues that a PEST mutation may not be sufficient for complete L-IC 
transformation in our model. Although 5' activating deletions in Notch1 were 
readily observed in these mouse leukemic cells, we were unable to detect an 
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increase in 3' Notch1 transcripts in preleukemic progenitors (Figure 15 and Todd 
Ashworth, data not shown).  This result suggests that PEST region mutations 
precede 5' activating deletions in Notch1. This would leave us with the step-wise 
model of leukemogenesis being: Tal1/Lmo2 activation, Notch1 PEST mutations, 
Notch1 5’ deletions, followed by additional pathway activation and/or the onset of 
leukemia. 
Mouse L-ICs remain dependent on sustained Notch1 signals, as 
leukemia-initiating cell activity is significantly reduced in 4 of 5 mouse T-ALLs 
treated with GSIs.  The L-IC dependence on Notch1 is consistent with the critical 
role of Notch1 in normal DN3 thymic expansion, survival and metabolism423,424. 
Additional support for NOTCH1 in the maintenance of L-IC activity comes from 
studies by Armstrong and colleagues who expand primary human T-ALL cells on 
a mouse stromal cell line that expresses the human NOTCH ligand DELTA-like 1. 
GSI treatment of these primary T-ALL cells arrests their growth in vitro and 
reduces the ability of these primary leukemic cells to initiate disease in NOD/SCID 
mice262. Collectively, both studies implicate NOTCH1 in the regulation of L-IC 
maintenance. To further solidify this finding, we GSI treatment reduced the 
absolute number of DN3 cells while the absolute numbers of DP, SP, and other 
DN populations remained unchanged (Figure 16). There is a possibility that 
because CD25 is a Notch1 target gene425, the apparent decrease in the DN3 
population could reflect a population of DN3-like cells that has simply lost surface 
CD25 expression. However, because the absolute number of other T-ALL 
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populations analyzed did not appear to increase to indicate such a population, this 
is likely not the case. This provides additional evidence that the DN3 population is 
dependent on Notch1 for its survival. 
Precisely how Notch1 contributes to L-IC activity is unknown. The Notch1 
target genes c-Myc and Hes1, have been implicated in stem cell self-renewal and 
thymic progenitor expansion, respectively221,314,426,427.  Leukemic or cancer stem 
cells have been shown to activate gene expression programs similar to those 
expressed in embryonic stem cells (ESC) and c-Myc expression is one of four 
transcription factors capable of reprogramming differentiated adult cells back to a 
pluripotent state428. Thus, constitutive Hes1 and/or c-Myc activation may confer 
“stem cell-like” properties on committed thymic progenitors and these signals 
may work in concert with survival pathways activated by Notch1.   
Although this study reveals a clear L-IC dependence on Notch1, our data 
argue that additional genetic events contribute to complete L-IC transformation.  
The nature of these events will require further purification of the L-IC from the 
DN3 population to determine activation of specific pathways. Candidate genes 
for L-IC transformation are most likely involved in survival and the prevention of 
apoptosis. The activation of the Notch1 pathway drives the cells into rapid 
proliferation, a stress that in a normal cell would result in apoptosis. Thus, 
activation of genes such as Bcl-2 or Bcl-XL (possibly via c-Myb – see Appendix 
III) could contribute to L-IC transformation. While Notch1 and c-Myc (see Chapter 
IV) contribute to the self-renewal of L-ICs, it is also possible that additional self-
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renewal genes may also need to be expressed in these cells to ensure that the L-
IC does not become exhausted. Genes such as Lyl1, Hhex, Bmi1, and Gfi1 could 
be candidates for increased self-renewal in the L-IC population. 
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Methods 
Mice 
A cohort of Lck-Tal1/Lmo2 transgenic mice was generated and monitored daily 
for the onset of leukemia112. To generate the Tal/Lmo2/TNR cohort, Lck-
Tal/Lmo2 mice were mated with TNR/+ mice (STOCK Tg(Cp-EGFP)25Gaia/J # 
005854, Jackson Laboratories, Bar Harbor, ME). Tal1/Lmo2/TNR mice are 
maintained on a mixed background ((C57BL/6J x SJL/J)F2 x FVB/N). To control 
for differences in genetic background, all preleukemic studies were performed 
using TNR/+ control littermates. Lck-Tal1/Lmo2 leukemic cells or purified 
subpopulations of leukemic cells were transplanted into syngeneic recipient 
FVB/N mice (6-8 weeks old, Jackson Lab, Bar Harbor, ME).  All mice were 
maintained in pathogen-free conditions according to institutional animal care 
guidelines. L-IC frequency was determined using Poisson distribution statistics 
and the L-Calc Version 1.1 software program (StemCell Technologies, Inc., 
Vancouver, Canada).  For the GSI studies, transplanted mice were treated with 
vehicle or GSI for 3 weeks as described previously261.  Mice were monitored daily 
for disease development and weighed to monitor GSI-associated toxicity. 
Kaplan-Meier survival and statistical analyses were performed using GraphPad 
Prism 4.0 software (GraphPad Software, Inc.). The hazard ratio and its 95% 
confidence interval was also measured, comparing the vehicle- and GSI-treated 
groups and adjusting for the dilutions of leukemic cells, using the Cox 
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proportional hazards model analysis.  A two-sided P value of <0.05 was 
considered statistically significant. 
FACS analysis 
Single cell suspensions of Lck-Tal1/Lmo2 leukemic cells were stained with CD4-
PE-Cy5 and CD8-PE or with a lineage cocktail consisting of CD4-PE, CD8-PE, 
B220-PE, GR1-PE, MAC1-PE (BD Pharmingen, San Diego, CA Cat #553654, 
553033, 553049, 553089, 553128, 557397). Lineage negative cells were then 
stained with CD44-APC (BD Pharmingen, San Diego, CA Cat #559250) and 
CD25-PE-Cy7 (eBioscience, San Diego, CA Cat #25-0251-82). Dead cells were 
excluded by propidium iodide staining. Flow cytometric analysis and sorting was 
performed on the FACS Caliber and FACS LSRII (Becton Dickinson, Franklin 
Lakes, NJ), respectively. Data was analyzed using Flow-Jo (Tree Star Inc., 
Ashland, OR). 
RNA Analysis 
RNA was extracted from murine thymocytes or leukemic cells using Trizol. cDNA 
was synthesized using Superscript First Strand Synthesis Kit (Invitrogen). cDNA 
was quantified using the SYBR green kit (Qiagen) using specific primers to c-Myc 
F: 5’- CTGTTTGAAGGCTGGATTTCCT-3’, R: 5’-CAGCACCGACAGACGCC-3’; 
and Deltex F: 5’- TGCCTGGTGGCCATGTACT-3’, R: 5’-
GACACTGCAGGCTGCCATC-3’. Copy number was normalized to β-Actin using 
the ΔΔCT method. 
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Notch1 sequencing 
To determine the Notch1 mutational status, DNA isolated from preleukemic 
sorted thymic populations or mouse T-ALL cells was amplified by PCR using Pfu 
DNA polymerase (Stratagene, Cedar Creek, TX) with primers specific for exon 
34 of the Notch1 gene248. PCR products were run on a 1.5% agarose gel, 
purified (QIAquick Gel Extraction Kit, Qiagen, Valencia, CA), and cloned into the 
TOPO TA cloning vector (Invitrogen, Carlsbad, CA) for sequencing using the 
universal M13 primers. 
Clonality analysis  
To determine clonality, rearrangements of the TCR-Vβ chain were assayed by 
standard qualitative PCR analysis, using Pfu DNA polymerase (Stratagene, 
Cedar Creek, TX) and primers specific for mouse TCR Vβ1-Vβ18 genes and 
constant region as described in429. Vβ1 –Vβ18 primers were each paired with the 
following Vβ constant primer (Vβ - 5'- GGCTCAAACAAGGAGACCTTGGGTGG - 
3'). The amplification was performed using a Stratagene Robocycler Gradient 96 
starting with a 2 minute 94°C denaturation, followed by 30 cycles consisting of 20 
seconds at 94°C, 12 seconds at 55°C, and 30 seconds at 68°C and a final 
elongation step of 10 minutes at 68°C. PCR products were purified on a 2% 
agarose gel, subcloned and confirmed by sequencing.   
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Table 4. Multiple Notch1 mutations are detected in preleukemic Lck-
Tal1/Lmo2 thymic progenitors. 
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Figure 9.  Notch1-active thymic progenitors are oligoclonal. Using specific 
primers for Vβ1-18, TCR Vβ mRNA expression was examined in wild type and 
sorted GFP+ DN3 and 4 thymic progenitors isolated from preleukemic Lck-
Tal1/Lmo2 mice.  Three mice were examined; one representative experiment is 
shown. Vertical lines have been inserted to indicate repositioned gel lanes. (Sorts 
performed by Kathleen Cullion, analysis performed by Jessica Tesell) 
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Figure 10. Notch1 protein expression is similar in leukemic DN3 and DP 
cells. One Lck-Tal1/Lmo2 T-ALL was sorted into DN3 and DP populations. Cells 
were lysed and analyzed for Notch1 expression by immunoblotting. A murine T-
ALL cell line (720) was treated with GSI for 48 hours as a control for the Notch1 
Val1744 antibody. This data was presented for reviewers only. 
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Figure 11. GSI treatment reduces Notch1 protein expression in primary T-
ALLs after 48 hours in vitro. Three primary T-ALLs and the cell line 720 were 
treated in vitro with DMSO or Compound E for 48 hours. Cells were lysed and 
Notch1 protein levels were determined by immunoblotting. (This figure was 
presented for reviewers only) 
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Figure 12. GSI administration to leukemic mice results in decreased Notch1 
target gene expression. Mice transplanted with primary mouse leukemic cells 
were treated with vehicle or GSI, and c-Myc (A) or Deltex1 (B) expression 
analyzed by real time quantitative PCR. c-Myc (C) and Deltex1 (D) mRNA levels 
were also monitored at the time of disease recurrence. Copy number was 
normalized to β-actin using the ΔΔCT method. 
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Figure 13. Notch1 inhibition targets the L-IC in Lck-Tal1/Lmo2 mouse T-
ALLs. Mouse Lck-Tal1/Lmo2 T-ALLs with Notch1 mutations were treated with 
vehicle or GSI for 48 hours in vitro, stained and analyzed by flow cytometry.  
Leukemic cells were serially diluted and transplanted into syngeneic mice and 
treatment was continued for 3 weeks.  GSI was administered using an 
intermittent dosing regimen and transplanted mice were monitored for disease 
development.  Kaplan Meier survival curves were generated with GraphPad 
software. 
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Figure 14. Transplanted mice treated with GSI continued to gain weight 
throughout the treatment period. Recipient mice transplanted with mouse T-
ALLs 1928, 1426, and 1007 were treated with vehicle or 150mg/kg GSI (MRK-
003) using an intermittent dosing regimen. Vehicle mice were given an equal 
volume of methylcellulose by oral gavage. The animals were weighed once per 
week, with GSI administered immediately following transplant and at 1 and 2 
weeks post-transplant. 
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Table 5. Notch1 inhibition reduces L-IC frequency and/or activity. 
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Table 6. Notch1 inhibition reduces L-IC frequency and/or activity. 
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Table 7. Summary of GSI responses in vivo. 
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Figure 15. Mouse T-ALLs examined in the GSI treatment study express high 
levels of intracellular Notch1, harbor insertions/deletions that result in 
PEST truncation and express aberrant 3' transcripts. (A) Mouse T-ALL cell 
lysates were examined for intracellular Notch1 protein levels by immunoblotting 
with Notch1 Val1744 (Cell Signaling). Jurkat is a human T-ALL cell line that 
expresses full length ICN1; FVB is wild-type thymus; 2906 is a mouse tumor with 
truncated ICN1; 1007, 1426, 1928, 2544, and 3304 are the mouse Lck-
Tal1/Lmo2 T-ALLs examined in Figure 13. (B) DNA was isolated from the mouse 
TALLs and amplified with primers specific to exon 34 of the Notch1 gene. PCR 
product was cloned into the TOPO TA cloning vector for sequencing using the 
universal M13 primers. Mutations were then analyzed using MacVector software. 
(C) Ratiometric Notch1 quantitative RT-PCR analysis of mouse Lck-Tal1/Lmo2 
T-ALLs. The relative amounts of transcripts containing 5' (exons 1 and 2) and 3' 
(exons 30 and 31) Notch1 sequences were determined for primary tumors (pri) 
and transplanted tumors (trans) as previously described. Each determination was 
made in triplicate. (Data from section C performed by Todd Ashworth) 
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Figure 16. GSI targets the L-IC population in Lck-Tal1/Lmo2 T-ALLs. Primary 
Lck-Tal1/Lmo2 leukemic cells were treated with DMSO or GSI (Compound E) for 
48 hours. Cells were counted using trypan blue exclusion, stained with CD4, 
CD8, CD25, and CD44 antibodies, and populations were analyzed by flow 
cytometry. Fold change in absolute number of each population are shown. Three 
T-ALLs were analyzed, one representative is shown. (This figure was presented 
for reviewers only) 
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CHAPTER IV 
 
 
 
 
 
 
 
c-Myc silencing or inhibition prevents 
disease initiation in mice and impairs the 
growth of relapsed pediatric T-ALL cells 
  
   96 
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preparation. 
 
The manuscript has been edited for this thesis so that the results only include 
experiments performed by Jessica Tesell; data generated by others are noted.  
  
   97 
Introduction 
We have demonstrated that Notch1 inhibition reduces the L-IC population 
and prevents disease initiation in our mouse T-ALL model (Chapter III). In this 
same model, we have shown that the L-IC is a subset of the DN3 population251. 
At this stage in development, Notch1 and its target gene c-Myc are critical for 
thymocyte differentiation. In the absence of either Notch1 or c-Myc, thymocyte 
development is blocked at the DN3 stage210,319,423,430,431. c-Myc in particular is 
critical for the expansion of DN3 cells to DN4 and DP cells319. These data led us 
to hypothesize that Notch1 may be acting through c-Myc in the leukemic DN3 
cells to promote L-IC expansion and survival. 
Notch1 regulates proliferation by directly stimulating c-Myc and Cyclin D3 
expression110,170,172,259 and by inhibiting the p53 pathway and cyclin dependent 
kinase inhibitors such as p21 and p27(reviewed in74).  Retroviral expression of c-
Myc had been shown to rescue mouse and human T-ALL cells from the effects of 
NOTCH1 inhibition110,172. As discussed in Chapter I, two recent reports have 
shown that c-Myc universally amplifies transcription. In contrast to conventional 
thinking, it is thought that c-Myc does not regulate the transcription of a set of 
target genes. Instead, c-Myc is able to amplify the transcription of active genes in 
a given cell type by binding E-box sites in “open” chromatin325,326.  
These findings led us to hypothesize that c-Myc inhibition may interfere 
with multiple biological processes associated with L-ICs including extensive 
proliferation, survival and self-renewal, as well as metabolic and/or epigenetic 
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changes associated with drug resistance. In this Chapter, we used specific 
shRNAs to c-Myc as well as a pharmacological approach to examine the role of 
c-Myc in the murine T-ALL L-IC.  
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Results 
c-Myc silencing prolongs survival and reduces the frequency of leukemia-
initiating cells 
To test a requirement for c-Myc in L-IC expansion and self-renewal in vivo, 
we infected primary mouse T-ALLs with retroviruses encoding shRNAs to c-Myc 
or Renilla luciferase, with a separate promoter driving GFP expression. GFP-
positive leukemic cells (Figure 17) were transplanted into syngeneic recipients 
and an in vivo limiting dilution assay performed to estimate L-IC frequency, as 
described previously251. In 3 of 4 primary mutant-Notch1 mouse T-ALLs 
examined, silencing of c-Myc resulted in statistically significant increases in 
overall survival (Figure 18A-C) and an overall 17-fold decrease in L-IC frequency 
(Table 8). 
None of nine mice transplanted with c-Myc silenced leukemic cells from 
mouse T-ALL 4673 developed disease, whereas 100% of the mice (n=9) 
transplanted with the Renilla transduced leukemic cells succumbed to disease 
with a mean latency of 28 days (Figure 18A; p<0.0001; Table 9). Since all of the 
mice transplanted with the control cells developed disease and c-Myc silencing 
completely interfered with leukemia initiation in transplanted mice, we were 
unable to estimate the fold reduction in L-IC frequency. We found no evidence of 
leukemia in the surviving mice, nor were GFP-positive cells detected in the bone 
marrow (Figure 21), suggesting that the L-ICs had been eliminated in these mice. 
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c-Myc suppression in mouse T-ALLs  5109 and 5059 also resulted in significant 
increases in overall survival (Figure 18B and C), with 4 and 6-fold reductions in 
L-IC frequency, respectively (Table 9). These studies reveal that c-Myc mediates 
L-IC survival and/or expansion in vivo. 
In contrast, c-Myc inhibition in mouse T-ALL 6124 had no statistically 
significant effect on survival or L-IC frequency (Figure 18D p<0.33 and Table 9). 
At the time of transplant, all 4 mouse T-ALLs examined showed a similar 
reduction in c-Myc protein levels (Figure 19A, B average 47%, range 43-70%) 
and sort purity was consistently between 94-99% (Figure 17). Since a similar 
reduction in c-Myc protein levels was achieved (Figure 19 A/B), it is unclear why 
c-Myc suppression was less effective in vivo in this mouse T-ALL. One possibility 
is that leukemia 6124 is less dependent on c-Myc for its growth.  To examine this 
possibility, remaining GFP-positive leukemic cells were cultured short-term in 
vitro.  In the three mouse T-ALLs examined, c-Myc silencing interfered with 
growth in vitro and depleted the cultures of viable leukemic cells (Figure 19C). 
The increase in cell number observed in the shMyc-transduced 6124 cells 
reflected the emergence of GFP-negative or non-silenced leukemic cells (not 
shown). In spite of the variability observed in vivo (Figure 18), the growth of the 3 
mouse T-ALLs examined including 6124 appeared similarly c-Myc dependent in 
vitro (Figure 19B). This likely reflects silencing of the LTR driving the expression 
of the shRNA in vivo. 
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Tumors that develop from the transplantation of shMyc-transduced 
leukemic cells escape shRNA silencing. 
When animals became diseased after primary transplant, GFP and c-Myc 
expression levels were examined in tissues infiltrated with leukemic cells. In most 
transplanted mice, the leukemic cells remained GFP-positive and harbored the 
retroviral provirus (Table 10). One of fifteen mice transplanted with c-Myc-
silenced 5059 leukemic cells developed GFP-negative disease and the proviral 
DNA was not detected; indicating that disease in this animal likely resulted from 
the expansion of contaminating GFP-negative leukemic cells that were not 
transduced with the retrovirus. 
 Eleven of 39 mice transplanted with shMyc-transduced cells developed 
disease but appeared to express c-Myc at levels similar to that observed in the 
Renilla-transduced leukemic cells (Figure 20A), suggesting that c-Myc 
suppression was not maintained in these diseased mice. The leukemic cells 
retained GFP expression (Figure 20B), but showed no detectable decrease in c-
Myc RNA levels (Figure 20A and not shown). The LTR driving the expression of 
the c-Myc shRNA may have been silenced, leaving the PGK promoter driving 
expression of GFP intact (Figure 20C). Promoter methylation is common when 
using murine retroviruses that drive expression with an LTR. We saw an 
approximate 10-fold GFP fluorescence intensity in the recipient animals 
compared to pre-transplant (Figure 17 vs. Figure 20B), consistent with the loss of 
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transcription from the LTR. Thus, those mice transplanted with shMyc-
transduced cells that developed disease escape from c-Myc-silencing, supporting 
our data that c-Myc is required for leukemia initiation.  
c-Myc mediates L-IC self-renewal  
In order to determine whether the Notch1-c-Myc pathway mediates L-IC 
self-renewal, we sacrificed the primary transplants that failed to develop disease 
after 120 days. Consistently, we were unable to detect GFP-positive leukemic 
cells in the spleen or bone marrow of these mice by flow cytometry (Figure 21 
and data not shown).  To further demonstrate that c-Myc silencing depletes the 
L-IC population and does not induce arrest or quiescence, bone marrow cells 
were pooled from primary transplants and 5 x 106 cells were transplanted into 
secondary recipients. The secondary transplants were then monitored for 
evidence of disease for an additional period of 120 days. None of the 17 
secondary recipients developed leukemia (data not shown), suggesting that c-
Myc is required for the perpetuation or self-renewal of the L-IC.  
JQ1 treatment rapidly induces apoptosis of murine T-ALL cell lines in vitro.  
Although these c-Myc shRNAs have been reported to suppress c-Myc 
expression in vivo331, shRNAs can have off-targets effects432–434, which could 
have effects on L-IC activity. Therefore we also undertook a pharmacological 
approach to inhibit c-Myc using the bromodomain-4 (Brd4) inhibitor JQ1 
developed by James Bradner and Jun Qi at DFCI. While not a specific c-Myc 
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inhibitor, JQ1 has been shown to reduce c-Myc mRNA and protein in 
hematologic malignancies435. Treatment with gamma secretase inhibitors (GSI) 
to prevent Notch1 activation reduces c-Myc expression. However, when human 
T-ALL cell lines are treated with GSI in vitro, it is growth arrest and not apoptosis 
that is primarily observed110,172,260,436. Agents that induce cell cycle arrest are not 
considered ideal cancer therapeutics, as they fail to induce apoptosis and may 
contribute to the development of drug resistance. Moreover, chronic GSI 
administration is associated with gastrointestinal toxicity due to on-target effects 
of Notch inhibition in the intestine207,437.  
We hypothesized that JQ1 treatment may have greater anti-leukemic 
activity than to GSI on mouse T-ALL proliferation and survival in vitro.  We 
treated mouse Tal1/Lmo2 T-ALL cell lines with the GSI compound E (1uM) or 
with 250nM JQ1 for 24, 48 and 96 hours. We performed cell cycle analyses, 
monitored cell growth and viability and quantified the number of apoptotic 
leukemic cells.  JQ1 treatment for 24 or 48 hours induced G0/G1 cell cycle arrest 
(Figure 22A and B) followed by an increase in subG1 cells evident at 96 hours 
(Figure 22B). In contrast and as expected, GSI-induced cell cycle arrest was 
detected at 96 hours (Figure 22B, third panel p<0.0098) with no significant 
increases in subG1 or Annexin V-positive leukemic cells (Figure 22B-D).  Overall, 
JQ1 treatment reduced the proliferation of all 4 murine T-ALL cell lines examined 
(Figure 22C) and induced apoptosis by 96 hours (Figure 22D) GSI treatment 
arrested mouse leukemic growth but failed to induce apoptosis (Figure 22C,D).  
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This is in contrast to our published studies on Lck-Tal1 mouse T-ALLs and cell 
lines, which undergo apoptosis following GSI treatment for 72 hours110. 
To compare the effects of GSI or JQ1 treatment on c-Myc expression 
levels, mouse T-ALL cell lines were treated with DMSO, compound E (1uM) or 
increasing concentrations of JQ1 for 48 hours and c-Myc mRNA levels quantified 
by quantitative PCR. Optimal reductions in c-Myc mRNA levels were observed in 
leukemic cells treated with 250nM JQ1 (Figure 22E). Notably, similar reductions 
in c-Myc RNA levels were also observed in the GSI treated cultures (Figure 22E). 
We examined the expression of additional c-Myc target genes to determine if 
JQ1 treatment reduced c-Myc activity. Expression of four c-Myc target genes 
(Cdk4, Apex1, Fbl, and Tk1) were decreased upon JQ1 treatment (Figure 23), 
indicating that the c-Myc transcriptional program was impaired. These data 
suggest that JQ1 can be used as a tool to modulate c-Myc expression, although 
other genes are probably also targeted with JQ1 treatment. 
Although GSI treatment resulted in an average 7-fold (range 3.8-11) 
reduction in intracellular Notch1 expression, more modest effects on c-Myc 
protein levels (average 1.5-fold, range 1.2 – 2.3) were observed in the GSI-
treated cultures compared to controls (Figures 22F, 22G). In contrast, JQ1 
treatment resulted in an average 4.3-fold decrease in c-Myc protein levels 
(Figures 22F, 22G, range 1.8 – 8.6). In sum, the mouse T-ALL cell lines 
appeared more sensitive to the effects of JQ1 treatment than to GSI in vitro.  
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JQ1 treatment prolongs mouse T-ALL survival in vivo 
Treatment of mouse Tal1/Lmo2 T-ALL cells with JQ1 in vitro induced 
apoptosis of the leukemic cells (Figure 22), suggesting that JQ1 treatment may 
extend the survival of leukemic mice.  To examine the effects of JQ1 treatment 
on leukemic initiation, mice were transplanted with 105 leukemic cells and either 
vehicle or JQ1 was administered for three weeks.  Mice were monitored for 
evidence of disease and effects of treatment on disease initiation and overall 
survival were determined. JQ1 treatment resulted in significant increases in 
overall survival in the 3 mouse T-ALLs examined (Figure 24; 8236 and 7624 
p<0.0001 and 7118 p<0.008). JQ1 treatment prevented disease initiation in all 10 
mice transplanted with cells from mouse T-ALL 8236 and in 8 of 10 JQ1 treated 
mice transplanted with leukemic cells from mouse T-ALL 7624.  Although JQ1 
treatment extended the survival of mice transplanted with leukemia 7118 
(p<0.008), no significant effect on disease penetrance was observed. JQ1 
treatment prolonged the survival of the transplanted mice, revealing that the 
inhibitor has clear anti-leukemia activity in mice and in some cases, the data 
suggested that JQ1 might interfere with disease initiation in vivo. 
JQ1 targets the mouse L-IC 
 JQ1 treatment has been shown to interfere with c-Myc activity and reduce 
tumor cell line growth in conventional xenograft models of several hematological 
malignancies307,308,331,435,438, however its effect(s) on leukemia stem or -initiating 
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cells or on models of relapse has not yet been addressed.  In order to quantify 
JQ1 effects on mouse L-IC frequency and/or activity, we transplanted three 
independent murine T-ALLs into recipient mice under in vivo limiting dilution 
conditions. Mice were then treated daily with vehicle or 50mg/kg of JQ1 for three 
consecutive weeks and transplanted mice were monitored for development of 
disease. JQ1 treatment reduced estimated L-IC frequencies (as measured by 
Poisson statistics) in all three mouse T-ALLs examined by an average of 9.3-fold 
(Table 11). JQ1 administration also significantly prolonged the survival of mice 
transplanted with mouse T-ALLs 7162 and 7116 (Figure 25 p<0.05 and Table 
12), where L-IC frequency decreased by 24-fold and 14-fold, respectively.  
However, in JQ1 treated mice transplanted with 7474 leukemic cells where L-IC 
activity was reduced only 3-fold, no significant effects on disease latency were 
observed (Figure 25 p<0.28 and Table 12).  
  Overall, fifteen of thirty-two (47%) mice treated with vehicle developed 
disease whereas five of thirty-three mice (15%) treated with JQ1 succumbed to 
T-ALL (Table 11).  To determine whether the JQ1 treated mice that developed 
disease remained responsive to the inhibitor, leukemic mice were given a single 
dose of vehicle or JQ1 prior to sacrifice and c-Myc mRNA levels quantified using 
real time quantitative PCR. We found c-Myc mRNA levels significantly reduced in 
the JQ1 treated mice compared to vehicle treated controls, indicating that the 
leukemic cells remained responsive to the inhibitor (in terms of c-Myc repression) 
and had not developed resistance in vivo (Figure 24D). Disease recurrence in the 
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JQ1-treated mice could reflect compound instability in mice435 or indicate that 
treatment for 3 weeks is not sufficient and that continuous JQ1 administration 
may be required for complete remission. 
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Discussion 
c-Myc silencing by an shRNA approach or a non-specific pharmacologic 
approach to inhibit c-Myc reduces L-IC frequency and prevents disease initiation 
in most primary recipients (Figures 18, 24, and 25). Bone marrow cells isolated 
from primary recipients who failed to develop disease were pooled and 
transplanted into secondary recipients. None of these animals (n=17) developed 
disease, arguing that c-Myc suppression or inhibition eliminates the L-IC in these 
mice or interferes with the ability of these cells to self-renewal.  In the c-Myc 
shRNA studies, transduced cells expressed GFP and GFP-positive cells could 
not be detected in primary or secondary recipients (Figure 21).  These studies 
suggest that c-Myc suppression eliminates the L-IC population and reveal a 
critical role for c-Myc in mouse L-IC survival (or activity). These data also suggest 
that JQ1 may prove beneficial for T-ALL patients, either added to induction 
therapy or as a means to treat induction failure and relapse.   
Consistent with its role as an amplifier of gene expression325,326, inhibiting 
c-Myc should also result in reduced expression of the genes already active in T-
ALL. Classically, c-Myc was thought to control metabolism and cell growth, as 
well as proliferation, but it could also contribute to the activation of other self-
renewal genes in the L-IC. While we do not yet have evidence that the T-ALL L-
IC is quiescent, it is possible that c-Myc and its cell cycle target genes are able to 
push the L-ICs into S-phase in order to proliferate and initiate disease. Similarly, 
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c-Myc could control the metabolism of these cells resulting in a perfect balance of 
growth and quiescence. 
Self-renewal of T-ALL L-ICs likely involves several pathways and thus c-
Myc inhibition could be an efficient way to target many or possibly all of them. 
Administration of JQ1 to cell lines and to mice inhibits c-Myc expression and has 
effects on cell cycle, growth, ribogenesis, and nucleotide metabolism(reviewed 
in282), all of which could play a role in the generation or maintenance of T-ALL L-
Cs. Of course, all these effects of JQ1 may not be directly due to c-Myc 
suppression, but also due to other genes affected by the compound. 
JQ1 treatment significantly impaired the growth of murine T-ALL cell lines 
and was more effective at achieving cell cycle arrest and apoptosis than GSI 
(Figure 22).  Although GSI treatment is expected to reduce intracellular Notch1 
and c-Myc protein levels110,251,261, c-Myc protein levels were approximately 3-fold 
more reduced in the JQ1 treated mouse T-ALL cells than the GSI treated cells in 
vitro. Human T-ALL cell lines were also more sensitive to JQ1 than GSI 
treatment where 2-3 fold increases in apoptotic cells were observed in JQ1-
treated cultures compared to GSI (Justine Roderick, data not shown). This may 
reflect more complete c-Myc inhibition in the JQ1 treated cells, where Notch1 
independent pathways of c-Myc activation are also inhibited. Alternatively, other 
Brd4-dependent targets may be affected in the mouse leukemic cells.  
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Interestingly, we found that JQ1 was also able to reduce Notch1 target 
genes in addition to c-Myc target genes. Hes1, and PreTα expression were both 
significantly decreased upon JQ1 treatment (Figure 23). Notch1 mRNA was 
unaffected by JQ1 treatment, and protein levels were decreased in some lines, 
but not significantly reduced overall (Figure 22 F, H). It is possible that JQ1 is 
able to affect the processing of the Notch1 protein through downregulation of the 
proteases responsible for its maturation. This would result in decreases in 
Notch1 protein and its target genes, but not the mRNA. Alternatively, these 
Notch1-regulated genes may also be Brd4 dependent.  
In the c-Myc shRNA experiments, the 4-6 fold differences in L-IC 
frequency observed in T-ALLs 5109 and 5059 had significant effects on disease 
latency (Figure 18 and Table 9). In contrast, transient JQ1 treatment resulted in 
3-fold reductions in L-IC frequency in T-ALL 7474, but did not significantly extend 
survival (Figure 25 and Table 11). Presumably, the JQ1 treatment did not 
eliminate all of the L-ICs in this T-ALL, leaving these cells able to initiate disease 
once treatment had ceased.  
T-ALL 6124 did not respond significantly to c-Myc silencing in vivo, but we 
do not believe that this is due to c-Myc independence. When transduced with c-
Myc shRNA or treated with JQ1 in vitro, T-ALL 6124 exhibited reduced 
proliferation and increased apoptosis. It is likely that the c-Myc shRNA was 
silenced rapidly in vivo, resulting in re-expression of c-Myc and thus disease 
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initiation. Likewise, disease initiation was not impaired when T-ALL 7118 was 
treated with JQ1 in vivo, but JQ1 was able to reduce c-Myc mRNA and 
significantly extend disease latency. In vitro, T-ALL 7118 responded with similar 
kinetics as T-ALL cell lines 4673 and 5109 (Figure 26), again indicating that this 
T-ALL is JQ1-sensitive. 
These findings reveal a central role for c-Myc in murine L-IC growth and 
survival.  It remains to be determined whether JQ1 treatment targets the human 
L-IC in vivo but our data indicate that JQ1 is able to increase survival of mice 
engrafted with relapsed or IF T-ALL cells (Justine Roderick, data not shown). It is 
not clear from these studies whether c-Myc has a distinct role in the L-IC as 
compared to the leukemia as a whole. In vitro studies demonstrate a clear role 
for c-Myc in the growth and survival of T-ALL cells (Figures 19 and 22) while in 
vivo studies establish a necessity for c-Myc in the initiation of T-ALL in recipient 
mice (Figures 18 and 24). The precise c-Myc target genes involved in each of 
these biological processes are likely different, but are not currently understood. 
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Methods 
Mice 
 Tal1/Lmo2 transgenic mice were maintained and monitored daily for 
development of leukemia112,251. All animal procedures used in this study were 
approved by The University of Massachusetts Medical School Institutional Animal 
Care and Use Committee.  
In vivo studies 
 To estimate the effects of c-Myc silencing or JQ1 treatment on L-IC 
frequency, Tal1/Lmo2 mouse T-ALLs were each serially diluted and transplanted 
into syngeneic recipient as described previously251. For shRNA studies, cells 
were sorted for GFP expression 48 hours post retroviral infection, serially diluted 
and transplanted into syngeneic recipient mice. For JQ1 studies, recipient mice 
were injected IP with vehicle (10:90 DMSO:10%hydroxypropyl-beta-
cyclodextrin)(Sigma) or 50mg/kg JQ1 daily for 3 weeks. Mice were monitored for 
any signs of drug toxicity and sacrificed when disease was evident. L-IC 
frequency was calculated using Poisson distribution analysis and the ELDA 
software414. 
Cell culture 
 Primary mouse Tal1/Lmo2 T-ALL cells were plated in RPMI with 20% 
FBS, 1% pen/strep and 1% L-glutamine (Gibco). IL7 (2ng/ml), Flt3L (5ng/ml) and 
SCF (10ng/ml) (R&D) were added to the culture media every 2-3 days until the 
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leukemic cells adapted to in vitro culture (approximately 2 weeks). At this time, 
cells were infected with retroviruses439 encoding shRNA to c-Myc or Renilla 
luciferase.  Leukemic cells were spinfected for 15 minutes with neat virus plus 
20% serum and cytokines. Fresh media was added after 5 hours of incubation at 
37°C.  
FACS analysis 
 Single-cell suspensions of Tal1/Lmo2 leukemic cells were stained with cell 
surface antibodies and analyzed as previously described251. For in vivo shRNA 
studies, retrovirally transduced leukemic cells were sorted for GFP expression on 
the FACSAria (BD Biosciences). For cell cycle analysis, leukemic cells were fixed 
in 70% ethanol overnight and then were stained with PI for DNA quantification. 
Immunoblotting 
 To monitor c-Myc expression levels, leukemic cells were lysed in RIPA 
buffer and total protein run on a 4-12% Bis-Tris gel (Invitrogen). Nitrocellulose 
membrane was probed with antibodies to c-Myc clone N262 (Santa Cruz), 
Notch1 Val1744 (Cell Signaling), and Erk1/2 loading control (Cell Signaling). 
Blots were imaged and quantified using ImageLab Software (BioRad). 
Expression analyses 
 RNA was extracted and cDNA synthesized as previously described; cDNA 
was quantified using specific c-Myc primers251. The copy number of c-Myc was 
normalized to the copy number for β-actin using the ΔΔCT method. For in vivo 
target validation, mice were treated with a single dose of vehicle or JQ1 
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(50mg/kg) and leukemic tissues were harvested 2 hours later and analyzed as 
above.  
 DNA was isolated from recipient mice in shRNA study using Trizol 
(Invitrogen). Primers were designed against GFP (F: 5’-
TATATCATGGCCGACAAGCA-3’; R: 5’-CCTACAGGTGGGGTCTTTCA-3’) and 
standard qualitative PCR was performed with Taq polymerase. The amplification 
was performed using a Stratagene Robocycler Gradient starting with a 5-minute 
95°C denaturation, followed by 30 cycles consisting of 1 minute at 95°C, 1 
minute at 57°C, and 1 minute at 72°C with a final elongation at 72°C for 10 
minutes. PCR products were run on a 1% agarose gel and imaged with UV light. 
Cell viability and death assays 
 Tal1/Lmo2 leukemic cell lines were treated with 1uM Compound E (Alexis) 
or with increasing doses of JQ1 (Bradner, DFCI). The number of viable leukemic 
cells was calculated after 48 and 96 hours using a trypan blue exclusion assay. 
Cell cycle analysis was performed at 48 and 96 hours following treatment by 
staining cells with propidium iodide followed by flow cytometry. Metabolic activity 
was assayed after five days by the addition of CellTiter-Glo chemiluminescence 
reagent (Promega) and measured using a Beckman Coulter DTX 880 plate reader. 
Absorbance values were normalized to DMSO control for each patient sample and 
cell lines.  
Statistical measures 
 Kaplan-Meier survival curves and statistical analyses were performed 
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using GraphPad Prism software, Version 5.0. The hazard ratio and its 95% 
confidence interval was also measured, comparing the c-Myc and Renilla shRNA 
groups or vehicle and JQ1 treated groups and adjusting for the dilutions of 
leukemic cells, using the Cox proportional hazards model analysis. A 2-sided P 
<0.05 was considered statistically significant. Student’s t-tests were performed on 
proliferation and Annexin V data using GraphPad Prism software, Version 5.0. 
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Figure 17. Sort purity of shRNA-infected leukemic cells prior to transplant. 
Post-infection with retrovirus, cells were sorted on a FACS Aria (BD Biosciences) 
for GFP expression. Percent of GFP-positive cells before and after sorts are 
shown for tumors A 5109 and B 6124. 
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Figure 18. Silencing of c-Myc prolongs survival in mice transplanted with 
murine T-ALL cells.  Four independent murine Tal1/Lmo2 T-ALL cells were 
infected with retroviruses encoding an shRNA to c-Myc or Renilla luciferase. 
Cells were sorted for GFP expression, serially diluted and transplanted into 
syngeneic recipients via intraperitoneal (IP) injection.  Transplanted mice were 
monitored for evidence of disease. The survival curve for each group of mice was 
estimated using the Kaplan-Meier method and the difference in overall survival 
between the two groups assessed by the log-rank test. A 4673 p<0.0001, B 5109 
p<0.02, C 5059 p<0.024, D 6124 p<0.33.  
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Table 8. Silencing of c-Myc reduces L-IC frequency. 
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Table 9. Silencing of c-Myc reduces L-IC frequency. 
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Figure 19. Reduced c-Myc protein levels and impaired growth in vitro in c-
Myc-silenced leukemic cells. A. Reduced c-Myc protein levels in c-Myc-
silenced leukemic cells. Protein was isolated from murine Tal1/Lmo2 T-ALLs 
infected with retroviruses encoding shRNAs to c-Myc or Renilla luciferase and c-
Myc and Erk1/2 protein levels were determined by immunoblotting. B. c-Myc 
suppression impairs bulk leukemic growth in vitro. Cell viability was 
calculated via a trypan blue exclusion assay. Four independent mouse T-ALLs 
were analyzed; three are shown.  
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Table 10. Most leukemic mice contained GFP+ and proviral+ cells. 
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Figure 20. Myc-silenced mice that develop disease contain GFP+ cells but 
do not exhibit Myc knockdown. A. Mouse leukemic cells were isolated from 
mice transplanted with shRen or shMyc infected mice. RNA was isolated and c-
Myc mRNA levels determined by quantitative real time PCR. Copy number was 
normalized to β-actin using the ΔΔCT method. Each point represents a single 
mouse examined. B. Leukemic tissues were dissociated into a single cell 
suspension and GFP expression determined by flow cytometry. One 
representative from each group of tumor 5059 is shown. C. Map of pLMN vector 
used in these studies. 
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Figure 21. No GFP-positive cells remained in transplanted animals 120 days 
post-transplant. Mice that failed to develop disease 120 days post-transplant 
were sacrificed. Bone marrow cells were isolated and analyzed by flow 
cytometry. No GFP-positive cells were present in any animals examined. Two 
representative mice from each group are shown.   
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Figure 22. JQ1 treatment induces rapid cell cycle arrest and apoptosis of murine 
T-ALL cells. Murine T-ALL cell lines were treated with JQ1 (250nM) or with Compound 
E (1uM), unless otherwise noted. A. Murine T-ALL cell lines were left untreated or 
treated with JQ1 or compound E for 24 hours and then stained with propidium iodide 
followed by flow cytometry. One representative plot from mouse T-ALL 5109 is shown. 
B. JQ1-induced cell cycle arrest is evident at 24 hours.  Murine T-ALL cell line 5109 
was treated with JQ1 or compound E for 24, 48 and 96 hours and the percentage of 
cells is subG1, G0/G1 and S phases determined. C. Mouse T-ALL cell lines are more 
sensitive to treatment with JQ1 than GSI. Four mouse T-ALL cell lines (4673, 5109, 
5059 and 6124) were treated with DMSO, JQ1 or compound E for 96 hours and the total 
number of viable cells was calculated via trypan blue exclusion assay.   
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Figure 22, continued. D. JQ1 induces apoptosis of mouse T-ALL cells. Four mouse 
T-ALL cell lines were treated with vehicle, JQ1 or compound E and the percentage of 
apoptotic cells determined by Annexin V and 7AAD staining followed by flow cytometry. 
Combined analysis of Annexin V+ and Annexin V/7AAD+ cells are shown. E. Reduced 
c-Myc mRNA levels in JQ1 and compound E treated cells. RNA was isolated from 
leukemic cultures treated with vehicle, JQ1 or compound E for 48 hours and c-Myc 
expression was analyzed by quantitative real-time PCR. Copy number was normalized 
to β-actin using the ΔΔCT method. F. c-Myc protein levels were significantly reduced 
upon treatment with JQ1. Protein was isolated cells treat with from DMSO, JQ1 and 
Compound E for 48 hours. Intracellular Notch1, c-Myc, and Actin levels were determined 
by immunoblotting. G., H. c-Myc protein is more significantly decreased with JQ1 
compared to GSI, but Notch1 is not affected by JQ1. Four biological replicates were 
performed as in F. Average fold change in c-Myc protein (G) or Notch1 protein (H) was 
calculated for each treatment and is represented by each point on the graph. Data are 
means ± SD. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001; NS, not significant.  
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Figure 23. JQ1 treatment reduces c-Myc mRNA, expression of c-Myc target 
genes, and expression of Notch1 target genes. Murine T-ALL cell lines were 
treated with JQ1 (250nM) or Compound E (1uM) for 48 hours. RNA was isolated 
and c-Myc, Cdk4, Apex1, Fbl, Tk1, Notch1, Hes1, and PreTα expression were 
analyzed by qPCR. Copy number was normalized to β-actin using the ΔΔCT 
method. A. 5109, B. 5059, C. 6124. 
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Figure 24. JQ1 treatment of leukemic mice significantly prolongs survival 
and reduces c-Myc expression. A-C. Tal1/Lmo2 mouse T-ALLs were 
transplanted into syngeneic recipients. JQ1 was administered at 50mg/kg daily 
starting the time of transplant and continuing for 3 consecutive weeks. Mice were 
monitored for disease and sacrificed when they became moribund. Survival was 
estimated using the Kaplan-Meier method and the difference in overall survival 
between the two groups assessed by the log-rank test. D. Diseased mice 
remain responsive to JQ1 treatment. At disease presentation, mice were re-
treated with a single dose of JQ1 at 50mg/kg. Leukemic tissues were harvested 
after two hours and RNA isolated. c-Myc expression was analyzed by 
quantitative real-time PCR. Copy number was normalized to β-actin using the 
ΔΔCT method. Data are means ± SD.  **p<0.01, ***p<0.001, ****p<0.0001 
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Table 11. JQ1 treatment reduces L-IC frequency. 
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Figure 25. JQ1 treatment extends survival of recipient mice when cells are 
transplanted in limiting dilution. Tal1/Lmo2 mouse T-ALLs were transplanted 
into syngeneic recipients via limiting dilution. JQ1 was administered at 50mg/kg 
daily starting the time of transplant and continuing for 3 consecutive weeks. Mice 
were monitored for disease and sacrificed when they became moribund. Survival 
was estimated using the Kaplan-Meier method and the difference in overall 
survival between the two groups assessed by the log-rank test. 
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Table 12. JQ1 treatment reduces L-IC frequency. 
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Figure 26. Similar growth inhibition is observed among T-ALLs following 
JQ1 treatment. Primary T-ALL 7118 (A) and T-ALL cell lines 4673 (B) and 5109 
(C) were cultured in the presence of DMSO or increasing concentrations of JQ1 
(100-1000nM) for 48 hours. Metabolic activity was assessed by MTS. Results are 
presented as an average of 3 biological replicates. 
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Discussion 
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This thesis research has focused on defining and understanding the T-
ALL L-IC. An extraordinary amount of emphasis must be placed on accurately 
estimating L-IC frequency so that this assay can be used as a tool for testing 
targeted therapeutics. I have validated the assay for measuring L-IC frequency 
using two different transplantation methods and have shown that L-IC frequency 
is not influenced by transplantation method or microenvironment. I have also 
tested therapeutics in the Lck-Tal1/Lmo2 mouse model using this assay and 
have shown that both Notch1 and c-Myc inhibition target the L-IC.  
Inhibiting the Notch1-c-Myc pathway in L-ICs 
 It is clear from our studies (and others) that oncogenic pathways can drive 
L-ICs. The Notch1-c-Myc pathway is critical for T-ALL maintenance, and I have 
shown that the pathway drives T-ALL L-ICs as well. I showed that inhibiting either 
Notch1 (Chapter III) or c-Myc (Chapter IV) reduces the L-IC frequency and/or 
activity in murine T-ALL, confirming that this pathway is important in L-IC biology. 
Because of the inappropriate activation of this pathway in patient samples and 
mouse models of T-ALL, there is likely a therapeutic window for drug 
development. Directly targeting an active pathway involved in self-renewal of the 
L-IC will eliminate these cells while hopefully leaving normal tissues unharmed. 
Targeting the L-IC could also reduce or eliminate cardiac toxicities and 
morbidities caused by harsh chemotherapy, steroids, and radiation 
regimens23,440,441. 
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 In my hands, both GSI and JQ1 resulted in decreases in murine T-ALL L-
IC frequency (Tables 5 and 12, respectively). While GSI was approximately 2-
fold better than JQ1 (19-fold vs. 9.3 fold) at reducing the frequency of L-ICs, it is 
likely that this reflects JQ1 instability in vivo. The specific shRNAs to c-Myc 
resulted in a 17-fold decrease in L-IC frequency, very similar to that of GSI. This 
could suggest that c-Myc is the critical gene regulated by Notch1 in the L-IC 
population, as both GSI and c-Myc silencing resulted in an almost identical 
phenotype. However, other Notch1 target genes such as Cyclin D3 and Hes1 
would have to be inhibited to definitively come to this conclusion. The half-life of 
JQ1 in vivo is only approximately 1.5 hours, while the half-life of the MRK-003 
compound (GSI) is close to 18 hours and is not cleared from the system for up to 
3 days after administration. JQ1 is able to reduce c-Myc expression to a greater 
degree than GSI or c-Myc shRNA (Figure 22 and Figure 19, respectively), but 
probably has other targets than c-Myc in T-ALL. Together, these data suggest 
that perhaps if JQ1 were more stable, it would be as effective, if not better than 
GSI treatment in terms of L-IC inhibition. 
 Historically, a definitive c-Myc signature has not been defined in cancer 
cells, despite c-Myc expression being detected in almost 70% of human 
cancers(reviewed in282). During the course of our experiments, we became 
aware of several papers revealing insight into the c-Myc transcriptional program. 
First, c-Myc was found to be a universal amplifier of gene expression using ChIP-
seq studies and total mRNA quantifications in multiple cell types, including T-
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cells325,326. Second, “super-enhancers” were found at the c-Myc locus, and other 
critical genes, in multiple myeloma. Using ChIP-seq to the chromatin activator 
Brd4, these super-enhancers were found to be up to 15 times larger than normal 
enhancers, have increased occupancy of chromatin modulators and activated 
histone marks. This results in increased gene transcription at a particular locus. 
Morever, it was shown that super-enhancers were found genes important for the 
survival and proliferation of multiple myeloma cells, such as IRF4 and PRDM1. 
Importantly, these super-enhancers can be disrupted with agents that inhibit 
transcription initiation and elongation complexes, such as JQ1 and a homologue, 
iBET442.  
 JQ1 is able to disrupt chromatin and global transcriptional programs by 
inhibiting the binding of Brd4 to acetylated histones, specifically at super-
enhancers, like the one controlling c-Myc442. While Notch1-inhibition results in the 
downregulation of a discrete set of genes, JQ1 has the ability to disrupt critical 
growth genes within a cell in a fairly nonspecific manner. It is thought that the 
super-enhancers are located at gene necessary for the growth and survival of a 
given tissue or malignancy, so disrupting these has great potential for efficacy 
and the possibility of a therapeutic window. In multiple myeloma, JQ1 treatment 
was able to disrupt the super-enhancers and affect the expression of multiple 
genes critical to the survival of the multiple myeloma cells442. While our attempt 
at a JQ1 microarray was not successful (Appendix IV, Table 18 and data not 
shown), there is other evidence that JQ1 does inhibit a broad spectrum of genes 
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that have roles in cell growth and survival307,308,331,438. This indicates that the 
effects of JQ1 on leukemic cells are likely not due solely to c-Myc repression, but 
also due to broader effects on chromatin and other critical cellular processes. 
 Notch1 inhibitors reduced L-IC frequency and/or activity in the Lck-
Tal1/Lmo2 mouse model of T-ALL in 4 out of 5 T-ALLs tested (Figure 13). Two of 
the five T-ALLs were completely cured with GSI treatment while an additional two 
T-ALLs showed significant increases in survival and decreases in L-IC frequency 
upon GSI treatment. T-ALL 1007 did not respond at all to GSI treatment. It is 
unclear as to what caused these differences in response, but if these drugs were 
to be used in the clinic, it would be helpful to understand which patients would 
respond to GSI treatment and which would not. In our hands, the GSI response 
did not correlate to Notch1 expression or mutational status. All T-ALLs tested 
expressed high amounts of intracellular Notch1 and sequencing revealed 
mutations in the PEST domain. All of these T-ALLs also were found to have 5’ 
deletions in the Notch1 locus (Figure 15), indicating that these T-ALLs 
theoretically should have responded to Notch1 inhibition. Our T-ALL model has 
activation of the PI3K/mTOR pathway261, as well as inactivation of the Ink4a/Arf 
locus111. Both of these events could contribute to GSI resistance. Under 
conditions of Notch1 inhibition, even though there is evidence of Notch1 
mutations, the T-ALLs can upregulate an alternative pathway to facilitate their 
survival. Specifically, T-ALL 1007 did present with decreased Pten protein and 
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activated Akt (Appendix I), which could have allowed for its survival during GSI 
treatment. 
 We currently do not have a way to identify which patients will benefit from 
GSI therapy. Because of this and the GSI-associated toxicities, c-Myc may be a 
better target in this disease. In T-ALL, c-Myc is the most critical gene regulated 
by Notch1, being the only gene tested so far to be able to fully rescue the cell 
cycle arrest and apoptosis caused by GSI administration110,172. It is becoming 
increasingly evident that c-Myc is the driver of proliferation and differentiation in 
T-ALL cells and that cells can find many ways to upregulate its expression. As 
discussed in Appendix III, TAL1 has been shown to upregulate c-MYB in human 
T-ALL cell lines and patient samples119. c-Myc is also a target of c-Myb443, so this 
could be an additional pathway that activates the c-Myc oncogene. Under 
conditions of Notch1 inhibition, this Tal1-Myb-Myc pathway should still be active 
and so c-Myc may be able to mediate GSI resistance. The Akt pathway and loss 
of Pten expression can also increase c-Myc transcriptional activity by inactivating 
the kinase activity of GSK-3β, which phosphorylates c-Myc and targets it for 
degradation444.  
In Lck-Tal1/Lmo2 T-ALLs, JQ1 inhibited proliferation and induced 
apoptosis in leukemic cell lines in vitro (Figure 22) and prolonged survival in vivo 
(Figure 24). Importantly, JQ1 treatment decreased L-IC frequency in vivo (Table 
11), demonstrating that the drug could prevent or treat relapse in patients. When 
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compared to GSI in vitro, JQ1 treatment resulted in increased apoptosis, 
decreased proliferation, and greater inhibition of c-Myc activity (Figures 22, 23). 
The increase in apoptosis compared to GSI is most likely due to JQ1 inhibiting 
additional Brd4-dependent targets that affect leukemic growth and survival. 
Possible candidates for these additional target genes could be c-Myb, Bcl-XL, or 
other critical T-cell differentiation genes.  
Some mouse T-ALLs did not fully respond to c-Myc suppression or 
inhibition in vivo (T-ALLs 6124 and 7118 in Chapter IV). We do not believe that 
these data point to the presence of a “Myc-independent” subset of T-ALLs. In 
contrast, our evidence suggests that there are a number of complex events that 
take place when these leukemias are transplanted in vivo. T-ALL 6124 did not 
respond significantly to c-Myc shRNA in vivo, but did show decreases in 
proliferation in vitro. These cells also underwent cell cycle arrest and apoptosis 
following JQ1 treatment in vitro. Notably, greater effects on proliferation in T-ALL 
line 6124 were seen with JQ1 when compared side by side to a re-infection with 
c-Myc shRNA (not shown). As mentioned in Chapter IV, it is likely that the c-Myc 
shRNA was rapidly silenced in T-ALL 6124 in vivo. The pressures of initiating 
disease in vivo are likely very strong and therefore cells that have an advantage, 
such as a clone that has silenced the retroviral LTR, are selected to initiate 
disease. Likewise, a clone that has other specific molecular characteristics such 
as additional pathway activation (i.e. PI3K/Akt or Ras) could be selected for in 
vivo and thus result in a different phenotype than what was seen in vitro. This 
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may have been the case in T-ALL 7118 (Chapter IV) or 1007 (Chapter III, 
Appendix I). 
While JQ1 treatment significantly extended survival in vivo, it failed to 
inhibit disease initiation in any of the recipient mice from T-ALL 7118. We do not 
think that the decreased response in T-ALL 7118 is due to issues with drug 
administration or the emergence of a Myc-independent clone. Re-administration 
of JQ1 decreased c-Myc expression in vivo. This revealed that c-Myc is inhibited 
with the 50mg/kg dose of JQ1 in leukemic tissues in vivo, but may not inhibit 
other important target genes at this dose in T-ALL 7118. It is also possible that 
this repression is short lived, as JQ1 has been shown to have a half-life on the 
order of 1.5 hours in vivo. Coupled with the short, approximately 30-minute half-
life of the c-Myc protein itself, this could have resulted in rapid re-expression of c-
Myc in vivo. Primary cells from the 7118 T-ALL were treated with JQ1 in vitro and 
showed sensitivity similar to murine leukemic cell lines (Figure 26; IC50=273nM, 
cell line range 163-343nM, not shown), indicating that this T-ALL is not inherently 
resistant to JQ1 treatment. 
Possible causes of GSI resistance 
 We have seen variable responses to GSI in vivo and so it is probable that 
additional genetic events contribute to T-ALL development and may influence 
responses to GSI treatment. We did find evidence of Pten loss and Akt pathway 
activation in T-ALLs with moderate to no GSI response in vivo (Appendix I). Pten 
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loss and subsequent Akt pathway activation correlated with decreased disease 
latency (Table 13), suggesting that Pten loss results in development of more 
aggressive T-ALLs. It is still unclear if the activation of the Akt pathway enriches 
for L-ICs or if it results in accelerated growth of existing L-ICs. It is also possible 
that the loss of Pten made the leukemic cells GSI resistant, a mechanism of GSI 
resistance in human T-ALL cell lines420. Mutations in additional oncogenes or 
tumor suppressors may also emerge upon transplant and is an area of active 
interest in our lab. 
 Over the course of these experiments, we have noticed that treating the 
Lck-Tal1/Lmo2 T-ALLs in vitro resulted in a decreased GSI response compared 
to what was seen with Lck-Tal1 T-ALLs. Previously, our lab showed robust cell 
cycle arrest followed by apoptosis in GSI-treated murine cell lines within 48 
hours248. The Lck-Tal1/Lmo2 T-ALL cell lines tested in Chapter IV did not 
undergo cell cycle arrest until 96 hours of treatment and did not undergo 
apoptosis at all in that time. It is possible that Lmo2 expression somehow is able 
to confer Notch1-independent survival signals. 
 Studies in CD2-Lmo2 transgenic mice have revealed a unique gene 
signature associated with overexpression of Lmo2 in the developing 
thymus137,405. The Lmo2 gene signature is closely associated with the Lyl1 T-ALL 
signature, a more immature subclass of T-ALL, and with ETP-ALL samples. 
These signatures are associated with the induction of stem cell genes such as 
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Hhex, c-Kit, and Nfe2. Hhex in particular has been shown to induce self-renewal 
in thymocytes, like Lmo218. Hhex is a transcriptional repressor that activates Wnt 
signaling by repressing the transcriptional repressor Tle4445. In Lmo2-expressing 
cells, Wnt activation may be one mechanism whereby cells resist the effects of 
Notch1 inhibition through upregulation of genes such as Cyclin D1 or c-Myc. Wnt 
activation may not override the requirement for Notch1 signaling, but under 
conditions of Notch1 inhibition, this parallel pathway could contribute to leukemic 
cell survival and a GSI-resistant phenotype. 
Recently, in the same mouse model, Lmo2-expressing thymocytes were 
shown to induce a hematopoietic stem cell-like signature in part by upregulating 
Nfe2, Hhex, Lyl1, Gata2, and N-Myc while downregulating death receptor genes 
such as Fas1405. This Notch1-independent, and possible Tal1-independent, 
signature may be able to keep cells alive longer under conditions of Notch1 
inhibition and prevent apoptosis by continuing the production of key cell growth 
genes.  
Defining and characterizing the L-IC 
 We are confident in the validity of the assay used to calculate the L-IC 
frequency in murine T-ALL (Chapter II), so we can use it to further define 
characteristics of the L-IC. The critical need for additional cell surface markers to 
define the L-IC is discussed in Appendix II. At this point, we are confident that the 
L-IC is a subset of the DN3 population, but the precise cell has not yet been 
   142 
defined. Once we further enrich the population by using additional cell surface 
markers, we may able define additional pathways that mediate L-IC activity and 
design targeted therapies. 
 c-Kit postivity ranges from 1-60% of DN3 cells (average 16%, Table 14) 
and could potentially enrich for the L-IC by 2-100 fold. While c-Kit could 
potentially define functional subsets of the L-ICs (Appendix II), it is likely that 
additional markers will be needed because of the low frequency (0.003-0.05%) 
estimated in Lck-Tal1/Lmo2 T-ALLs. For the purpose of sorting cells and 
enriching the L-IC population, it would be most beneficial to start with members 
expressed on the extracellular surface and those shown to export 
chemotherapeutics. Other intracellular transporters may also be analyzed to 
determine other biological characteristics of the L-IC. 
 In breast cancer, chemotherapy enriches for T-ICs374. Drugs like 
topoisomerase inhibitors, alkylating agents, and anti-metabolites kill the rapidly 
dividing cells in the tumor, leaving a slow cycling T-IC population behind, primed 
to mediate relapse. It may be possible to enrich for an L-IC population in T-ALL 
by using conventional T-ALL induction therapies such as vincristine or 
methotrexate. A recent study reported that glucocorticoid (dexamethasone) 
treatment selects for a resistant population in T-ALL that expresses L-IC 
markers447, but further analysis was not performed on this population beyond 
clonality assessment.  A short burst of treatment that does not eradicate disease 
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should leave a population of cells that could be then be analyzed for cell cycle 
status, altered gene expression, cell surface markers, and L-IC activity. Murine T-
ALLs and T-ALL patients usually show a very good initial response rate to 
induction regimens, however, so determining an appropriate therapeutic window 
would be critical. 
 Other possibilities for L-IC enrichment could be targeted toward the 
altered metabolic state found in cancer cells. Because of rapid cell growth and 
availability of key nutrients, cancer cells will often switch from normal glycolysis 
to glutaminolysis448. This process will produce energy from glutamine instead of 
glucose and is controlled in part by c-Myc449. Therefore in T-ALL, looking at 
glutamine transporters such as ASCT2, may be a beneficial way to enrich for L-
ICs.  ASCT2 has been shown to mediate malignant growth in a variety of 
malignancies such as brain, breast, prostate, and lung cancers450,451. It is also 
possible that glucose transporters are still important to the L-ICs, as GLUT3 has 
been shown to be implicated in maintenance of germinal, neural, and skeletal 
muscle stem cells452–454 and has roles in angiogenesis in cancer cells(reviewed 
in455). 
L-IC assay validation 
 While we have validated the L-IC assay and are confident with the L-IC 
frequency calculated in our model, some questions still remain. Other groups 
have measured L-IC frequency in animals that are either sub-lethally irradiated or 
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immunodeficient113. Tremblay and colleagues used a similar mouse model pSIL-
Tal1/Lck-Lmo1, and reported L-IC frequencies of 1%, approximately 10-fold 
higher than what we have found. Importantly, my colleague Kathleen Cullion and 
the Tremblay group found the DN3/DN4 thymocyte population enriched in L-IC 
activity, indicating that the L-IC population is the same in two models with similar 
driving oncogenes. This points to additional differences in assay design and 
mouse models to yield such different L-IC frequencies. These differences could 
range from sublethal irradiation to genetic background to the oncogenic 
promoter. 
 Sublethally irradiating mice serves to make space in the thymus and bone 
marrow by killing some, but not all, of the hematopoietic cells and 
lymphocytes456. This reduction in thymic and bone marrow cellularity reduces 
competition in these niches398. Changes in microenvironment can also occur with 
irradiation including stromal remodeling, increased cytokine production, and DNA 
damage(reviewed in457). Theoretically, sublethal irradiation might result in the 
engraftment of more L-ICs due to the increased space and decreased 
competition. However, my preliminary data do not suggest that irradiation affects 
the frequency of the T-ALL L-IC (not shown). This is consistent with the data 
presented in Chapter II, in that the T-ALL L-IC is not influenced by changes in 
microenvironment. Additional T-ALLs will need to be analyzed to solidify these 
results. 
   145 
 The effect of the recipient immune system on L-IC frequency is a more 
difficult issue to address. Severely immunocompromised mice such as 
NOD/SCID (NS) or NSG mice have little to no functional lymphocytes, decreased 
dendritic cell function and defective macrophages. NS mice have no B- or T- 
cells and thus no adaptive immunity458 while NSG mice also have limited innate 
immune capabilities, with likely only limited natural killer (NK) cells contributing to 
an immune response. Not only do these deficiencies reduce cellularity in the 
bone marrow and thymus, but they also prevent any sort of competition or host 
immune response459. As a result, these mice are used to engraft normal and 
malignant human cells. Because these mice can be used to engraft normal cells 
(without self-renewal capabilities), it may be too permissive to accurately 
calculate L-IC frequency. Tremblay and colleagues used a Rag-/- host113, which 
results in a lack of mature T-cells, so this could be another source of variation 
between our data. 
 Recently, increasing evidence has surfaced that the host (or patient) 
immune system plays a valuable role in eliminating cancer cells from the body. 
NK cells are able to recognize tumor cells based on their cell surface expression 
of various proteins and target these cells with cytotoxic perforin and granzyme 
molecules (reviewed in460). Specifically, NK cells can recognize if a cancer cell is 
expressing too little or two much major histocompatibility complex (MHC) I on the 
cell surface and remove these cells from the body461. In our murine 
transplantation model, the NK cells in the syngeneic transplants could be 
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eliminating some of the T-ALL cells from circulation before they are able to 
initiate disease, thus resulting in an apparently low L-IC frequency. Other 
immune cells such as cytotoxic T-lymphocytes (CTLs) or innate immune cells 
other than NK cells could contribute to this response as well. In preliminary 
experiments comparing wild type recipients and NSG mice, murine T-ALL cells 
showed a 10-fold increased penetrance (L-IC frequency) and slightly decreased 
latency in the NSG mice in two out of three experiments (not shown).  
These data could indicate that the L-IC assay in syngeneic recipients may 
not be the best readout for L-IC frequency, as it may be underestimating the 
number of cells contributing to disease. Alternatively, one could argue that a 
patient would likely have at least some level of NK and other immune cell activity 
in the body and therefore an assay should be conducted where these cells are 
present. We have not conducted experiments to examine the cell surface 
molecules present on our murine T-ALLs to see if different populations may be 
more immunogenic than others, but it is also possible that the only reason we do 
not see L-IC activity in more mature DP populations is that they are able to 
trigger an immune response in the host animal. Sort experiments will need to be 
done to determine whether DP cells have any L-IC activity in 
immunocompromised mice. 
 Lastly, a source of L-IC frequency variation could be traced to genetic 
differences in the oncogenes used to drive T-ALL. Tremblay and colleagues used 
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the SIL-Tal1 model, where Tal1 expression is driven by a ubiquitous promoter in 
the genome107,108, while the Lck promoter is only expressed in immature T-cells. 
Expression levels of Tal1 have not been compared between these two models; 
however, variation could be present that cause differences in L-IC frequency. 
The differences between Lmo1 and Lmo2 used as cooperating oncogenes in the 
two T-ALL models are probably negligible, as the two genes share homology and 
functional overlap. 
T-ALL Heterogeneity 
 In Chapter II and Appendix I, I showed that clonal selection events take 
place when primary murine T-ALLs are transplanted into recipient mice. Not all 
leukemic clones have the same ability to transfer disease, providing additional 
evidence for functional heterogeneity in these T-ALLs. I also noticed that 
leukemic clones that exhibit Pten loss emerge in transplanted mice, where the 
primary leukemia expressed wild-type levels of the protein. This clone 
presumably possesses all the same qualities of an L-IC, but the proliferative and 
survival advantages gained from the Pten mutation allowed this clone to become 
dominant. These data indicate that while we know that T-ALL is organized in a 
functional hierarchy, there is emerging evidence of clonal dominance in T-ALL as 
well. 
 The data presented in this thesis, along with recently published work, help 
to reveal a more detailed picture of T-ALL pathogenesis (Figure 27). We have 
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known that the Lck-Tal1/Lmo2 model of T-ALL results in a DN3 block in 
thymocyte differentiation before leukemogenesis. We now know that Lmo2 is 
able to induce self-renewal in these cells and that Notch1 mutations occur 
preleukemically (Table 2). This aberrant pool of DN3 thymocytes expands but 
retains the ability to differentiate, most likely once the Notch1-c-Myc pathway 
becomes prominently activated. There must also be additional genetic events 
that occur before the onset of disease because Notch1 mutations occur in the 
preleukemic state, before the onset of T-ALL. One possible event is 5’ deletions 
in the Notch1 locus that remove the extracellular domain and render the protein 
ligand-independent. These mutations were not detected at the preleukemic stage 
(4-6 weeks old), but are prominent in murine T-ALLs (6/7 examined)249,251. The 
leukemic DN3 cells remain dependent on the Notch1-c-Myc pathway as they 
initiate disease in the mouse in a cell autonomous manner. This thesis provides 
evidence that T-ALL is driven by both the cancer stem cell (hierarchical) model of 
leukemogenesis and the clonal evolution model. These data advocate for the 
development of anti-L-IC therapies in T-ALL. Specifically, I have shown evidence 
for the further development of inhibitors that target the Notch1-c-Myc pathway 
while maintaining a low toxicity profile in patients. 
Future directions: 
 Our main goal for this project is to define and target the L-ICs in our 
murine T-ALL mouse model, and ultimately in patients. To do this, we must purify 
the L-IC based on surface markers and/or biological properties (discussed in 
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Appendix II). Options on how to do this have also been discussed already in this 
thesis. It would also be interesting to determine whether the L-IC population is 
different in Lck-Tal1, Lck-Lmo2 and/or Lck-Tal1/Ink4aArf+/- mice (models we 
already have available in the lab). The immunophenotypes of these T-ALLs are 
slightly more differentiated than the Lck-Tal1/Lmo2 mice described here and so it 
is possible that the L-IC population or resulting L-IC frequency may be different. 
This type of analysis could reveal differing roles for the Tal1 and Lmo2 
oncogenes in the disease in terms of self-renewal and/or L-IC frequency. 
Performing L-IC assays in these additional mouse models will also solidify the 
universality of the L-IC/stem cell hypothesis in the pathogenesis of T-ALL.  
Future experiments will revolve around determining the functional 
characteristics of the human T-ALL L-IC. An L-IC frequency has not yet been 
definitively determined in T-ALL patients using immunodeficient mice, but 
functional populations have been defined. In human T-ALL, the initiating cell is 
thought to be an early T-cell progenitor that is CD34+ and CD7+. In human T-cell 
development, this would compare to a DN2/DN3 cell that is beginning to commit 
fully to the T-lineage. These data correlate roughly to the population defined in 
mouse models of the disease. These data also indicate that the NSG model for 
engrafting T-cells is not entirely permissive, as CD34- and CD7- cells had limited 
engraftment abilities in these mice. 
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 Along with defining an L-IC population in human T-ALL patient samples, 
we will attempt to target this L-IC with therapies, and potentially shRNAs to 
specific oncogenic pathways. This latter experiment has been daunting in the 
past due to viability issues with primary patient samples, but progress is being 
made in the lab and we are optimistic that we will soon be able to infect these 
cells. If infection of the patient samples is successful, we should be able to 
perform unbiased in vivo shRNA screens with the samples to determine critical 
pathways involved in the self-renewal of T-ALL patient samples. 
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Figure 27. A model for T-ALL development. The forced expression of Tal1 and Lmo2 
in the developing thymus causes a block in development and the accumulation of DN3 
cells that gain the ability to self-renew. Activation of the Notch1-c-Myc pathway occurs in 
these cells via PEST region mutations and 5’ deletions at the Notch1 locus. The self-
renewing DN3 thymocytes gain the ability to expand into an oligoclonal T-ALL. Only the 
DN3 cells in the tumor have the ability to transfer disease to recipient mice, but there can 
be clones within the T-ALL with differing transplant capabilities. One event documented 
in this thesis was the loss of Pten upon T-ALL transplant, thus giving a leukemic clone a 
selective advantage. In theory, if one DN3 cell could be transplanted or if a clonal DN3 
population could be sorted out, resulting disease should be clonal. 
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Appendix I: Clonal selection for Pten loss 
occurs upon T-ALL transplant 
  
   153 
Introduction 
 Pten was discovered as a tumor suppressor in the 1980’s when a part of 
chromosome 10 was found to be deleted in a set of malignant gliomas462. Later it 
was identified as the cause of a number of familial benign harmartoma 
syndromes, including Cowden syndrome463 and mapped to the 10q23 deletion464. 
Pten is considered a haploinsufficient tumor suppressor because even partial 
losses in protein expression can result in large phenotypic changes465. The Pten 
model of tumorigenesis is considered a continuum model because slight changes 
in Pten dosage can dictate not only tumor susceptibility but also the progression 
of disease(reviewed in466). 
 Pten is a lipid phosphatase involved in negatively regulating the PI3K-Akt 
signaling pathway 467,468. Pten dephosphorylates and thus deactivates PIP3, 
which activates PDK1. Once activated, PDK1 phosphorylates Akt at Thr308, thus 
activating the Akt and mTOR signaling cascades. The Akt pathway promotes cell 
survival, proliferation, cell growth, angiogenesis, and metabolism by 
phosphorylating downstream proteins such as GSK3β, FOXO, Bcl-2, BAD, 
MDM2, and p27(reviewed in469). Akt is also able to activate the mTORC1 
complex, which phosphorylates the p70S6K and promotes cell growth and 
survival(reviewed in470). Thus, many tumors find ways to decrease Pten 
expression, therefore activating these critical oncogenic pathways. 
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Both the PI3K and Akt pathways are able to help promote the metabolic 
reprogramming of cancer cells, known as the Warburg effect471. Cancer cells, 
due to their excessive growth, increase glycolysis and lactate production in 
cells(reviewed in472). The PI3K and Akt pathways help to increase glucose 
uptake473 and allow cells to increase lipid and macromolecule synthesis 
pathways474. Pten deletion has also been linked to promoting tumor-permissive 
stroma in mouse models of breast cancer and human breast cancer cell 
lines475,476 and is indeed deleted in many breast cancer patient samples386,477. 
In adult tissue stem cells, such as HSCs, Pten deletion caused a decrease 
in the HSC pool and a coordinate increase in T-ALL and AML L-IC 
populations339,478,479. Treatment of mice with rapamycin, an inhibitor of mTOR 
signaling, decreased the L-IC pool and restored the self-renewal capacity to 
HSCs340,480. This is consistent with additional reports, which found that increased 
mTOR signaling depletes stem cells by activating critical cell cycle and 
senescence checkpoints(reviewed in480). Pten-null mice are viable, but develop a 
variety of malignancies, including T-ALL and AML481. Pten deletions have also 
been found in T-ALL patient samples at diagnosis, and after relapse of the 
disease336,482,483. These findings indicate a critical role for Pten loss in the 
transformation of normal stem and progenitor cells. 
Pten is regulated by a variety of genetic and epigenetic processes. Notch1 
signaling, for example, is able to promote Pten transcription through CSL or 
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repress its transcription through activation of c-Myc484,485. Pten transcription is 
also repressed by the proto-oncogenes Bmi-1 and c-Jun486,487. miRNAs488 and 
competitive endogenous RNAs (ceRNAs)489 regulate Pten at the translational 
level by inhibiting translation or acting as decoys to miRNA repression, 
respectively. At the post-translational level, Pten can be modified by 
phosphorylation, acetylation, or ubiquitination events and the number and 
location of these modifications will dictate whether the activity of Pten is 
increased or decreased. These modifications can also affect the localization of 
the protein, which can in turn affect the ability of Pten to act on its targets. Finally, 
Pten can be regulated by protein-protein interactions, which can increase or 
decrease the phosphatase activity of the catalytic domain by stabilizing or 
destabilizing particular residues(reviewed in 490). 
In some human T-ALL cell lines, Pten loss has correlated with GSI 
resistance420. The Notch1 target gene Hes1 is a repressor of Pten, such that 
when Notch1 is active in cells, Pten expression decreases and Akt signaling 
increases, furthering T-ALL cell growth and proliferation491. When GSIs are 
administered to cell lines with intact Pten, Hes1 repression of Pten decreases 
and therefore so does Akt signaling; the cells respond by undergoing G1 arrest. 
In cell lines where Pten expression is lost, GSIs seem ineffective because the 
activation of the Akt pathway continues in the absence of Notch1 signaling. This 
observation was not corroborated when using murine T-ALL cell lines or T-ALL 
patient samples, so the notion that Pten loss confers GSI resistance is still under 
   156 
debate. Recent reports, however, have shown that Pten loss is able to 
deregulate c-Myc expression, thus increasing its oncogenic potential444,492. 
Because c-Myc has been shown to rescue the effects of Notch1-
inhibition110,172,259, c-Myc deregulation via Pten loss could be another way T-ALLs 
appear resistant to GSI treatments. 
In this Appendix, I will discuss experiments undertaken to determine the 
cause of the variability seen in GSI responses in our mouse model of T-ALL (III). 
We examined the Pten locus in the T-ALLs used for the study described in 
Chapter III and found that some tumors underwent Pten loss upon transplant in 
recipient mice. However, attempts to determine the mechanism by which this 
loss occurred in these T-ALLs were not entirely successful. 
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Results 
 As I completed the in vivo GSI studies described in Chapter III of this 
thesis, we tried to explain the differences in the responses to GSI across the 
various tumors. We found a correlation between disease latency and response to 
GSI; specifically, aggressive leukemic growth was associated with GSI 
resistance in vivo (Table 4). Some tumors (1007, 1928, 3304) were more 
aggressive than the others (1426, 2544) but this aggressiveness did not correlate 
with an increase in L-IC frequency. Thus we hypothesized that additional growth 
and survival pathways may be activated in these leukemias. 
 We started our investigation with looking at Pten expression in these T-
ALLs, based on evidence that Pten loss confers GSI resistance in human T-ALL 
cell lines. We found that in the three T-ALLs that were most aggressive (1007, 
1928, 3304), decreased disease latency was associated with decreased Pten 
expression (Figure 28). Because Pten is a prominent negative regulator of Akt 
signaling, we examined levels of phosphorylated Akt (p-Akt). Indeed, the T-ALLs 
that expressed Pten upon transplant (1426, 2544) expressed little to no p-Akt 
while the T-ALLs that lost some degree of Pten expression showed increased 
levels of p-Akt (Figure 28B and Table 13).  
 In order to determine the mechanism of Pten loss/decrease in these 
murine T-ALLs, we analyzed mRNA and protein of the tumor tissues before and 
after transplant (Table 13). The T-ALLs examined expressed low levels of miR-
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19b (Figure 29A), a miRNA that negatively regulates Pten translation493,494. This 
was surprising, as miR-19b is expressed as a part of the miR-17-92 cluster, 
which is activated by c-Myc. It is still possible that Pten levels in these murine T-
ALLs are being modulated by other miRNAs. 
 T-ALL 3304 expressed a decreased amount of Pten mRNA as compared 
to T-ALLs 1426 and 2544 (Figure 29B), which maintained Pten protein 
expression upon transplant. It is possible that the Pten mRNA is being targeted 
for degradation by a miRNA other than miR-19b. More likely, the L-ICs 
developed a mutation or deletion in the Pten genomic sequence in the recipient 
mice, either resulting in decreased mRNA expression or decreased mRNA 
stability. Alternatively, this particular clone existed in the primary T-ALL and that 
the mutation gave the clone a selective advantage in the recipient mice, as seen 
in patient samples when engrafted into immunodeficient mice336. Lastly, 
epigenetic silencing could have taken place in T-ALL 3304. SALL4 has been 
shown to remodel the Pten locus by recruiting HDACs495; or it is possible that the 
locus underwent DNA methylation to prevent transcription(reviewed in466). 
 In T-ALL 1928, Pten mRNA was decreased in the recipient mice, however 
very low levels of Pten mRNA were detected in the primary T-ALL (Figure 29B). 
It is unclear why Pten protein was detected with little to no mRNA expression 
being detected. The primary tumor material from these studies were used to 
publish the manuscript described in Chapter III, and so unfortunately not enough 
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material remained to repeat these experiments.  In T-ALL 1007, no changes in 
Pten mRNA were detected in recipient mice, while protein levels were quite low 
in the recipient animals (Figure 28B, 30B). In this T-ALL, it is likely that miRNAs 
are important, although it is unclear which one(s). Possible candidates include 
miR-17, another member of the oncogenic miR-17-92 cluster494,496–498, and miR-
21, a miRNA implicated in solid tumors for inhibiting Pten translation499,500.  
 Technical hurdles throughout these experiments prevented optimal data 
analysis. Primary T-ALL material was limiting and was not prepared in buffers to 
preserve phosphorylated epitopes and so p-Akt could not be compared before 
and after transplant. There were also difficulties in preparing lysates from frozen 
leukemic tissues from recipient mice. We think that this may explain why 
increased p-Akt was not observed in 1007 and 3304 (Figure 28). In retrospect, 
lysates should have been prepared from fresh leukemic tissues so that 
phosphorylated proteins could be examined. 
 We obtained Ptenfl/fl mice501 to determine if loss of Pten alters murine T-
ALL L-IC frequency or if loss simply activates the Akt pathway and results in 
increased T-ALL growth and survival. It was difficult to determine this by using 
data from the tumors in our GSI study because at the time of analysis, some 
tumors had lost Pten and some had retained it. The L-IC frequency in the Lck-
Tal1/Lmo2 model of T-ALL is highly variable, so it would be best to compare the 
effects of Pten expression within a single tumor, not across a small sampling of 
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tumors. Since data was inconclusive, we turned our focus to the Notch1 target 
gene c-Myc to examine self-renewal and proliferation of T-ALL L-ICs (Chapter 
IV). 
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Discussion 
 In this small study, we have shown that genetic selection occurs in murine 
T-ALLs upon transplant into recipient mice. Pten loss, either de novo or through 
selection for a specific clone, takes place in a subset of T-ALLs and this loss 
correlates to more aggressive disease in vivo. Although in this cohort of mice the 
loss of Pten expression did not correlate with GSI resistance, other groups have 
shown that PTEN loss does mediate resistance in human T-ALL cell lines420. A 
larger number of leukemias and more rigorous genetic experimentation are 
required to resolve these issues and to find a definitive answer as to what 
mediates GSI resistance. 
 It is possible that when Pten loss is selected for in T-ALL, this event also 
increases the L-IC frequency. Increased Akt pathway signaling has not yet been 
linked to increased cancer initiating cell activity, but it has been shown to 
increase oncogenic potential of T-ALL482,502. We hypothesized that the apparent 
increase in T-ALL aggressiveness could be a reflection of increased L-IC 
frequency. Because murine T-ALLs are oligoclonal, and not all clones remain in 
transplanted mice (Chapter II), transplantation of single clones may resolve some 
of the inconsistencies in Pten expression that we see upon transplant. 
Transplanting clones in this way from a single T-ALL would also determine 
whether Pten loss confers changes in L-IC frequency, within a single leukemia.  
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 Coupled with the TCR-Vβ clonality selection discussed in Chapter II, these 
experiments show that serial transplantation selects for leukemic clones in 
recipient mice. Thus, serial transplantation could be used as a model for relapsed 
T-ALL because transplantation selects for the most aggressive leukemic sub-
clones. We know that the disease is oligoclonal based on TCR-Vβ expression. It 
is possible that with serial transplantation, we could bring this down to a clonal T-
ALL. If we are able to transplant a single L-IC, we would be able to come to a 
conclusion about the role if Pten in T-ALL initiation. 
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Methods 
Mice 
All mouse experiments were performed according to IACUC standards as 
described in Chapters II, III, and IV of this thesis.  
Immunoblotting 
Protein was isolated from primary T-ALLs and leukemic tissues from recipient 
mice. Samples were run on a 4-12% Bis-Tris gel (Invitrogen) and blotted with 
antibodies to Pten (Cell Signaling catalog #9552), phospho-Akt (Cell Signaling 
catalog # 4060S), total Akt (Santa Cruz catalog # sc-8312), and total Erk1/2 (Cell 
Signaling catalog # 9102S).  
Expression analyses 
mRNA was isolated from primary T-ALLs and leukemic tissues from recipient 
mice using Trizol reagent (Invitrogen). cDNA was synthesized and expression of 
Pten mRNA quantified by qPCR using specific primers: F5- 
TGGATTCGACTTAGACTTGACCT’-3’, R5’- GCGGTGTCATAATGTCTCTCAG-
3’. Expression was normalized to β-Actin expression using the ΔΔCT method. 
miRNA was isolated from primary T-ALLs and leukemic tissues from recipient 
mice using the miRVana kit (Ambion). Specific miRNA cDNA was generated 
using the TaqMan kit for miR-19b and expression was quantified by qPCR. 
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Expression of miR-19b was normalized to expression of the housekeeping 
miRNA sno202. 
  
   165 
 
 
 
 
Figure 28. Pten protein decreases upon transplant and results in increased 
Akt signaling. A. Protein was isolated from primary T-ALLs before transplant 
and Pten expression was analyzed by immunoblotting. B. Protein was isolated 
from snap-frozen tissue from recipient mice. Pten, p-Akt, and total Akt levels 
were analyzed by immunoblotting.  
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Figure 29. There is no correlation between miR-19b expression and 
reduced Pten expression in transplanted T-ALLs A. miRNA was isolated from 
leukemic tissues of recipient mice. miR-19b expression was analyzed using the 
TaqMan qPCR assay and was normalized to snoRNA202. Data shown are the 
average of three experiments. B. Total mRNA was isolated from leukemic tissues 
from primary leukemias and recipient mice (denoted R) and cDNA synthesized. 
Pten expression was analyzed by qPCR and normalized to β-Actin via the ΔΔCT 
method. Data shown are the average of three experiments. 
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Table 13. Loss of Pten expression correlates with decreased GSI sensitivity 
and increased p-Akt. 
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Appendix II: Attempts to further characterize 
the L-IC population  
   169 
Introduction 
 The focus of my dissertation research has been to identify and 
characterize the murine T-ALL L-IC and then target pathways to inhibit its growth 
and survival. Our current data on the Lck-Tal1/Lmo2 L-IC suggest that the L-IC is 
a subset of the DN3 population (251 and Table 1). The percent of DN3 cells does 
not correlate with L-IC frequency (Table 1) and therefore further purification is 
necessary in order for a definitive L-IC population can be determined. Because of 
the low frequency of L-ICs in the Lck-Tal1/Lmo2 model of T-ALL, it is likely that 
more than one marker will be necessary to purify the population. 
 c-Kit, also known as CD117, is a cell surface cytokine receptor that binds 
stem-cell factor (SCF) and initiates PI3K, Stat(1,3,5), and MAPK signaling 
cascades503,504, all of which promote cell survival, proliferation, and differentiation 
of hematopoietic cells505. c-Kit-/- mice present with hematopoietic, germ cell, and 
melanoblast defects506. Expression of c-Kit is critical to early thymocyte 
development, specifically thymocytes in the DN1 and DN2 stages507. Its 
expression is decreased in T-cells between the DN2b and DN3a stages of 
thymocyte development, but low expression is retained until the cells reach 
DN4/DP. Single-positive T-cells do not express c-Kit, except briefly during CD8 
stimulation(reviewed in40). 
The interleukin-7 receptor (IL7R) consists of a heterodimer of 2 subunits: 
IL7Rα (CD127) and the common-γ receptor (CD132). Once engaged with its 
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ligand, IL7, the IL7R initiates a signaling cascade mediated by the JAK/STAT5 
and PI3K/mTOR pathways(reviewed in399). One of the main functions of the IL7R 
is to promote survival and inhibit apoptosis in developing thymocytes. The 
expression of IL7R is critical for early T-cell specification and differentiation, but 
expression decreases starting at the DN3 stage until it is undetectable in single 
positive thymocytes508,509.  
As mentioned in the Chapter I, the DN3 population can be divided into two 
subpopulations (DN3a and DN3b) based on the expression of CD2753. CD27 is a 
member of the TNF family of cell surface receptors and initiates MAPK and NFκB 
signaling after binding its ligand CD70, thereby promoting proliferation of T-
cells510–512. Expression is absent in T-cells until the DN3b stage of development 
as the receptor has critical roles in developing long-term immunity in mature T-
cells. The expression of CD27 also correlates with the downregulation of Notch1 
signaling in normal developing thymocytes419. The transition of T-cells from the 
DN3a to DN3b stage marks the transition from quiescence to rapid 
proliferation(reviewed in40). This marker also has leukemic implications: in CML, 
the expression of CD27 is associated with increased L-IC activity513. 
 This Appendix will discuss attempts to define the L-IC based on cell 
surface markers normally expressed on T-cells (CD27) and those expressed on 
more immature progenitor cells (c-kit and IL7R). I also conducted some 
preliminary experiments with BrdU incorporation to determine if the L-IC 
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population consists of quiescent or rapidly dividing cells within our murine T-
ALLs. 
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Results 
I stained seventeen primary T-ALLs and four preleukemic thymi (mice age 
4-6 weeks) for the expression of c-Kit because of its role in early thymocyte 
survival and differentiation. Normal thymocytes express c-Kit at the DN1 and 
DN2 stages, but expression begins to decrease during the transition from DN2 to 
DN3. On 3/4 preleukemic DN3 and 4/4 preleukemic DN4 cells, there appears to 
be some aberrant expression of c-Kit (Table 14). This expression is decreased or 
undetected in transformed T-ALLs, except for two leukemias (3264 and 4018) 
that expressed high levels of c-Kit in the DN3 compartment. These data suggest 
that c-Kit may have a role in the preleukemic differentiation block caused by 
overexpression of Tal1 and/or Lmo2 and potentially could contribute to self-
renewal of this population. In fact, the Tal1 complex is thought to control the 
expression of c-Kit at the DN1/DN2 stage in normal hematopoiesis94, so it likely 
drives expression of c-Kit in these preleukemic progenitors.  
c-Kit expression appears to decrease upon leukemic transformation, but 
can still be detected on 9/17 of the T-ALL DN3 populations examined. This is 
somewhat surprising, as Notch1, whose expression is high in murine T-ALLs, 
can also influence c-Kit expression514. c-Kit could be used as a marker to sort T-
ALLs and enrich for the L-IC population but it does not seem to be a universal or 
consistent marker on the leukemic DN3 cells. Based on its expression in 
leukemic DN3 cells, c-Kit could potentially result in a 3-10 fold enrichment of the 
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L-IC population. Unfortunately, we did not perform L-IC assays with the 17 T-
ALLs examined, so a correlation between c-Kit expressing DN3 cells and L-IC 
frequency was not made. 
Because the IL7R promotes survival in thymocytes, we hypothesized that 
it may also promote survival in the T-ALL L-IC and possibly serve as a marker to 
enrich the LIC population. Eleven primary murine T-ALLs and four preleukemic 
thymi were analyzed for expression of IL7Rα on the surface of DN3 cells (not 
shown), but results were inconclusive. Staining needs to be optimized and 
analysis repeated. IL7R expression is still an interest in our lab, especially in light 
of recent reports citing activating IL7R mutations in T-ALL515. 
In order to determine the DN3a/DN3b profile in the Lck-Tal1/Lmo2 mouse 
model of T-ALL, staining was performed on three primary T-ALLs and four 
preleukemic thymi. This analysis revealed that nearly all the preleukemic and 
leukemic DN3 cells expressed CD27 and potentially were derived from the DN3b 
subset (Table 15). Based on the characteristics of normal DN3a/b cells40, we 
could hypothesize that T-ALL L-ICs are highly proliferative. This would be 
consistent with the activation of the Notch1-c-Myc pathway at this stage in T-ALL. 
Alternatively, it is possible that there is a small quiescent population in the DN3a 
subset and that this subset contains the L-IC. 
A population of quiescent L-ICs has been described in AML that is 
consistent with normal HSC biology342,361. We attempted to examine the 
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proliferative properties of the Lck-Tal1/Lmo2 L-ICs by performing in vivo BrdU 
uptake assays. Leukemic mice were injected with BrdU and leukemic cells were 
stained for flow cytometry one hour later. BrdU staining of three primary T-ALLs 
along with thymi of two age-matched wild-type mice revealed that only a small 
portion of the leukemic DN3 cells are dividing at any given time, similar to the 
phenotype in normal thymocytes (Figure 30). These experiments may have been 
limited by the timing of the BrdU injections or by age of the wild type mice. 
Because the wild-type mice were age-matched to the diseased mice, perhaps 
the thymus had involuted to a point where cells were no longer cycling. As they 
stand, these data do not provide enough evidence to claim that there is a 
quiescent DN3 population in murine T-ALLs.  
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Discussion 
 The expression of c-Kit on the surface of DN3 cells could serve as a 
marker to sort DN3 cells and determine the L-IC frequency of the positive and 
negative populations (Table 14). It is possible that c-Kit helps contribute to the 
accumulation of pre-L-ICs in the thymus as judged by the increased expression 
of c-Kit on 3/4 preleukemic DN3 populations examined. Upon transformation, c-
Kit expression may only remain on the small population L-ICs. Consistently, c-Kit 
is present on preleukemic DN4 cells, but absent on the leukemic DN4 population. 
This could reflect the developmental block at the DN stage in preleukemic mice 
where expression decreases once the cells transform and differentiate towards 
DP blasts. It has been shown that c-Kit activation confers radioprotection to 
cells516,517. The activation of c-Kit on a subset of the DN3 population could 
mediate the radioprotection observed in CD2-Lmo2 thymocytes.  
 Because most of the cells in the preleukemic and leukemic the Lck-
Tal1/Lmo2 thymi do express CD27, this population is unlikely to be helpful in 
enriching for the L-IC population, but could elucidate more about L-IC biology. In 
one of the preleukemic thymi examined, there appeared to be a small population 
of cells that did not stain positively for CD27 expression (Table 15). This CD27-
negative population did not persist in any of the three T-ALLs examined. If further 
analysis confirms these preleukemic data, perhaps a lack of CD27 expression 
could indicate a population enriched in L-IC activity. The DN3a population is 
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blocked in the G1 phase of the cell cycle while the TCR-Vβ chain is rearranged 
and expressed; cells then progress through the cell cycle once positive selection 
of the thymocytes begins40. This G1 population could represent a quiescent L-IC 
population in T-ALL. At this point, however, this CD27-negative population does 
not persist in our murine T-ALLs, and we do not have evidence of a quiescent L-
IC. 
 Until the L-IC is further purified, an alternative to BrdU staining might need 
to be used to define cycling status of the L-IC population. The low percentage of 
BrdU incorporation in the murine T-ALLs could be an indication that the leukemic 
cells are not proliferating in the thymus. When disease is evident, the thymus is 
enlarged and it is probable that cells are unable to obtain the proper amount of 
nutrients; cells egress from the thymus and infiltrate the spleen, liver, bone 
marrow, kidneys, and lymph nodes. Analysis of these other sites of leukemic 
burden could distinguish whether leukemic DN3 are cycling more in other areas 
of the body.  
Alternatively, Hoechst 33342 staining could be performed. This stain is 
incorporated into the minor groove of DNA and can be used for cell cycle 
analysis518. However, when excited using both the red and blue lasers, the 
fluorescence can be plotted and a side population identified519. In murine bone 
marrow, the side population enriches for the HSC population520. This staining 
technique could be used with the Lck-Tal1/Lmo2 T-ALLs to determine if there is a 
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population that effluxes the Hoechst stain. Most importantly, cells stained with 
Hoechst stain can be sorted and live cells potentially transplanted into the L-IC 
assay to determine if there is a functional consequence of dye efflux. 
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Methods 
Flow cytometry 
All flow cytometry experiments were performed as previously described using 
either the FACSCalibur or LSRII machines (BD). Antibodies to c-Kit (eBioscience 
catalog #35-1171-82), CD27 (eBioscience catalog#11-0271-85) and IL7R (BD 
catalog#555288) were titrated and used at optimal concentrations for this cell 
type. The IL7R antibody was biotinylated and used with a streptavidin secondary 
antibody (eBioscience catalog#17-4317-82). BrdU uptake assays and staining 
were performed according to instructions provided in the APC BrdU Flow Kit (BD 
catalog #552598).  
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Table 14. c-Kit expression on Lck-Tal1/Lmo2 preleukemic and leukemic 
thymic subsets 
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Table 15. Increased CD27 expression is found on preleukemic and 
leukemic DN3 cells 
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Figure 30. BrdU uptake assays reveal that leukemic DN3 cells have similar 
cycling status to wild-type thymocytes. Three mice with T-ALL and age-
matched wild-type mice were injected with BrdU and rested for one hour before 
thymomas (T-ALL) or thymi (wild-type) were harvested and stained for surface 
antibodies and internal BrdU. DAPI is used as a DNA dye. Plots shown were 
gated on live DN3 cells. 
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Appendix III: c-Myb plays a role in T-ALL L-IC 
survival and/or activity  
   183 
Introduction 
 The c-Myb transcription factor is encoded by the cellular homologue of the 
v-myb oncogene discovered in the avian leukemia viruses AMV and E26. It is a 
helix-loop-helix transcription factor expressed in hematopoietic cells521,522, 
intestinal epithelial cells523, and the adult brain524 and recognizes the DNA 
sequence C/T-A-A-C-G/T-G525. c-Myb has been shown to regulate self-renewal 
in these normal tissues and has been implicated in the pathogenesis of breast 
cancer526,527, colon cancer528,529, and a variety of leukemias (AML, CML, T-ALL) 
79,530–535.  
 The target genes of c-MYB range from housekeeping genes to T-cell 
genes to proto-oncogenes(reviewed in443). Many of the genes activated by c-
MYB are involved in cell cycle progression, such as cyclins and cyclin-dependent 
kinases536–538. Other target genes of c-MYB inhibit apoptosis, such as BCL-2 and 
BCL-XL539–541. In murine knockout models, it was found that that c-Myb is 
required for erythropoiesis in the fetal liver; null mice were severely anemic and 
did not survive to birth521. Using a conditional knockout model in the 
hematopoietic system, Lieu and colleagues showed that c-Myb is required for 
self-renewal of hematopoietic stem cells542 and the development of T-cells543. c-
Myb is required for progression through the DN3 stage, survival of DP 
thymocytes, and maturation of CD4-single positive cells544,545. Any of these 
checkpoints could be critical to the survival of T-ALL cells. 
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 In human T-ALL, both somatic duplications and translocation events have 
been shown to activate the c-MYB locus and contribute to disease 
pathogenicity532,533. In the case of translocation t(6;7)(q23;q34), the c-MYB locus 
is introduced into the TCRβ locus, which drives its expression in differentiated T-
cell blasts532. c-Myb expression is normally decreased after T-cells reach the 
DN3 stage of thymocyte development, but not entirely eliminated545,546. A 
proliferation/mitosis signature, consistent with the activation of c-Myc, Cdk1, and 
Cyclins A, B, and E, characterizes this unique subset of T-ALL532.  
 In MLL-AF9 driven AML, c-Myb was found to promote self-renewal of the 
L-ICs and inhibition of c-Myb ablated leukemia in diseased mice439. In human T-
ALL, c-MYB was found to be a direct target of TAL1 and is highly expressed in 
TAL1-positive T-ALL cell lines. Together, these data led us to hypothesize that c-
Myb may control self-renewal in our Lck-Tal1/Lmo2 mouse model of T-ALL. The 
experiments described in this appendix show that silencing of c-Myb in murine T-
ALLs led to increased survival and decreased L-IC frequency in recipient mice. c-
Myb inhibition was also shown to reduce self-renewal of L-ICs and reduce 
proliferation of bulk leukemic cells. 
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Results 
 In order to determine if c-Myb plays a role in the T-ALL L-IC, we silenced 
expression of the protein using retroviruses expressing shRNA to c-Myb, as 
described in Chapter IV of this thesis. The same primary murine leukemias were 
used and manipulated simultaneously with the shMyc cells, therefore the same 
shRen cells from that experiment were used as the control for these experiments. 
When we transplanted the shMyb cells into recipient mice, we saw very similar 
results to the shMyc study. Three out of four T-ALLs showed significant 
increases in overall survival (Figure 31 A-C) and an overall 34-fold reduction in L-
IC frequency (Table 16), range 7-fold to cure (Table 17). This indicates a critical 
role for c-Myb in leukemic initiation and maintenance.  
 As in the shMyc study, mice transplanted with T-ALL 4673 shMyb cells did 
not develop disease (n=9). There was no evidence of disease in the surviving 
mice and no GFP-positive cells found in the bone marrow, suggesting that the L-
IC had been completely eliminated. T-ALLs 5109 and 5059 showed significant 
increases in survival upon c-Myb silencing and 7- to 18-fold decreases in L-IC 
frequency, respectively (Figure 31B-C; p<0.007, p<0.008; Table 17). These data 
confirm that c-Myb expression is required for L-IC expansion in vivo. Surprisingly, 
these results are actually more dramatic than what we saw with the shMyc cells 
(Figure 18, Tables 8 and 9) suggesting that c-Myb plays a larger role in the T-
ALL L-IC compared to c-Myc. In contrast to the c-Myc study, T-ALL 6124 showed 
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a 3-fold decrease in L-IC frequency upon c-Myb silencing (Table 17). However, 
this decrease in L-IC frequency did not result in a significant increase in overall 
survival of the recipient mice (Figure 31D, p<0.18).  
It is unclear why all T-ALLs did not respond to the c-Myb shRNA in a 
similar manner in vivo. We examined the effects of c-Myb inhibition on leukemic 
growth by plating the GFP-positive sorted cells in an in vitro growth assay and 
monitoring their proliferation over time. In all three T-ALLs tested, c-Myb silencing 
resulted in decreased proliferation and increased dead cells in the culture (Figure 
32A). Consistent with the shMyc studies, T-ALL 6124 showed the least response 
to the Myb shRNA and a coordinate increase in GFP-negative cells in the culture. 
All murine T-ALLs appeared dependent on c-Myb for their growth. Knockdown of 
c-Myb protein in the retrovirally infected cultures was quite strong (Figure 32B), 
with an average knockdown of 5-fold (range 2- to 8- fold). This could explain the 
increased response to the shRNA in vivo compared to the shMyc experiments 
where knockdown averaged only 2-fold (range 1.4- to 2.3- fold).  
 When animals became diseased after transplantation with leukemic cells, 
GFP expression and c-Myb levels were examined in tissues exhibiting leukemic 
burden. Most of the mice that we were able to analyze had GFP-positive 
leukemia (not shown), but several animals were found deceased so we were 
unable to determine GFP expression. Unlike the shMyc studies, decreased c-
Myb expression was apparent in all recipient mice examined (Figure 33). This 
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suggests that the shRNA was not silenced in the recipient mice and therefore 
disease initiation occurred even with decreased c-Myb levels.  
 To investigate the effects of c-Myb silencing on self-renewal of the murine 
T-ALLs, we performed secondary transplant experiments. 120 days after initial 
transplant, all surviving mice were sacrificed and tissues analyzed for GFP 
expression. We were unable to detect GFP-positive cells in the bone marrow or 
other lymphoid tissues, indicating a lack of transplanted leukemic cells (Figure 
34). Bone marrow cells were pooled and 5 x 106 cells were transplanted into 
secondary recipients. None of the 17 secondary transplants became diseased 
after an additional 120 days (not shown), suggesting that c-Myb is required for L-
IC self-renewal, despite the fact that knockdown was maintained in primary 
recipients that became diseased. This assay ensures that shRNA to c-Myb did 
not simply induce quiescence of the leukemic cells in the primary recipients.  
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Discussion 
 Here, I have shown a clear role for c-Myb in the maintenance and self-
renewal of T-ALL L-ICs. Silencing of c-Myb with specific shRNAs resulted in 
decreased proliferation of T-ALL cells in culture. Importantly, decreased 
expression of c-Myb resulted in an average of 34-fold fewer L-ICs and significant 
effects on overall survival.   
 Probably the most interesting result in this study was that leukemic mice 
maintained knockdown of c-Myb at disease presentation. This finding suggests 
that that c-Myb may not be required for L-IC activity because c-Myb depleted L-
ICs were capable of disease initiation. This contrasts with our study of c-Myc in 
Chapter IV where all diseased animals had silenced or escaped the shRNA and 
restored c-Myc expression in order to initiate disease. However, compared to the 
c-Myc study with the same exact tumors transplanted at the same time, c-Myb 
silencing resulted in a 34-fold decrease in L-IC frequency whereas c-Myc 
silencing resulted in a 17-fold reduction of L-ICs. This could indicate a more 
prominent role for c-Myb in L-ICs or could simply reflect a discrepancy in the 
levels of knockdown between the two experiments. Additionally, these results 
indicate that T-ALL dependence on a particular gene for growth in vitro does not 
correlate to the dependence in vivo. 
 Upstream of c-Myb, Tal1 could be mediating a stem cell phenotype in 
these T-ALL cells. TAL1 directly activates c-MYB in T-ALL119 and c-Myb is 
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involved in the maintenance of normal HSCs521,522. The transcriptional program 
initiated by c-Myb expression points to increased cell survival and decreased 
apoptosis529,536,537,539–541,547,548. Enforced Tal1 expression causes a block in T-cell 
differentiation112,114, and it is possible that c-Myb expression is what allows these 
cells to remain alive long enough to incur additional mutations such as activating 
mutations and 5’ deletions in the Notch1 locus138,248. This protection from death 
could then be extended to the L-IC, as c-Myb activates Bcl-XL and Bcl-2539,540,547, 
two genes shown to be elevated in certain chemotherapy-resistant L-ICs. 
 Future experiments could include in vitro studies such as ChIP-seq, array 
CGH, and other types of profiling to reveal additional mechanisms of c-Myb 
activation, but these questions are not as interesting as the potential functional 
experiments. Completely ablating c-Myb at various points of leukemic 
transformation would allow us to further define its role in the L-IC. By using c-
Mybfl/fl mice mated into our Lck-Tal1/Lmo2 transgenic mouse lines, we could use 
various transgenic or knock-in Cre lines to confirm our shRNA results. Depending 
on which specific Cre is used, deletion should be more efficient than shRNA and 
this method would allow for deletion at different time points in development prior 
to leukemia. This strategy would also allow us to differentiate effects of leukemic 
cell engraftment and leukemia-initiating capabilities. Our lab has obtained these 
mice and begun the mating process. 
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 The role of c-Myb in T-ALL is not entirely clear, but these preliminary 
studies support an important role in the self-renewal of the murine L-IC.  
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Methods 
Mice, Cell Culture, Flow cytometry 
All experiments described in this Appendix were performed at the same 
time and with the same reagents as experiments described in Chapter IV of this 
thesis. 
Expression Analyses 
mRNA was isolated from retrovirally infected T-ALLs and T-ALL cell lines 
treated with JQ1 as described in Chapter IV. qPCR was performed on cDNA 
using the following primers for c-Myb expression: F:5’ 
GAGCACCCAACTGTTCTC-3’, R:5’- CACCAGGGGCCTGTTCTTAG-3’ Protein 
expression was evaluated by immunoblotting using a monoclonal anti-c-Myb 
antibody (Millipore Cat# 05-175). 
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Figure 31. Silencing of c-Myb prolongs survival in mice transplanted with 
murine T-ALL cells.  Four independent murine Tal1/Lmo2 T-ALL cells were 
infected with retroviruses encoding an shRNA to c-Myb or Renilla luciferase. 
Cells were sorted for GFP expression, serially diluted and transplanted into 
syngeneic recipients via intraperitoneal (IP) injection.  Transplanted mice were 
monitored for evidence of disease. The survival curve for each group of mice was 
estimated using the Kaplan-Meier method and the difference in overall survival 
between the two groups assessed by the log-rank test. A 4673 p<0.0001, B 5109 
p<0.007, C 5059 p<0.008, D 6124 p<0.18.  
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Table 16. Silencing of c-Myb reduces L-IC frequency. 
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Table 17. Silencing of c-Myb reduces L-IC frequency. 
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A. 
 
 
 
 
 
Figure 32. Impaired cell growth and reduced c-Myb expression in c-Myb-
silenced leukemic cells. A. c-Myb suppression impairs bulk leukemic 
growth in vitro. Cell viability was calculated via a trypan blue exclusion assay. 
Four independent mouse T-ALLs were analyzed; three are shown. B. Reduced 
c-Myb protein levels in c-Myb-silenced leukemic cells. Protein was isolated 
from murine Tal1/Lmo2 T-ALLs infected with retroviruses encoding shRNAs to c-
Myb or Renilla luciferase and c-Myb and Erk1/2 protein levels were determined 
by immunoblotting. Quantification of the blot is shown below 
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A.  
 
 
B.  
 
 
Figure 33. Myb-silenced mice that develop disease contain GFP+ cells and 
exhibit Myb knockdown. A. Mouse leukemic cells were isolated from mice 
transplanted with shRen or shMyb infected mice. Thymi were dissociated into a 
single cell suspension and GFP expression determined by flow cytometry. One 
representative from each group of tumor 5059 is shown. B. RNA was isolated 
from thymi and c-Myb mRNA levels determined by quantitative real time PCR. 
Copy number was normalized to β-actin using the ΔΔCT method. 
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Figure 34. No GFP-positive cells remained in transplanted animals 120 days 
post-transplant. Mice that failed to develop disease 120 days post-transplant 
were sacrificed. Bone marrow cells were isolated and analyzed by flow 
cytometry. No GFP-positive cells were present in any animals examined. Two 
representative mice from each group are shown.   
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Appendix IV: Microarray following JQ1 
treatment in vivo 
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The data presented in this Appendix go with Chapter IV. A gene expression array 
was attempted using murine T-ALLs treated with JQ1 in vivo. Results were 
inconclusive and so were not included in the main body of this thesis. 
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Results 
JQ1 inhibits c-Myc in vivo 
 To determine the mechanism of action of JQ1 in T-ALL, we designed an in 
vivo microarray. Three independent murine T-ALLs were each transplanted into 
four recipient mice. Upon disease presentation, two mice were treated with 
vehicle or 50mg/kg of JQ1. Two hours post-injection, tumor tissue was harvested 
and total RNA isolated and sent for oligonucleotide profiling (see Methods for 
greater detail). JQ1 treatment significantly (p<0.05) changed the expression of 
524 genes with a fold change cutoff of 1.5; 376 were downregulated upon 
treatment while 148 were induced (not shown). Upon ranking this list (Table 18), 
we found that the E47/HEB-regulated gene Rag1 was the most highly modulated 
(fold change, -5.7, p<0.03) and c-Myc was ranked 13th  (fold change of -3.2, 
p<0.04). We found a relatively small number of genes to be modulated in our 
microarray, especially considering the vast number of genes known to be 
regulated by c-Myc. Known target genes such as Cdk4, Fbl, Apex1, and Tk1 
were not found on the array, despite being reduced by JQ1 in all three cell lines 
tested (Figure 23).  
Technical error introduced by attempting to perform a microarray with 
leukemic tissues might have caused variation in gene expression among the T-
ALLs examined. Normal cells in the tissue could have also affected the results or 
compound availability in vivo may have not been uniform across the animals 
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examined. Indeed, gene expression values differed from one vehicle-treated 
mouse to the next, within a single T-ALL analyzed. Because JQ1 reduces cell 
cycle and inhibits apoptosis (Figure 22C,D), it is likely that genes controlling 
these pathways should be found on an array for JQ1 treatment. If the tissues 
processed from the animals were at different proliferation states at the time of 
harvest, this could increase variability even further.  
Gene expression profiling should be repeated with murine T-ALL cell lines 
where technical variation would be limited. An ideal experiment would take place 
at an early time point during JQ1 treatment when gene expression is changing, 
but when the arrest and apoptosis are not yet apparent. Established cell lines 
would be treated for a time course to determine the optimum balance of these 
factors and then both technical (2-3 repeats of same cell line) and biological (2-3 
cell lines) replicates would be submitted for microarray analysis. Hopefully, this 
would reduce the noise and variability both within and across T-ALL samples 
examined. Further analysis of the effects of significantly changed genes on T-
ALL biology could determine a genetic mechanism of action for JQ1. This 
experiment could also elucidate additional genes critical for T-ALL maintenance 
that have not yet be studied. 
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Table 18. Top 50 repressed and induced genes following JQ1 treatment 
Gene Symbol Gene Description P  FC 
Rag1 recombination activating gene 1   0.0341 -5.7260 
Ccr4 chemokine (C-C motif) receptor 4   0.0159 -5.7188 
Slc16a5 solute carrier family 16, member 5   0.0049 -4.3560 
Tmem229b transmembrane protein 229B   0.0091 -4.0645 
Naip3 NLR family, apoptosis inhibitory protein 3   0.0205 -3.5799 
Arpp21 cyclic AMP-regulated phosphoprotein, 21   0.0423 -3.4594 
Sla src-like adaptor   0.0146 -3.4116 
Il1rl2 interleukin 1 receptor-like 2   0.0066 -3.3810 
Arsi arylsulfatase i 0.0027 -3.3637 
Tcrg-V3|Tcrg-
V2 T-cell receptor gamma, V3 | T-cell receptor gamma, V2   0.0155 -3.3450 
Lpar4 lysophosphatidic acid receptor 4   0.0263 -3.1848 
Myc myelocytomatosis oncogene   0.0437 -3.1729 
Il12rb2 interleukin 12 receptor, beta 2   0.0033 -3.1584 
Trat1 T cell receptor associated transmembrane adaptor 1   0.0051 -3.1435 
Il5ra interleukin 5 receptor, alpha   0.0004 -3.0937 
Tnfrsf8 tumor necrosis factor receptor superfamily, member 8   0.0052 -3.0010 
Tnfsf10 tumor necrosis factor (ligand) superfamily, member 10   0.0007 -2.9721 
Cd226 CD226 antigen   0.0174 -2.9180 
Gpr174 G protein-coupled receptor 174   0.0229 -2.9110 
Cd27 CD27 antigen 0.0091 -2.8525 
Gm239 predicted gene 239   0.0017 -2.7914 
Gm885 predicted gene 885   0.0006 -2.7681 
Narg2 NMDA receptor-regulated gene 2   0.0473 -2.7680 
Rpp38 ribonuclease P/MRP 38 subunit (human)   0.0087 -2.7397 
Ubash3a ubiquitin associated and SH3 domain containing, A   0.0455 -2.7359 
Mir363 microRNA 363   0.0377 -2.7308 
Tmem173 transmembrane protein 173   0.0053 -2.7060 
Ikzf2 IKAROS family zinc finger 2   0.0121 -2.6943 
Zfp72 zinc finger protein 72   0.0075 -2.6593 
Ifi202b interferon activated gene 202B   0.0068 -2.6467 
Prssl1|Fstl3 protease, serine-like 1 | follistatin-like 3   0.0014 -2.6351 
Prkcq protein kinase C, theta   0.0241 -2.5738 
Ifi203 interferon activated gene 203   0.0441 -2.5049 
Art2b ADP-ribosyltransferase 2b   0.0086 -2.4902 
Cd28 CD28 antigen 0.0002 -2.4796 
Rasgrp1 RAS guanyl releasing protein 1   0.0387 -2.4744 
Mcoln3 mucolipin 3 0.0437 -2.4548 
Ms4a6b 
membrane-spanning 4-domains, subfamily A, member 
6B   0.0127 -2.4358 
Prr11 proline rich 11   0.0486 -2.4039 
Gm10673 predicted gene 10673   0.0194 -2.4036 
Cd2 CD2 antigen 0.0342 -2.4021 
Ccdc125 coiled-coil domain containing 125   0.0142 -2.3834 
Slfn8 schlafen 8 0.0466 -2.3777 
Rtp4 receptor transporter protein 4   0.0118 -2.3632 
Slc40a1 solute carrier family 40, member 1   0.0484 1.9810 
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Chchd7 coiled-coil-helix-coiled-coil-helix domain containing 7   0.0066 1.9876 
Lyn Yamaguchi sarcoma viral (v-yes-1) oncogene homolog   0.0152 1.9888 
Dag1 dystroglycan 1   0.0249 1.9935 
Ifrd1 interferon-related developmental regulator 1   0.0025 2.0117 
Larp1b La ribonucleoprotein domain family, member 1B   0.0065 2.0211 
Chka choline kinase alpha   0.0105 2.0244 
Zfand2a zinc finger, AN1-type domain 2A   0.0045 2.0245 
Csf1r colony stimulating factor 1 receptor   0.0076 2.0752 
Ppp1r13b 
protein phosphatase 1, regulatory (inhibitor) subunit 
13B   0.0288 2.0811 
Cited2 Cbp/p300-interacting transactivator 2   0.0039 2.0962 
Arid5a AT rich interactive domain 5A (MRF1-like)   0.0367 2.1071 
Jund Jun proto-oncogene related gene d   0.0389 2.1471 
Hist1h2bg histone cluster 1, H2bg   0.0367 2.1539 
Sgk1 serum/glucocorticoid regulated kinase 1   0.0240 2.1610 
Mfge8 milk fat globule-EGF factor 8 protein   0.0495 2.1719 
6430548M08Rik RIKEN cDNA 6430548M08 gene   0.0024 2.1733 
Serpina1e 
serine (or cysteine) peptidase inhibitor, clade A, 
member 1E   0.0470 2.1760 
B230325K18Rik RIKEN cDNA B230325K18 gene   0.0193 2.1850 
Dnajb9 DnaJ (Hsp40) homolog, subfamily B, member 9   0.0484 2.2274 
Gcg glucagon 0.0123 2.2588 
Ero1lb ERO1-like beta (S. cerevisiae)   0.0123 2.2663 
Arrdc3 arrestin domain containing 3   0.0424 2.2860 
Mylip myosin regulatory light chain interacting protein   0.0221 2.2905 
Rnf146 ring finger protein 146   0.0304 2.3479 
Sesn2 sestrin 2 0.0269 2.3558 
Serpina1b 
serine (or cysteine) preptidase inhibitor, clade A, 
member 1B    0.0158 2.3571 
Baiap2 
brain-specific angiogenesis inhibitor 1-associated 
protein 2   0.0190 2.4263 
Hist1h3d histone cluster 1, H3d   0.0381 2.4478 
Cnnm4 cyclin M4 0.0278 2.5110 
Tiparp TCDD-inducible poly(ADP-ribose) polymerase   0.0218 2.5171 
Cirbp cold inducible RNA binding protein   0.0488 2.5373 
Rgs2 regulator of G-protein signaling 2   0.0136 2.5410 
Habp4 hyaluronic acid binding protein 4   0.0033 2.5806 
Ins2 insulin II 0.0217 2.6836 
Txnip thioredoxin interacting protein   0.0081 2.7543 
Hexim1 hexamethylene bis-acetamide inducible 1   0.0042 2.7566 
Iapp islet amyloid polypeptide   0.0114 2.9620 
Lyve1 lymphatic vessel endothelial hyaluronan receptor 1   0.0411 3.0694 
Gadd45b growth arrest and DNA-damage-inducible 45 beta   0.0253 3.0923 
Ins1 insulin I 0.0330 3.2085 
Larp1b La ribonucleoprotein domain family, member 1B   0.0075 3.3594 
Chac1 ChaC, cation transport regulator-like 1 (E. coli)   0.0237 3.6694 
Hist2h3c2 histone cluster 2, H3c2   0.0258 4.3948 
Cd74 CD74 antigen 0.0344 4.6995 
Hist1h2bc histone cluster 1, H2bc   0.0198 5.2753 
Hist1h1c histone cluster 1, H1c   0.0037 6.8435 
P, p-value; FC, fold change  
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Methods 
 
Gene expression array 
 Three independent murine T-ALLs were each transplanted into four 
recipient mice. Upon disease presentation, two mice were treated with vehicle or 
50mg/kg of JQ1. Two hours post-injection, tumor tissue was harvested and total 
RNA isolated, followed by cleanup using the RNeasy kit (Qiagen). Quality of 
mRNA was assessed using a nanochip on the Agilent Bioanalyzer 2100 (Agilent 
Technologies) and samples were processed for oligonucleotide microarray 
profiling. Affymetrix Mouse Exon 1.0 ST arrays were processed and analyzed 
using GeneSpring GX12.1 software (Agilent Technologies). Data was normalized 
using the Robust Multi-Array Analysis (RMA) summarization algorithm with data 
transformation set to the median of each sample. Probe sets were filtered on 
expression and P values for differential expression were determined, with p<0.05 
being considered statistically significant, and a cutoff of 1.5-fold being used for 
further analysis. 
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List of primers 
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List of antibodies 
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